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Abstract 
The blood–brain barrier (BBB) is a selective system of endothelial cells, joined through the tight 
junctions, that protect and maintain the homeostasis of the Central Nervous System (CNS). Only 
small molecule or drugs, with high lipid solubility and a lower molecular mass under 400–500 Da, 
can cross the BBB in pharmacologically significant amounts, limiting the uptake of most therapeutic 
agents into the brain.  
Currently, the management of neurological with aggressive and invasive techniques (surgery, see 
Appendix 3), achieves higher therapeutic effect compared to conventional delivery methods, such as 
systemic administration via intravenous injection or oral administration. However invasive 
techniques achieve less compliance. 
This has led to the development of vogue treatments such as nose-to-brain technologies (see 
Appendix 2), FUS-induced BBB opening, fusion protein chaperones, stem cells, gene therapy, use 
of natural compounds and neuroprotectants, in order to increase the neuroavailability of various 
advanced drug delivery systems. These strategies provide promising alternatives that are able to 
ameliorate the treatment of brain disease. 
At this purpose, several nanocarriers ranging from the more established systems, e.g. polymeric 
nanoparticles, liposomes, niosomes and micelles to the newer systems, e.g. nanoemulsions, micro- 
and nano-bubbles, nanosuspensions and nanogels, have been studied for the delivery of therapeutics 
to CNS. Many of the proposed nanomedicines can be effectively transported across various in vitro 
and in vivo BBB models by endocytosis and/or transcytosis, and demonstrated early preclinical 
success for the management of CNS conditions such as brain tumours, HIV encephalopathy, 
neurodegenerative disease and acute ischemic stroke. Future development of CNS nanomedicines 
need to focus on increasing their drug-trafficking performance and specificity for brain tissue using 
novel targeting moieties, improving their BBB permeability and reducing their neurotoxicity. 
Targeted drug delivery is a means of concentrating drugs at a specific site relative to other parts of 
the body. It spares the rest of the body from toxic effects of the drug and it is also a potential means 
of improving therapeutic index. 
This Ph.D. thesis focused on the study of the formulation of different nanocarriers for brain delivery 
by two different administration route: 
v Focused Ultrasound-mediated drug delivery, a technique that offer a unique non-invasive 
avenue to deliver drugs to the brain through transient opening of the BBB by using of ultrasound 
in combination with gas-filled bubbles. Our laboratory developed new carriers, the 
“Bubblesomes”®, able to combine the characteristics of a drug carrier and a contrast agent 
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(theranostic system). When focused ultrasound is applied in presence of drug loaded nanobubbles 
intravenously administered, inertial cavitation is induced, due to the rapid expansion and violent 
collapsing of bubbles. This can cause the temporal and fully reversible opening of BBB due to 
the enhanced endothelial porosity and vascular permeability phenomenon called sonoporation, 
resulting in an increased drug uptake.  
v Intranasal drug delivery, a non-invasive route to reach directly the brain, circumvent the BBB, 
from the nose along the olfactory and trigeminal nerve pathways. These nerve pathways initiate 
in the nasal cavity at olfactory neuroepithelium and terminate in the brain.  
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1. Brain delivery 
 
Conventional drug delivery systems fail to deliver numerous neuropharmaceutical agents to the CNS 
for treatment of brain diseases such as cancer therapy, schizophrenia, epilepsy, insulin-dependent 
diabetes, Parkinson’s disease and Alzheimer’s disease. [1] 
The primary cause of the limited access of many drugs is the presence of three barriers: (1) the blood-
brain barrier (BBB), that regulates the exchanges between the blood and the brain, (2) the arachnoid 
epithelium and (3) the choroid plexus epithelium, which separate the blood from the cerebrospinal 
fluid (CSF). 
In particular, the BBB plays a key role for the protection of the brain from several pathogens and 
toxic substances, including drugs, and for maintaining its homeostasis. 
The BBB surrounds the cerebral microvessels and it is composed by the endothelial cells strongly 
joined by the tight junctions. 
The tight junctions are composed by transmembrane proteins: claudins, occluding and junctional 
adhesion molecules. Their membranes are localized in two different cellular sites: luminal, in the 
blood side, and abluminal, in the brain side. 
Functionally, this barrier is regulated by several cell types: the astrocytic end-feets, pericytes and 
neurons. [2] 
Molecules may cross the BBB following two fluxes, from the blood to the brain parenchyma, or vice 
versa, by efflux transporters, controlling the brain concentration of exogenous substances in the brain.  
Several pathways are involved in the transport through the BBB, as shown in the figure 1. [3] 
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Figure. 1 Transport pathways across blood brain barrier. 
 
 
• Transcellular passive diffusion: this mechanism involves the transport of endogenous molecules 
(e.g. drugs) and it mainly depends by the drug properties and the concentration gradient. 
Generally, only the small molecules, with a molecular weight less than 400 Da and a high lipid 
solubility, are able to cross BBB by this way in a significant amount. Furthermore, this way is 
favored for unionized substance with have a log P value near to 2 and a cumulative number of 
hydrogen bonds not beyond 8-10 and. [4]  
• Carrier-mediated transcytosis: the essential nutrients, metabolites and neurotransmitters, such 
as glucose, iron or amino acids, are transported into the CNS through specific carriers, e.g. the 
glucose transporter 1, large neutral amino acids transporter 1, etc.  
• Receptor-mediated endocytosis: concern the internalization in the brain of insulin, transferrin, 
lactoferrin, immunoglobulin, epidermal growth factor and low density lipoproteins. These 
molecules are internalized from the abluminal side of the brain and transported to the side pole of 
cells through a lysosome. This process is receptor-mediated and the receptor is specific for each 
molecule.  
• Absorption-mediated endocytosis: starts with the interaction between the negative charges on 
the cellular membrane and a cationic substance, followed by endocytosis of the molecules in the 
brain.   
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• Efflux transporter: concern a large number of endogenous and exogenous substances are 
pumped out of the brain by the efflux transporters, such as P-glycoproteins or the multi-drug 
resistance-related proteins). [5] 
Therefore, many polar drugs are unable to reach the brain because of the absence of paracellular 
pathways on the BBB. 
Consequently, a significant number of CNS diseases seem to have no efficient therapy and many 
promising therapeutic agents are not further investigated because of their inability to achieve 
sufficient levels in brain through systemic administration.  
Since various active drugs for the CNS diseases do not reach the brain in therapeutic concentrations, 
many drug are administrated in excessive doses with the associated risk of systemic side effects. [6] 
Currently strategies to increase drug delivery to the brain provide the use of invasive or non-invasive 
approaches. 
Invasive approach requires: the intraventricular or intracerebral infusion of the neurotherapeutic 
agent, the intrathecal implantation of formulation or the transitory permeability increase of BBB, for 
example by using mannitol. [7] 
Unfortunately, these techniques shown a high risk of complications for the patients, like infections or 
oedema. Moreover, they are expensive, require hospitalization with a long recovery period and a high 
surgical expertise. [8] 
Non-invasive approach includes various types of drug modifications: chemical, by using prodrugs or 
drug conjugates, biological, through the conjugation of drug with antibodies or by peptides as carrier 
and the use of colloidal drug delivery. 
Despite many researchers having developed several methods to overcome the BBB, obtaining very 
promising in vitro results, only a few number of strategies have shown good results when applied in 
vivo. 
Therefore, new strategies are necessary to go through CNS barriers to fulfill efficient treatment of 
neurological diseases. 
 
2. Nanotechnology for brain delivery 
 
In the last years, the design and development of nanocarriers as drug delivery systems involved many 
research team, in particular, to enhance the drug delivery to the CNS. 
In 1980, Paul Ehrlich referred to a drug delivery systems (DDS), as a ‘magic bullet’, designed to 
achieve a selective target avoiding the healthy tissue and organs. Afterwards many researchers have 
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formulated several carriers to enhance the brain delivery including liposomes, niosomes, ethosomes 
and colloidosomes. [9, 10] 
Despite promising researches, only few nanocarriers have actually shown significant clinical potential 
and practical application. Among commercially available nanocarriers, vesicular carriers, such as the 
liposomes, are present in quite a large number. (Table. 1) 
	
	
Product Drug Type of system 
Abraxane® Paclitaxel  Nanoparticles 
Caelyx®/Doxil® Doxorubicin Liposomes 
Emend® Aprepitant Nanoparticles 
Mepact® Mifamurtide Liposomes 
Myocet® Doxorubicin Liposomes 
Pegasys® Interferon 2a Polymer-protein conjugate 
Rapamune® Sirolimus Nanoparticles 
Zevalin® Ibritumomab tiuxetan Antibody-conjugate 
 
Table. 1 Clinically approved nanocarriers. 
 
 
The use of liposomes as drug delivery is encouraging, but still it presents same problems such as their 
physico-chemical instability and leakage of entrapped drug. Synthetic phospholipids are expensive 
and the natural phospholipid show a variable degree of purity. [11] 
In addition to these vesicular systems, other carriers are able to encapsulate drug to be delivered to 
the brain: cyclodextrins, dendrimers, nanoemulsions and nanoparticles. [12, 13] (Figure. 2) 
 
 
 
Figure. 2 Drug delivery systems. 
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Ideally, a drug delivery system for the brain should be: 
Ø nontoxic, biodegradable and biocompatible; 
Ø nanometric; 
Ø stable in vivo and in vitro; 
Ø able to void the RES (reticulo-endothelial system) to prolong the blood circulation time;  
Ø prepared by scalable and cost-effective manufacturing process; 
Ø able to avoid drug alteration (chemical degradation/alteration or protein denaturation); 
Ø able to control the drug release. 
The nanocarriers exhibit numerous advantage for drug delivery, including cargo protection from 
enzymatic degradation and an increase of drug dosage delivered to target sites, so limiting the 
systemic side effects.    
Vesicular nanocarriers show a hydrophilic core, able to entrap water-soluble drugs and a hydrophobic 
shell that stabilize the system and entrap lipophilic drugs.  
Furthermore, the use of nanocarriers do not require any chemical modification of the therapeutically 
molecule for the brain delivery, since the system can mask the drug properties by entrapping it.  
The nanometric size range (10-1000 nm) potentially allows carriers to pass through several biological 
barriers, such as nasal mucosa or BBB [14, 15], and to reach to hitherto inaccessible disease sites.  
Several researchers show that the primary immune system is less active for the molecules with lower 
dimensions then hundred nanometers, allowing for longer blood circulation of these carriers.  
The surface of nanocarrier may be functionalized to improve their pharmacokinetic and 
biodistribution. For example, the surface PEGylation induces steric repulsion from blood opsonins 
(molecules which improve phagocytosis) enabling enhancement of the in vivo longevity of 
nanocarrier and the capability of extravasation through the endothelium of inflammatory tissues (the 
enhanced permeability and retention effect). 
Alternatively, the functionalization of DDS by using biologically active ligands eases the targeting 
of specific cells.  
Among the several features that the nanocarriers can acquire, one of the most attractive is the stimuli-
responsive property. The application of a specific stimulus may cause structural or conformational 
changes in the DDS and consequently inducing capture and release of drugs, chemical reactions, and 
morphology transitions.  
These formulations may be sensitive to: (Figure. 3) 
• endogenous stimuli: including pH variations, redox gradients, the concentration of a specific 
enzymes, etc. For example, at the cellular level, pH sensitivity can trigger the release of the drug 
in the endosomes or lysosomes. Moreover, the nanocarrier can take advantage of the 
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microenvironmental changes associated to the inflammatory diseases, neoplastic diseases, 
infections or other pathological situations such as ischemia. 
• exogenous stimuli: for systems which are able to release the drug in response to externally applied
stimuli, such as temperature changes, ultrasound, magnetic and electric fields. In particular,
thermos-responsive drug delivery is governed by the change in the properties of at least one
component of the nanocarrier material with the temperature. Ideally, these systems should retain
their drug load at the physiological temperature and release the drug in correspondence of heated
body area, such as tumor area (≈ 40-42˚ C). Also, ultrasound waves in combination with drug-
loaded micro- or nano-bubbles can trigger the release of drug through the thermal/mechanical
effects generated by cavitation mechanisms or radiation force. [16]
Figure. 3 Examples of stimuli triggers for nanocarriers. 
A further advantage of these systems is the possibility to use them as imaging/contrast agents for 
several imaging techniques, such as ultrasonography, gamma-scintigraphy, magnetic resonance 
imaging, computed tomography.  
These systems are namely theranostic agents and combine both the diagnostic properties and the 
therapy in a single system. 
After injection, the theranostic agent containing drug can be tracked by an imaging techniques and, 
reaching the target site, release their contents, after exposure to specific stimuli. 
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1. Introduction 
 
1.1. Focused Ultrasound-mediated drug delivery  
 
Ultrasound (US) waves are mechanical pressure waves that propagate through a medium, with a 
frequency > 20 kHz. 
In the last 50 years, ultrasonography has been widely used as a non-invasive diagnostic technique 
that show a real-time imaging in clinical diagnosis.  
Since the blood shows a low back-scatter of US waves at clinical diagnostic frequencies (between 1-
40 MHz) ultrasound contrast agents (UCAs), have been developed to improve the visualization of the 
microvascularization.  
Recently, the deep research on ultrasound for diagnostic imaging has helped to expand and define its 
role in other fields, including therapy, such as the thermal ablation of a pathological tissue by using 
high intensity focused US (HIFU) [1], the break-down of calculi by lithotripsy [2], the stimulation of 
the tissue and bone repair by low-intensity US [3]. 
In particular, US have been established as a versatile tool to increase cellular permeability and 
enhance the drug uptake. 
Based on the used exposure condition, in terms of frequency, intensity, pressure and   duration, US 
has shown to improve the drug delivery by different mechanisms:  
Ø Thermal effect: the absorption of waves by a tissue can cause a localized temperature increase 
the, allowing drug release from a thermosensitive carrier, without tissue damage. [4] 
Ø Acoustic radiation force: when the US propagate through tissue, the energy can be absorbed by 
microbubbles (MBs) intravenously injected. This phenomenon generates a net force that pushes 
particles away from the ultrasound transducer promoting their extravasation and diffusion through 
a tumor matrix. [5] 
Ø Cavitation: during the alternating cycles of rarefaction and compression generated by US waves, 
MBs are able to expand and contract. [6] (Figure. 1) 
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Figure. 1 Several cavitation mechanisms due to US pressure wave.   
 
 
At low acoustic power, with a mechanical index (MI) of 0.1-0.5, MBs show a stable cavitation, 
resulting in nonlinear volumetric oscillation, the bubbles will oscillate but will not collapse. At 
high acoustic power, with MI greater than 0.5, the inertial cavitation is induced, because of the 
rapid expansion and violent collapse of MBs. This mechanism is often accompanied by the 
generation of shock waves and microstreaming, which can cause shear stresses on the adjacent 
cells, with a consequently increased endothelial porosity and vascular permeability, called 
sonoporation. Inertial cavitation can be useful in drug delivery to enhance the uptake of the drug 
intravenously injected into the cells through the temporarily permeabilized membranes due to the 
MBs implosion. [7] 
 
 
1.2. Ultrasound Contrast Agents (UCAs): from microbubbles to nanobubbles 
 
UCAs are generally gas-filled microsized bubbles with a biodegradable shell composed by 
phospholipid, polymer or protein, commercially available as contrast agent for ultrasound imaging. 
(Table. 1) 
 
 
 
 
 
 
B) Stable	Cavitation	
C) Inertial	Cavitation	
Rarefraction Compression
Ultrasound	pressure	waveA)
Implosion
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UCA Shell Gas 
Mean 
diameter 
(µm) 
Half-life 
(minutes) 
Stability after 
reconstitution 
(hours) 
Albunex® Albumin Air 4.3 1 – 1 4 
Optison® Albumin Octafluoropropane 2.0 - 4.5 2 – 4 0.5 
Definity® Lipid Octafluoropropane 1.1 - 3.3 2 – 10 12 
Imagent® Lipid N2/perfluorohexane 6.0 60 – 180 NA 
Sonovue® Lipid Sulphurhexafluoride 2.0 - 3.0 2 – 6 6 
Sonazoid® Lipid Air 2.0 60 – 120 NA 
Levovist® Lipid/ galactose Air 2.0 - 4.0 2 – 5 NA 
 
Table. 1 Characteristics of commercially available microbubbles.  
NA=data not available. 
 
 
The gas core usually is composed by air or a bioinert gas such as sulfur hexafluoride, nitrogen or a 
perfluorocarbon (PFC).  
Typically, UCAs show size between 1 – 10µm, approximately equal to red blood cell, and, after the 
intravenous administration, they remain trapped in the blood pool, limiting the UCAs clinical 
application only in the cardiovascular target, such as inflammation, thrombus and arteriosclerosis.  
Furthermore, they are cleared rapidly from the bloodstream due to their poor stability, captured by 
the reticuloendothelial system (RES) and then eliminated by the spleen. [8] 
Nevertheless, commercially available MBs show a short half-life during body circulation and they 
are unstable over time, in fact they must be reconstituted just before administration.  
Recently, to overcome these problems, nanoscale bubbles (nanobubbles, NBs) have been developed, 
but the research is still at the initial stage.  
 
1.3. General properties of nanobubbles 
 
The main advantage of these systems is their potential use as therapeutic drug carriers together with 
their diagnostic application as contrast agent. 
In particular, by using ultrasound, the drug loaded NBs can release drugs to target cells or tissues, 
after implosion. Furthermore, the uptake of the released drug into the cells is enhanced due to the 
temporarily permeabilization of the membranes, by sonoporation. 
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Moreover, these NBs can provide the protection of the drugs from degradation phenomena and the 
drug targeting to specific site of action, limiting toxicity and adverse effects. 
The NBs must be sufficiently stable circulating in the blood stream in order to reach the target site. 
Several factors affect the stability of NBs in the biological fluids: 
Ø Pressure: LAPLACE pressure is an important parameter which governs the in vivo dissolution 
rate of NBs.  
The gas pressure within a bubble is:  
 
∆P = Pi - Po = (2σ / r) 
 
where Pi and Po are the pressure inside and outside the bubble respectively in the bloodstream, σ 
is the interfacial tension and r is the bubble radius.  
LAPLACE pressure is inversely proportional to the bubble size, so smaller bubble will have a 
higher-pressure value than larger bubbles. When the inner gas leaves the core, the bubbles shrink 
and LAPLACE pressure increases, thereby increasing the gas dissipation rate and the system 
collapse. [9] 
Ø Gas entrapped: the air-filled bubbles dissolve very rapidly in the blood due to arterial pressure. 
NBs formulations can be stabilized by using gas with poor aqueous solubility, such as 
perfluorocarbons, reducing the dissolution of the gas in the bloodstream.  
Ø Shell composition: The thickness and the elasticity of the shell can determine micro/nanobubble 
stability, since they affect the gas exchange from the core to the external medium.  
Soft shells are characterized by a thin flexible shell of surfactant material that causes their high 
sensitiveness to the US waves, in fact they are able to oscillate and cause stable and instable 
cavitation. Phospholipid shells are the most elastic due to the hydrocarbon tails, so NBs covered 
by lipid with longer acylchains exhibit a longer shelf-life.  
Instead, hard shells (e.g. polymers) are less responsive to US compared to soft shells due to the 
fact they are cannot oscillate caused from acoustic waves application at low pressure. Only with 
high acoustic pressure, hard sells are able to produce cavitation phenomena. [10] 
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	Aim 
 
The aim of a part of this PhD project has been mainly focused on the formulation and 
characterization of a new theranostic carrier, the Bubblesomes® (NBs®), potentially able to act both 
as drug delivery system (therapy) and as contrast agent (diagnostic). 
 
In particular, the goals of this thesis can be summarized in the following points: 
 
ü Formulation and physico-chemical characterization of NBs® in order to obtain a theranostic 
agent. 
 
ü In vivo studies to investigate the non-invasive localized opening of BBB by using focused 
ultrasound (FUS) exposure, after NBs® systemic administration. 
 
ü Formulation and physico-chemical characterization of drug-loaded NBs®. 
 
All formulations of NBs® present in this PhD thesis have been patented:  
Appendix 1: Patent number WO 2017/178954 A1. 
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	Overview of experimental setup 
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	1. Experimental section 
 
1.1. Materials 
 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and dipalmitoylphosphatidylcholine (DPPC) 
were purchased from Avanti Polar Lipids.   
Dicetyl phosphate (DCP), Span® 20, cholesterol (Chol), Hepes salt {N-(2-idroxyethyl) piperazine-
N’-(2-ethanesulfonicacid)}, calcein, nile red, tetradecafluorohexane (PFC) were Sigma–Aldrich 
products (Sigma–Aldrich SRL, Milan, Italy).  
All other chemicals used throughout this investigation were of analytical grade and no additional 
purification was carried out.  
 
1.2. Preparation of NBs® 
 
The formulations selected in this project are: 
1) DMPC NBs® 
2) DMPC-DCP NBs® 
3) DPPC NBs® 
4) Span20 NBs® 
The NBs® have been prepared by using different phospholipids and surfactants, with cholesterol 
(Chol), in different molar ratio. (Table. 1) 
 
 
Components Ratio % 
DMPC-Chol 40-60 : 20-40 
DMPC-DCP-Chol 50-70 : 50-30 
DPPC-Chol 60-90 : 40-10 
Span20+Chol 30-50 : 70-50 
 
Table. 1 
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	All samples were obtained using the “film” technique according to the procedure described in the 
patent (Appendix 1) and summarize in figure 1. 
 
 
 
  
 
Figure. 1 Schematic representation of the NBs® preparation. 
 
 
The hydrophobic components, such as nile red, phospholipids/surfactants and cholesterol, in the 
reported ratios (Table 1), were dissolved in a mixture of organic solvents (3/1 v/v 
chloroform/methanol), evaporated in a rotavapor to obtain a “film”. [1]  
The dried film was hydrated by the addition of an aqueous phase (10 mM of hepes buffer pH 7.4 or 
a solution of calcein 0.01 M in hepes buffer) in order to obtain the NBs® dispersion. 
Liquid PFC in equilibrium with its gas was added to the dispersion in order to obtain nanobubble 
formulations.  
The dispersion was then sonicated for 15 minutes at 25°C using an ultrasound sonicator provided 
with a microprobe operating at a frequency of 20 kHz and an amplitude of 16% (Vibracell-VCX 
400-Sonics, USA) 
Finally, the NBs® were purified by centrifuge MPW-260R (MPW Med. Instruments) at 600 rpm for 
20 minutes at 25°C. 
 
1.3. Size, size distribution and z-potential 
 
Dynamic light scattering (DLS) was used to determine mean size and size distribution of NBs®.  
The sample was diluted 100 times with the hepes buffer in order to avoid multiscattering 
phenomena. NLBs mean size and size distribution (polydispersity index, PDI) were measured at 25 
!
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	°C using a Malvern Nano ZS90 light scattering apparatus (Malvern Instruments Ltd., 
Worcestershire, UK) at a scattering angle of 90.0°. 
The same apparatus was used for the evaluation of ζ-potential of NBs®.  
The Laser Doppler Anemometry was used and hence the electrophoretic mobility of the vesicles 
was measured. The ζ-potential value was calculated from the electrophoretic mobility using a 
Smoluchowsky constant F (Ka) of 1.5. [2] 
Measurement of the ζ-potential provides information on the physical-chemical characteristics of the 
particles in suspension and is extensively used to predict the stability of systems in relation to 
aggregation phenomena. A suspension is generally considered stable when the ζ-potential values 
are less than -30 mV or greater than +30 mV. 
The distribution curve for NBs® dimensions is characterized by a polydispersity index (PDI), which 
should not be greater than 0.25 for monodispersed populations. 
The analyses were performed at 25ºC and each value reported relates the average of three 
measurements of all samples. 
 
1.4. Acoustic analyses 
 
[Acoustic measurements were performed by Dr. Andrea Bettucci and Dr. Angelo Biagioni, 
Department of Basic and Applied Sciences for Engineering, Sapienza, University of Rome 
(Italy)] 
 
- Pulse-echo technique  
 
In order to determinate the acoustic behavior of the NBs® at different concentrations and at different 
time intervals to evaluate their shelf stability, the pulse-echo technique was used.  
This technique uses of the same physical principle (measurement of the intensity of the reflected 
echo) used for the formation of US images. So, it can be used to evaluate the efficiency of the NBs 
as a contrast medium in medical US imaging. The increase of attenuation of the US signal 
transmitted caused by the solution containing NBs is associated to an increase of the efficiency with 
which the incident elastic energy is scattered into space. 
In clinic, during a medical investigation, the increase of US reflection capacity (echogenicity) will 
registered by a sensor connected to the ultrasound unit. 
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	In this study, the pulse technique is used to measure the frequency spectrum of the NBs® scattering 
efficiency or to determine the US frequency at which the elastic energy is most diffused by the 
NBs® into space. 
The experimental apparatus is composed of an immersion transducer, that generates ultrasound 
bursts in the frequency band 11-17 MHz and centered at 14 MHz, a cylindrical test tube, which 
contains the bubble suspension, and a digital oscilloscope for data capture. The transducer is driven 
by an ultrasonic pulser-receiver (Panametrics 500PR) that generates and receives electrical signals. 
(Figure. 2) 
 
 
 
  Figure. 2 Pulse-echo apparatus 
 
 
The test tube is a Plexiglas hollow cylinder, with an inner total volume V=1.7 cm3, which is closed 
at one base by the emitting surface of the immersion transducer (it is not a focused transducer); the 
sample suspension can be placed into the test tube through a pipe on the lateral surface. The 
transducer can be used both in transmitting and receiving modes, hence, the ultrasound pulses 
emitted by the transducer are reflected by the opposite base and return back to the transducer, 
crossing twice the test tube containing the sample solution, and afterwards they go to the 
oscilloscope through the ultrasonic pulser-receiver.  
The spectrum of the detected signal gives the acoustic behavior of the NBs®.  
Firstly, the test tube was filled with hepes buffer to obtain the decrease of the ultrasound emitted by 
the transducer only by the hepes acoustic attenuation and it represents the reference signal. 
Successively, NBs® is added to the hepes in the test tube and the acoustic burst attenuation due to 
NBs® suspended in hepes is measured. 
Results are expressed as the mean of three experiments ± SD.  
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	Statistical data analysis was performed using the t-test. To evaluate if obtained differences in 
experimental results were statistically significant, P≤0.05 was used as the significance criterion. 
 
- Photoacoustic technique 
 
The photoacoustic technique measuring the decreasing amplitude of the resonance peaks 
corresponding to the intrinsic frequencies of an acoustic resonator used as a photoacoustic cell as 
the concentration of NBs® in the cell was varied. 
The photoacoustic cell, of brass, is an acoustically resonant structure of cylindrical shape having an 
internal volume of V = 7.68 cm3, within which was located the liquid solution which has to be 
characterized photoacoustically. (Figure. 3) 
 
 
 
Figure. 3 
 
 
An argon ion laser (wavelength 4880 Å units), periodically modulated in amplitude at a variable 
frequency between 50 and 2000 Hz, struck the liquid through a transparent window of the cell. The 
periodic heating of the liquid caused periodic variations in its volume which is reflected in 
displacements of a small polyvinyl membrane in contact with the liquid; these displacements were 
measured with a laser vibration meter. The measurement relating to gas content within the NBs® is 
based on the fact that the more gas is present in the micro/nanobubbles dispersed in the liquid, the 
greater will be the decrease in amplitude of the oscillation of the polyvinyl membrane at the 
resonant frequencies of the photoacoustic cell. [3] 
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	1.5. Morphology studies  
 
- Small Angle X-Ray Scattering (SAXS) 
 
[SAXS measurements were performed by Professor Elena Del Favero, Department of Medical 
Biotechnology and Translational Medicine, University of Milan, Milan (Italy)] 
 
SAXS measurements were performed in order to investigate the structural and morphological 
characteristics of the NBs®.   
The ERSF (European Synchrotron Radiation Facility, Grenoble, France) ID02 facility was used.  
SAXS measurements were obtained by keeping the position of the sample fixed and automatically 
moving the detector in a vacuum tube from 0.75 m and 10 m from the sample, so as to be able to 
gain access to a wide range of scattering wave vectors: 0.1 nm-1< q < 3 nm-1, where q = (4π/ λ) sin 
(θ /2), with λ being wavelength (~0.1 nm) and θ the scattering angle.  
The samples were placed in plastics capillaries (KI sheet, ENKI srl, Concesio, Italy) of internal 
diameter of 2 mm, thickness 0.05 mm and with 98% X-ray transmission, sealed with polyethylene 
caps. The capillaries were then mounted horizontally in a 6-station sample holder and were filled 
after they had been installed. In this configuration, it is possible to guarantee almost simultaneous 
measurements of empty and solvent samples under the same conditions; this is very important in 
order to be able to subtract backgrounds in an optimum way and compare the results obtained. 
In order to be able to carry out precise temperature measurements an ad hoc built thermostat 
suitable for fitting to the ID02 line was used; the temperature stabilization error within the 
capillaries was less than 0.05°C. 
The measurements were performed at 25°C and the exposure time of each measurement was very 
short, 0.1 s, in order to minimize any eventual radiation damage.  
The measured SAXS profiles report the diffracted radiation intensity as a function of momentum 
transfer, q. Some spectra for empty and solvent cells were also obtained, carefully compared and 
subtracted from the spectra of each sample. 
The analyses were performed to obtain information on size and morphology of the gas-loaded 
samples.  
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	- Cryogenic Transmission Electron Microscopy (Cryo-TEM) analyses 
 
[Cryo-TEM images were performed by Dr. Roberto Marotta, Research Technologist at the 
Electron Microscopy Laboratory, Nanochemistry Department of the Italian Institute of 
Technology (IIT), Genova (Italy)] 
 
Morphological characterization was performed on the NBs® formulations at cryogenic temperatures 
by (Cryo-TEM). 
This technique allows a study of the morphology and size of the vesicles, using as an electron beam 
radiation to produce the image of the observed sample. 
A sample drop (5 µL) was spread on a Lacey formar/carbon electron microscopy grid and preserved 
in a frozen state by using liquid ethane.  
The vitrification process was carried out by means of FEI Vitrobot System (settings: single blot of 3 
sec, offset of 1 sec, drying time and wait of 1 sec).  
The sample is observed at JEOL 2100 TEM (accelerating voltage: 200 kV, magnifications: 20,000x 
and 40000x) at low temperatures. 
 
1.6. NBs® stability studies 
 
The stability of NBs® stored at 25ºC and 4ºC was evaluated over time up to 90 days by determining 
size and ζ-potential ad different time intervals (1, 30, 60 and 90 days). 
Simultaneously, the acoustic attenuation was measured in order to confirm the presence of inner gas 
in the NBs® stored at 4ºC after 90 days.   
In addition, SAXS measurements were carried out on NBs® stored at 4ºC after 30 days. 
In order to study the stability of NBs® in the biological fluids, human serum or bovine serum was 
added to the sample until reached at 45% and the changes in dimensions and ζ-potential were 
measured for 3 hours at a temperature of 37°C. 
 
1.7. Bilayer analyses  
 
- Fluidity 
 
The fluidity of NBs® membranes was evaluated by using 1,6-diphenyl-1,3,5-hexatrine (DPH), as 
“fluidity probe”. [4] 
38
	DPH is a nonpolar fluorescent probe localized in the hydrophobic region of the bilayer membrane. 
The evaluation of fluorescence anisotropy (A) is a generally used method to determine the degree of 
molecular packing order in the hydrophobic bilayer region.  
Anisotropy value is inversely proportional to membrane fluidity, so a high value of A will 
correspond to a high structural order and low membrane fluidity. [5]  
DPH (2x10-4) was added in the first step of NBs® preparation (as reported previously). Fluorescence 
anisotropy measurements were carried out at room temperature with a Perkin-Elmer LS50B 
spectrofluorimeter at an excitation and emission wavelengths of 400 nm and 425 nm, respectively. 
The A value of the all formulations was calculated according to the following equation:  
 
A = [(IVV-IVH) x G] / [IVV + (2IVH x G)] 
 
where IVV and IVH are the parallel and perpendicular intensities, respectively, of the emitted 
fluorescence, compared to the direction of the vertically polarized excitation light. G is the grating 
correction factor representing the ratio between the vertically (IHV) and the horizontally (IHH) 
polarized emission when the excitation light is polarized in the horizontal direction. [6] (Figure.4) 
 
 
 
Figure. 4 
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	- Polarity and microviscosity 
 
The fluorescence experiments on NBs® loaded with Pyrene probe were carried out to evaluate the 
polarity and microviscosity of the bilayer in the vesicles. By fluorescence measurements is possible 
to investigate about the lateral distribution and the mobility of membrane compounds. 
Pyrene is a florescence probe, with a spectrum characterized by five emission peaks as monomer 
(from I1 to I5) and one as excimer (IE). (Figure. 5) 
 
 
 
Figure. 5 
 
 
The monomer and the excimer have different fluorescence signals and the ratio between the several 
fluorescence intensities is directly related to the probe distribution in the bilayer. In particular, the 
ratio I1/I3, corresponding to first and third vibration bands of pyrene spectrum, is related to the 
polarity of the probe environment. At low value of this ratio correspond to a non-polar environment, 
so the information obtained from this study refers to the bilayer of the vesicles pigeon-hole. [7] 
Pyrene can form intramolecular excimer based on the viscosity of the probe microenvironment [8], 
and it is estimated with the ratio IE/I3, where IE is the excimer intensity.  
 
1.8. Probes loaded NBs® 
 
In order to demonstrate the ability of NBs® to entrap drugs and gas, simultaneously, calcein 
(hydrophilic probe) and nile red (hydrophobic probe) were included within the NBs®. 
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	NBs® charged with the fluorescent probes were characterized in terms of acoustic efficiency, 
comparing it with that of the NBs® as such. 
 
 
 
2. Results 
 
2.1. Size, size distribution and z-potential 
 
The dimensions of NBs®, according to DLS measurements, are around 130-260 nm and the surface 
charge, expressed as the z-potential value, is from weakly to markedly negative (-4 / -71 mV). 
(Table. 2) 
 
 
Sample Dimensions (nm) ± SD z-potential (mV) ± SD PDI 
DMPC NBs® 151.90 ± 3.55 -4. 35 ± 0.15 0.20 
DMPC-DCP NBs® 130.10 ± 2.20 -70.90 ± 1.60 0.20 
DPPC NBs® 166.00 ± 1.88 -15.70 ± 0.57 0.10 
Span20 NBs® 243.30 ± 3.70 -41.90 ± 1.82 0.12 
 
Table. 2 
 
 
The PDI of all samples is always below 0.25, generally 0.2 or less. In particular, a vesicular 
suspension with a monodisperse population probably will behave uniformly both during storage and 
after administration in vivo in the distribution and cell internalization stages. 
 
2.2. NBs® acoustic efficiency 
 
Since NBs® are systems full of gas dispersed in a liquid, they act as diffusion (scattering) centers 
for an elastic wave propagating in the liquid and incident upon them. 
The acoustic efficiency of gas trapping within the NBs® was evaluated using pulse-echo technique. 
Figure 6 shows the change in attenuation, expressed as dB/cm at the frequency of 14 MHz, with the 
variation of DMPC NBs® and Span20 NBs® concentration.  
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Figure. 6 
 
 
There is a linear variation of the attenuation with the increase of NBs® concentration.  
Phospholipid NBs® (DMPC, DPPC and DMPC-DCP) show the maximum attenuation values (at a 
NBs® concentration in hepes of a little less than 40%) around of 18 dB/cm and surfactant NBs® 
(Span20) of 6-8 dB/cm. 
The obtained results show that the diagnostic power of NBs® is comparable or higher compared to 
micrometer-sized contrast agents SonoVue® (around 5-6 dB/cm) measured for the same quantity of 
micro- and nanobubbles in suspension. (Figure. 7) 
 
 
 
Figure. 7 
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	In addition, the frequency spectrum of the US signal attenuation shows that the US frequencies 
increases with the increase of Span20 NBs® concentration in hepes, reaching maximum values at 
the frequency range between 22 and 24 MHz. (Figure. 8) 
 
 
 
Figure. 8 
 
 
2.3. NBs® morphology 
 
- By SAXS analyses  
 
SAXS measurements show spectra having characteristic peaks corresponding to the internal 
distance within the particles, providing information about their local structure. 
As shown in the figure 9, the intensity profile of DMPC NBs® (line red) is quite different compared 
to a typical DMPC bilayer (line blue), mainly in the low q region.  
It is possible to recognize the form factor of the DMPC bilayer, superimposed to the form factor of 
a nanobubble, with hard interface between air and lipids (characterized by the q-4 intensity decay).  
In addition, the system results quite unilamellar, as no multilamellar structure peaks appear in the 
region q = 1 nm-1, and the size range of the NBs obtained by DLS measurements is confirmed. 
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Figure. 9 
 
 
In figure 10 is represented the hypothetical structure of the NBs®, according with SAXS 
measurements.  
 
 
 
Figure. 10 
 
 
The NBs® are characterized by an apolar double layer or bilayer membrane, containing an internal 
compartment in which an aqueous layer and the gas coexist.  
The presence of a lipophilic double layer stabilizes the structure of the NBs® preventing the escape 
of the gas contained within them, as after confirmed by stability studies.  
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	In addition, the lipophilic double layer may contain compounds of a lipophilic nature and the 
aqueous layer located between the lipophilic double layer and the central gaseous portion may 
contain compounds of a hydrophilic nature. 
 
- By Cryo-TEM analyses 
 
The morphology of NBs® was evaluated by Cryo-TEM analyses (Figure 11 and 12), in addition to 
SAXS studies.  
The images allow to evaluate the shape and dimension of different NBs®. 
 
 
 
Figure. 11 The image show the average of 5 tomographic slices of the DMPC NBs®. Scale bar 
200nm. 
 
200	nm 
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Figure. 12 The image show the average of 5 tomographic slices of Span20 NBs®.  
Scale bar 100nm.  
 
 
The dimensions obtained for all samples confirm the results acquired by DLS and SAXS 
measurements. In addition, all prepared NB® seemed to have a spherical shape.  
 
2.4. NBs® stability studies 
 
- Stability studies over time 
 
Stability tests surprisingly have proved that the NB® are extremely stables, as established by the 
DLS analysis, SAXS analysis and pulse echo analysis. 
Stability analyses of NBs® were assessed in terms of changes in dimensions and surface charge 
over a time interval of approximately 3 months at two different storage temperatures. (Figure. 13) 
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Figure. 13 
 
 
This study shows that the samples are stable up to 90 days at both storage temperatures because no 
significantly changes are assessed in the parameters investigated. 
SAXS measurements show that the morphology of NBs® containing gas are still stable after 30 
days. (Figure. 14 and 15) 
 
 
 
Figure. 14 
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Figure. 15 
 
  
Also, the acoustic efficiency of the NB® are measured as a function of time and it was found that 
they are capable of maintaining their acoustic properties unchanged after storage for three months, 
as established comparing the attenuation measured at the first day and after 90 days. (Figure. 16) 
 
 
 
Figure. 16 
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	The NBs® tested are stable in terms of maintaining dimensions and ζ-potential, persistence of 
acoustic signal and gas retention very much better than that of commercial products. 
For example, SonoVue® diluted according to the manufacturer’s specifications and measured using 
the same technique, it is found that the latter’s stability is reduced after approximately 100 hours, as 
evaluated by pulse-echo (Figure. 17) and photoacoustic (Figure. 18) measurements. 
 
 
 
Figure. 17 
 
 
 
Figure. 18 
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	- Stability studies in the biological fluids 
 
NB® are also stable for at least 180 minutes at temperatures simulating in vivo conditions (37°C and 
40°C) and for 180 min in the presence of 45% (v/v) of human and bovine serum. 
From the data shown in figure 19, it is clearly evident that the NB® are stable if placed in contact 
with human and bovine serum over the investigated time interval. 
  
 
 
 
Figure. 19 
 
 
Furthermore, the NB® are stable in terms of acoustic efficiency at temperatures simulating in vivo 
conditions (37°C and 40°C) up to 180 min., as shown in the figure 20. 
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Figure. 20 
 
 
 
2.5. Bilayer characterization 
 
In order to deep characterize the nature of the NBs® bilayer, fluidity, polarity and microviscovity 
have been evaluated.   
Fluorescence anisotropy data indicated that the vesicular bilayer is quite rigid and the values 
obtained are similar comparing vesicle with and without gas. (Table. 3)  
Furthermore, the data obtained in terms of polarity and microviscosity showed no significant 
change on the bilayer features in presence of gas inside the vesicles. 
  
 
Sample Fluidity  Polarity 
(I1/I3) 
Microviscosity 
(IE/I3) 
DMPC vesicles without gas 0.27 1.09 0.58 
DMPC NBs® 0.25 1.05 0.44 
DMPC+DCP vesicles without gas 0.26 1.06 0.47 
DMPC+DCP NBs® 0.24 1.07 0.43 
Span20 vesicles without gas 0.23 0.93 0.24 
Span20 NBs® 0.24 0.95 0.32 
 
Table. 3 
51
	These results point out that the gas in the all samples remains trapped in the inner core without 
conditioning the membrane properties, confirming the results obtained by morphology studies. 
 
2.6. Fluorescent probes loaded NBs® 
 
NBs® are capable to load both hydrophobic drugs in the double layer and hydrophilic drugs in the 
aqueous layer, along with gaseous compound, and are therefore potentially capable of being used in 
the therapeutic, diagnostic and theranostic fields. 
A hydrophilic fluorescent probe (calcein) and a hydrophobic one (nile red) have been loaded in the 
NBs®, in addition to the gas, to evaluate if physical chemical properties and/or stability remained 
unchanged. 
The Span 20 NBs® charged with the fluorescent probes were characterized in terms of acoustic 
efficiency, compared to Span20 NBs®, as shown in figure 21. 
 
 
 
Figure. 21 
 
 
Therefore, the co-loading of probes does not have affect the acoustic efficiency of the NBs®. 
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	2.7. Comparison between NBs® and MBs® 
 
The efficiency of trapping gas within the NBs® is also evaluated using a photoacoustic technique 
and the obtained results are compared with those obtained by SonoVue® evaluation. (Figure. 22) 
 
 
 
Figure. 22 
 
 
1.4 ml of SonoVue® solution were diluted in 7.68 ml of distilled water causing relative variations in 
vibration amplitude for the first and second resonance frequencies of the photoacoustic cell equal to 
(∆A1/A1)SV  0.77  and (∆A2/A2)SV  0.48, respectively. (Figure. 22 panel a)  
Instead, 0.7 ml of NBs® in 7.68 ml of hepes buffer generated a relative variation in vibration 
amplitudes at the two resonance frequencies of (∆A1/A1)NBs  0.54 and (∆A2/A2)NBs  0.33, 
respectively. (Figure. 22 panel b) 
Because the measured values for the NBs® were approximately 30% lower than those obtained with 
SonoVue®, the greater capacity for trapping gas within the NBs® must therefore be estimated to be 
30% greater than SonoVue®, for the same volume of micro/nanobubbles dispersed in the liquid. 
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	3. Conclusions 
 
The NBs® prepared are able to overcoming the limitation of existing UCAs in that they are more 
stable over time and extremely homogenous in shape and dimensions. 
NBs® have the following advantages: 
- nanometric-sized dimensions; 
- a double layer of a lipophilic nature made up of amphiphilic molecules; 
- the materials used for their preparation and the gas are not toxic; 
- stability in terms of acoustic efficiency, in aqueous solution at a storage temperature of 25 
and 4°C (at least 3 months), at temperatures simulating in vivo conditions (37 and 40°C) up 
to 180 min and also in the presence of human and bovine serum for 180 minutes at a 
temperature of 37°C; 
- not need to make use of preservative and reconstitution techniques such as lyophilisation 
and subsequent dehydration and the addition of gas. 
The possibility of adding both water-soluble and fat-soluble therapeutic and/or diagnostic agents to 
the NBs® according to the invention makes it possible to produce vectors for use in diagnostic, 
therapeutic and theranostic applications. 
In particular, these characteristics allow them also to be used when applied to pediatric and 
veterinary diagnostics, in particular small animals, avoiding the risk of the formation of 
microembolisms which might occur following the use of micro- or nano-sized bubbles which do not 
have uniform dimensions. 
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1. Introduction  
 
As previously reported, brain delivery of drugs in the treatment of neurological diseases is mainly 
restricted due to the blood-brain barrier. 
Recently, the possibility of the non-invasive localized opening of BBB by using focused ultrasound 
(FUS) exposure, in conjunction with systemically administered microbubbles (MBs) have attracted 
great attention as a new method to deliver active compounds to the brain. [1] 
Several researchers have established that the administration of MBs can effectively reversibly open 
the BBB, without damaging the brain tissue. [2, 3]  
Moreover, the use of FUS allows to target specific brain regions through the employment of 
stereotaxic coordinates and image guidance. [4] 
When an appropriate US pressure is applied in presence of injected MBs, the signal intensity of 
Magnetic Resonant Imaging (MRI) increase in the focal volume, due to the BBB disruption. The 
intensity is maximal immediately after the FUS applied and proportional to the applied pressure 
amplitude. Instead, only a small increase of the MRI intensity is observed without the injection of 
MBs. [5] 
The cellular mechanism that causes BBB opening is still unknown, but probably it is thought that 
when FUS is applied in presence of MBs systemically administrated, inertial cavitation is induced, 
due to the rapid expansion and violent collapse of bubbles. This can cause the temporal distension of 
tight junctions with a consequent increase of endothelial porosity and vascular permeability 
(sonoporation) and an increase of drug intracellular uptake. [6] 
Commercially available microbubbles (MBs) show inert gaseous cores coated by a lipid or albumin 
monolayer shell. These systems are used only as contrast agent in ultrasound imaging. However, 
clinical application is limited mainly due to their size (1-10 µm), preventing the extravasation out of 
the blood pool into brain, and short half-life in the systemic circulation. [7] 
The new formulated nanobubbles® (NBs®) combine the characteristic of drug delivery systems and 
of contrast agents (theranostic system).  
In fact, these vesicles are able to entrap drugs not bioavailable to target site of action, limiting their 
toxicity and adverse effects, to protect the drugs from degradation phenomena and finally to improve 
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	UCAs stability in the systemic circulation. 
1.1. Aim 
The aim of this work is the evaluation of the effect on the BBB opening by using different UCAs in 
terms of size and shell composition.  
In particular, the commercially available MBs, SonoVueâ, phospholipid (DMPC) and surfactant 
(Span20) NBsâ were employed. 
The BBB permeability induced by FUS in conjunction with SonoVueâ/NBsâ injection was confirmed 
by the presence of Evans blue (EB) dye in the brain parenchyma. 
FUS-induced BBB opening was studied in two different experiments in order to (1) determine the 
spread of dye into the brain after DMPC/Span20 NBs injection, (2) the time period of BBB opening 
after sonication using different sized UCAs and finally (3) analyse the spread of fluorescent dye 
calcein (as hydrophilic model drug molecules) deposition through BBB openings to confirm the 
ability of these carrier as drugs delivery systems. 
 
 
2. Materials and methods 
 
2.1. SonoVueâ 
 
Commercially available microbubbles, SonoVueâ (Bracco Diagnostics Inc., Milan, Italy), is 
composed of a phospholipid monolayer membrane composed by distearoyl-phosphatidylcholine 
(DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG·Na), and palmitic acid. The gas 
encapsulated within the lipid shell is a sulphur hexafluoride gas.  SonoVueâ have a mean diameter of 
3.0-4.5 µm and a concentration of approximately 5.0-8.0x108 bubbles/ml (as per manufacturer’s 
guidelines). 
Toxicology studies performed by manufacturer indicated that a single dose administered up to 
20ml/kg in humans, rats and monkeys does not show adverse side-effect. 
 
 
2.2. Bubblesomesâ 
 
For these experiments, DMPC and Span20 NBsâ are used. The preparation and characterization of 
both samples has been previously reported.  
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NBsâ containing the fluorescent probe calcein have been prepared in order to investigate the passage 
of a hydrophilic model drug across the BBB.  
 
2.3. NanoSight measurements 
 
In order to establish the volume of NBs® to inject in the mouse, the concentration of NBs® was 
calculated by using a NanoSight device.  
The NanoSight works using laser diffraction by scattering off particles within the solution, to 
determine their size distribution and concentration. The scan works at a frequency of 16 MHz using 
a dynamic image probe. 
 
2.4. Mice 
 
HSD2.BKO mice were generated by crossing 11-HSD2flx/flx mice (Artemis Pharmaceuticals, 
Cologne, Germany) with a Cre mouse line driven by the Nestin promoter [8], (Nestin is expressed in 
proliferating CNS cells).  
Studies were carried out in strict accordance with the UK Home Office Animals (Scientific 
Procedures) Act, 1986 and the European Communities Council Directive of 24 November 1986 
(86/609/EEC) and were assessed by the University of Edinburgh Ethical Review Committee.  
All experiments were performed blind to genotype on male mice using littermate controls. 
Only nestin.cre-HSD2f/f - cre negative mice were used in this study. 
 
2.5. BBB opening protocol 
 
All animal procedures were performed in accordance with the guidelines of our institutional animal 
committee.  
Each mouse was anesthetized with Isoflurane (Isofloâ, Abbott) and placed prone with its head 
immobilized by a stereotaxic apparatus (Figure. 1). 
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Figure. 1 
 
 
The fur on top of the head was removed using a depilatory cream and an ointment was applied on the 
eye to protect it during the surgery.  
The FUS transducer was placed on the intact scalp and skull of the mouse and the ultrasound coupling 
gel was used to eliminate any remaining impedance mismatch between the two surface. 
A single-element FUS transducer (central frequency: 3.5 MHz; focal depth: 5.5 mm) was driven by 
a function generator through a 50dB power amplifier to generate the FUS beam. The focus of the 
ultrasonic field was positioned to the desired region with its beam axis perpendicular to the surface 
of the skull. 
SonoVue® or DMPC/Span20 NBs® and Evans Blue (3 µl/mg) were injected via the tail vein of the 
mouse. Immediately after, pulsed FUS (peak-rarefactional pressure: 2.1 MPa; pulse length 35.000 
cycles at 10Hz; voltage 1 Vpp) was applied, once in each mouse brain, for 3 shots. Each shot consisted 
of 55 second of sonication with an interval of 5 second between each shot to allow the heat to 
dissipate.  
After 48 hours, animals were sacrificed and the brain was extracted. The brain specimens were placed 
in 10% buffered formalin to allow the fixation time. A cryostat was employ to obtain several sections 
of the brain intended to histological and fluorescence analysis. 
 
2.6. Evans blue dye extravasation 
 
To evaluate the integrity of the BBB, after FUS application in conjunction with SonoVue® or 
DMPC/Span20 NBs®, Evans Blue (EB) extravasation was examined.  
EB dye has binding affinity to serum albumin that, in the normal condition, it cannot across the BBB. 
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However, when BBB was opened, EB-tagged albumin extravasated from vasculature into the brain 
tissue. Consequently, the accumulation of EB dye could be quantified after extraction from the brain 
tissue using fluorescence imaging method. 
 
2.7. Fluorescence analysis 
 
Coverslips with anti-fade reagent DAPI (4’,6’-diamidino-2-phenylindole – a nuclear marker) were 
applied on the slide with the brain slide treated with calcein loaded DMPC/Span20 NBs® and EB dye. 
Glass slides were examined with a Zeiss confocal scanning laser microscope. Green fluorescence 
(calcein) was observed with a filter set at excitation and emission wavelengths of 492 and 520 nm, 
respectively. 
 
2.8. Histological analysis 
 
The brain matrix slices were paraffin processed, embedded and sectioned, according to standard 
procedures. Resulting sections were stained by haematoxylin and eosin (H&E). H&E-stained sections 
were analysed for histopathologic hallmarks of brain injury (haemorrhage, edema, inflammatory cell 
infiltrate). 
 
2.9. Statistics 
 
All data has the mean plotted ±SEM. The significance is calculated using an unpaired T-test unless 
otherwise stated. 
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	3. Results 
 
3.1. NBsâ concentrations  
 
All sample concentrations are shown in the Table 1, the concentration of SonoVue® is provided from 
the manufacturer. Each NBs® have been diluted (1x105) in order to inject a number of bubbles to that 
of SonoVue®.  
The final column shows the volume of each UCAs injected into the animal. 
 
 
Sample Dilution 
Concentration 
(bubbles/ml) 
Volume injected 
(µl/mg) 
SonoVue® - 5.0-8.0 x 108 0.3 
DMPC NBs® 
- 2.0-3.0 x 1013 
0.5 
1 x 105 2.0-3.0 x 108 
Span20 NBs® 
- 2.0-4.0 x 1013 
0.4 
1 x 105 2.0-4.0 x 108 
DMPC NBs®+calcein 
- 2.14 x 1013 
0.7 
1 x 105 2.14 x 108 
Span20 NBs®+calcein 
- 1.26 x 1013 
1.2 
1 x 105 1.26 x 108 
 
Table. 1 
 
 
3.2. In vivo opening of the BBB using NBsâ 
 
Figure 2 illustrates the total inspection profiles of the brain tissues, 48 hours after the sonication. The 
extravasation of EB dye bound to albumin - blue coloration spot - was observed in the brain to the 
unaided eye and it indicated that BBB was successfully opened by the combination of FUS and 
Span20 NBs® (A) and with DMPC NBs® undiluted (B) and diluted (D). For the mouse brain tissue 
treated with Span20 NBs® diluted (C), blue coloration spot was not visible, probably due to no BBB 
destruction. 
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Figure. 2 EB dye extravasation in the brain tissues after FUS exposure of mouse treated with 
Span20 NBs®, undiluted (A) and diluted (C), and with DMPC NBs®, undiluted (B) and diluted (D). 
 
 
The mouse brain tissue treated with Span20 NBs® (A) shows an EB dye extravasation more 
significant compare to DMPC NBs® (B and D). 
In particular, for the mouse brains treated with DMPC NBs®, the blue spot in the picture D (NBs® 
diluted) seemed to be more intensive compared to picture B (NBs® undiluted). 
 
3.3. Histological assessment 
 
The histological analysis (Figure 3, 4 and 5) - to detect the tissue injury in the brain – shows that no 
erythrocyte or haemorrhages were observed in the brain treated with Span20 NBs® (a) (n=4).  
Moreover, this analysis had confirmed that the surfactant NBs® diluted (c) did not open the BBB (no 
white shadow nearby to the BBB) (n=3). 
Instead, following the injection of phospholipids NBs® with different concentrations, the effect on 
the brain tissue was varying. A few erythrocyte extravasations (red spots on the brain parenchyma) 
were observed in the brain tissue treated with DMPC NBs® (b) that it does not appear to cause tissue 
necrosis (n=4). Whereas the histologic finding for the sample of DMPC NBs® diluted (d) suggest a 
high degree of tissue damage (n=4). 
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Figure. 3 Histology examination of brain tissues of mice sonicated using FUS with Span20 NBs®, 
undiluted (a) and diluted (c), and DMPC NBs®, undiluted (b) and diluted (d) (x4 magnified region). 
 
 
 
Figure. 4 H&E staining of the brain sections treated with Span20 NBs® undiluted (a) and DMPC 
NBs®, undiluted (b) and diluted (d) compared with the control (x4, x10 and x20 magnified region). 
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Figure. 5 Histology of the brain sections treated with DMPC NBs®, undiluted (b) and diluted (d) 
after H&E staining (x2 magnified region). 
 
 
3.4.  Volume of Evan's Blue into the brain following FUS disruption 
 
In order to evaluate the effect of different UCAs on the BBB opening, the different sized contrast 
agents have been employed using the same parameters previously mentioned. In particular, 
SonoVue® and Span20 NBs® have been injected in the mice and, following the sonication, the EB 
dye spread were observed into the brain of the mice euthanized after 24hours. (Figure. 6) 
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Figure. 6 Spread of EB following BBB disruption: In the panel (A) is shown the spread of Evan's 
Blue dye on the coronal brain sections (thick=1mm) of 4 mice treated with MBs® and NBs®. Panel 
(B): the percentage of area covered in the brain of EB dye was calculated through the overlay of a 
grid. Panel (C): the graph shows that the spread of dye following BBB disruption using SonoVue® 
or Span20 NBs® is no different. 
SonoVue® mean = 53.25 SEM +- 1.75 (n=4); Span20 NBs® mean =54.25 SEM +- 9.322 (n=4). 
 
 
The spread of EB observed appear very similar between the NBs and MBs. Using 4 mice for each 
UCAs, the spread of dye was calculated by using a grid, whereby the dyed regions were divided by 
the total brain section in order to calculate the percentage of dye covered regions (outline in figure 6 
A by red dashed lines). The percentage of spread of dye was plotted as a percentage (figure 6 C), 
showing there was no difference between the MBs and NBs on BBB disruptions. 
 
 
3.5. BBB closing after FUS application 
Time needed by BBB closing, after FUS application, was assessed. Initially, 24 hours were the time 
point chosen to confirm the BBB closing. The BBB was opened using FUS with both SonoVue and 
Span20 NBs, and the EB dye was administered 24h post sonication. No dye was observed in the brain 
at the 24h time point indicating that the BBB was completely closed (n=3). (Figure 7) 
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Figure. 7 Brain sections 24h post BBB opening (n=3). 
 
After, shorter time points were then evaluated at 0, 3, 6, 9 and 12 hours to identify how long the 
BBB is opened following disruption. (Figure. 8) 
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Figure.8 Duration of BBB opening after sonication. The BBB was opened using either SonoVue® 
(n=5) or Span20 NBs® (n=5) and at time point 0, 3, 6, 9 and 12-hour time points Evan's Blue dye 
was injected into the tail vein. 
 
EB dye entering the brain over the 12h but with reducing volumes entering as time progresses due to 
the barrier closing. At the 12h time point, the BBB is fully closed in the brain treated with the NBs 
and almost fully closed with MBs.  
Therefore, the opening of the BBB is prolonged with the SonoVue® compare to Span20 NBs, despite 
the volume of the EB dye entering over 24 hours not being different between the two UCAs. 
 
3.6. Volume of calcein delivered into the brain 
In order to demonstrate the ability of DMPC/Span20 NBs® to deliver drugs into the brain, the spread 
of fluorescent dye calcein (as hydrophilic model drug molecules) deposition was analysed. 
In this experiment, the NBs were used as a carrier to deliver calcein into the brain, where it is then 
released from the bubble into the surrounding brain tissue, after FUS application. 
Calcein loaded DMPC/Span20 NBs® were injected in the mice, in both concentrations (undiluted and 
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diluted) with EB dye and after 48 hours, to allow the calcein diffusion, the brain tissues were 
collected. (Figure. 9)  
 
 
 
Figure. 9 EB dye extravasation in the brain tissues after FUS exposure treated with Span20 NBs®, 
undiluted (E) and diluted (G), and with DMPC NBs®, undiluted (F) and diluted (H). This was a 
pilot study (n=1) to confirm the optimum concentration to elicit BBB opening.  
 
 
The EB extravasation was clearly visible for all brain treated with NBs®, in particular, it is greater 
for the undiluted NBs® (E and F) compare to diluted (G and H).  
Finally, in order to evaluate the volume of calcein delivered into the brain, the mice were treated with 
both NBs formulations undiluted.  
The presence of the calcein (green) in the brain parenchyma was visualized at the 488nm wavelength 
by using Azioskop microscope. (Figure. 10 A). 
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Figure. 10 Panel (A) Calcein release after FUS application in the brain treated with DMPC NBs® 
(n=5) and Span20 NBs® (n=5). Green: calcein; Red: EB; Blue: DAPI. Scale bars = 100µm. Panel 
(B) Quantification of calcein across the 5 brains for each brain. DMPC NBs® mean = 15.1 SEM ± 
2.304 (n=5). Span20 NBs® mean 34.327 SEM ± 1.44 (n=5). Statistical analysis = Unpaired T-test 
P=0.0002 *** F=2.562. 
 
 
The volume of calcein was calculated using ImageJ software quantifying the green fluorescence 
averaged over five regions for five brains. (Figure. 10 B)  
In particular, the brain section treated with Span20 NBs® (B) shows a major spread of calcein compare 
to the brain section treated with DMPC NBs® (A). 
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4. Discussion 
 
The use of focused ultrasound in conjunction with microbubbles has been demonstrated by several 
groups to successfully induce BBB opening noninvasively, locally and reversibly.  
Unfortunately, the in vivo studies with drug-loaded microbubbles are mainly restricted to 
cardiovascular targets and to tumour endothelia due to some their characteristics, e.g. the large size, 
rather short half-life (in the order of minutes) and after the injection their instability in the systemic 
circulation.  
To solve this problem, two new formulations of NBs are designed, DMPC and Span20 NBs®, which 
have smaller size and longer stability over time. These NBs show the advantage to deliver therapeutic 
agents of different nature (lipophilic and hydrophilic) and to obtain an ultrasound triggered drug 
release and permeabilization of cell membranes, simultaneously. 
In this study, DMPC/Span20 NBs® are used to achieve BBB opening after FUS application and 
calcein-loaded DMPC/Span20 NBs® were applied to demonstrate targeted drug delivery into the 
brain after FUS-induced BBB opening in the mice. Furthermore, the NBs® behaviour, after the FUS 
application, is compared to SonoVue®, a commercial contrast agent.  
It is interesting to note that the DMPC NBs®, diluted to achieve the same number of bubbles/ml of 
SonoVue®, show a greater BBB disruption, while Span poor or no BBB opening.  
After FUS application, the two formulations show opposite behaviour based on different 
concentrations used: in the brain treated with the Span20 NBs®, a decrease of the EB extravasation 
is assessed with the increase of sample dilution, whereas, in the mice treated with DMPC NBs®, the 
dilution of the sample leads a higher power of BBB disruption compared to undiluted sample. These 
differences could be caused by the smaller size and higher attenuation of DMPC NBs® in comparison 
to Span20 NBs®. Probably when the sample of DMPC NBs® was diluted and exposed to FUS, the 
oscillating bubbles had more space to oscillate with resulted to generate a larger stress on the BBB 
than the sample undiluted.  
The data suggest that EB extravasation of the brain treated with SonoVue® and Span20 NBs® are 
comparable in terms of concentration, but there is a difference in the time it takes for the BBB closing. 
In particular, the BBB is fully closed after 12 hours in brains treated with Span20 NBs®, instead, at 
the same time in the brain treated with MBs still is observed EB dye to investigate whether FUS-
targeted NBs® cavitation could deliver drug into the CNS following BBB disruption, calcein-loaded 
DMPC/Span20 NBs® are injected into the mice intravenously, previous FUS application.  
Calcein is a water-soluble polyanionic fluorescein derivative used as a fluorescent indicator in drug 
release studies.   
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	Fluorescence analyses show that the two formulations are able to spread calcein after FUS 
application, confirming the capability of these carriers to release therapeutic agents across the BBB. 
In particular, the formulation Span20 NBs® shows a higher calcein release than DMPC NBs®.  
 
5. Conclusions 
 
The in vivo experiments demonstrate that ultrasound-mediated DMPC and Span20 NBs® destruction 
has the potential to open the BBB tight junctions and trigger therapeutic agent deposition in the brain. 
It can be concluded that the NBs® formulated are a promising tool for both ultrasound imaging and 
drug delivery. 
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	1. Bubblesomes® as theranostic agent 
 
Bubblesomes® have been formulated in order to obtain a theranostic agent, therefore a system which 
provides diagnostic support and therapeutic treatment.   
Since Bubblesomes® can reflect the ultrasound, it should be possible not only to localize the drug 
release but also providing an image of this process and facilitating access of the drug to its target 
through cavitation mechanism.  
In previous studies, the ability of NBs® to entrap the gas and the hydrophilic (calcein) or hydrophobic 
(nile red) probes at the same time, maintaining unchanged their acoustic efficiency and physico-
chemical properties, have been already demonstrated. 
Afterwards, different drugs were entrapped in the NBs® and their theranostic potential application 
was evaluated in terms of drug entrapment efficiency, morphology and acoustic attenuation. 
NBs® have been loaded with two active compounds: 
v Hydrophobic compound: Curcumin is a natural compound extract from the rhizome of Curcuma 
longa Linn., with several biological activities, including antioxidant, anti-inflammatory, anti-
infective, anti-cancer and amyloid-β-protein inhibitor (for Alzheimer's treatment). [1] In addition, 
same reviews have shown the neuroprotective effects of curcumin against brain injury after 
intracerebral haemorrhage-induced BBB disruption in animal models. [2, 3] 
This effect can be helpful for BBB reconstruction after the FUS application after NBs® 
administration. 
Despite of the wide range of activities, the pharmaceutical application of curcumin is limited due 
to its physicochemical characteristics such as poor water solubility, low bioavailability, 
photodegradation, chemical instability and short half-life.   
v Hydrophilic drug: Pentamidine isethionate (for further details see paper (submitted): 
Pentasomes for delivery of pentamidine to CNS by intranasal route). 
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	2. Experimental section  
- Entrapment Efficiency 
 
The concentrations of curcumin and pentamidine in the NBs were determined by UV-Vis 
spectroscopy (Perkin-Elmer, lambda 3a) by dissolving the curcumin in a hydroalcoholic solution and 
pentamidine in hepes buffer. 
Spectrophotometric analyses were carried out at 425 nm for curcumin and 270 nm for pentamidine. 
The % entrapment efficiency (%EE) was calculated by applying the equation:  
 
EE% = [(Concentration of drug determined) / (Total concentration of drug loading)] X 100 
 
 
3. Results 
 
Drug-loaded NBs® are prepared as previously reported. Curcumin (2.5 mg/ml) is dissolved with the 
other hydrophobic components at the first step of NBs® preparation, instead Pentamidine (5mg/ml) 
is solubilized in hepes buffer and added to the formulation during the hydration step. 
After the NBs® preparation, the EE% is evaluated by UV-Visible spectroscopy.  
As shown in the table 1, both NBs® formulations show an excellent drug encapsulation efficiency.   
 
 
Sample EE% Concentration (mg/ml) 
DMPC-DCP NBs®+Curcumin 95  2.3 
DMPC-DCP NBs®+Pentamidine 70 3.5 
 
Table. 1 
 
 
Moreover, the efficiency of trapping gas within the NBs® in presence of different drugs was evaluated 
by comparing the NBs® without and within drugs (Figure. 1 and 2, respectively), in term of acoustic 
efficiency. 
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Figure. 1 Acoustic efficiency graph of DMPC-DCP NBs®. 
 
 
 
 
Figure. 2 Acoustic efficiency graphs of different drugs loaded DMPC-DCP NBs®. 
 
 
As shown in figures 1 and 2, the attenuation is similar for all examined samples, confirming that the 
co-entrapment of gas and drug does not affect the acoustic efficiency of NBs®. 
SAXS measurements were employed to examine the morphology of drugs loaded NBs®. (Figure. 3)  
The intensity profile of DMPC-DCP NBs® (the black line) shows the typical characteristics of a single 
double layer, since there are no peaks indicating a multilamellar structure in the region q=1 nm-1.  
In presence of PFC, the intensity profile changes drastically, in particular in the low q region (the red 
line). The trend of q-4 intensity decay is typical of interface between air and lipids, confirming the 
presence of nanobubble structures. 
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Figure. 3 SAXS analysis of DMPC-DCP NBs® compared to the vesicle without gas. 
 
 
In presence of drugs, the nanobubbles structure is confirmed by the presence of q-4 intensity decay. 
(Figure. 4) 
In the case of pentamidine (the green line), the peaks in position of q = 0.98-1.96-2.94 nm-1 indicate 
the presence of lipid multilayer with an interlamellar distance of 6.4 nm.  
The presence of curcumin change the membrane contrast profile (the violet line), in particular, in the 
upper q regions, the spectra are different, so it can be assumed that the drug is inserted into the lipid 
membrane.   
 
 
 
Figure. 4 SAXS measurements of different drugs loaded NBs®. 
 
 
All the obtained results confirm the ability of NBs® to co-deliver gas and active compounds.  
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	1. Introduction 
 
The nasal route has been conventionally restricted for delivery of therapeutic agent to the treatment 
of local diseases such as the nasal allergy, sinusitis, nasal infections and nasal congestion.  
Recently, intranasal drug delivery has attracted the interest of many researchers as an alternative 
method to circumvent the BBB and directly reach the brain.  
The intranasal delivery method for drug delivery in to the brain was discovered by Dr William H. 
Frey (1991), and now, it has demonstrated in both animals and humans to be an efficient and safe 
way to deliver exogenous molecules to the CNS. [1, 2, 3 and 4]  
The intranasal route offers several advantages but show limitation for the drug delivery showed in 
the table 1. 
 
 
 
Advantages Weakness 
• Non-invasiveness and safe method 
for drug delivery 
• Improving patient compliance 
compared to other conventional 
routes 
• Fast pharmacological activity onset 
achieved by the rich vascularization 
and high permeability of the 
epithelium of nasal mucosa 
• Large surface area for absorption 
• Presence of porous endothelial 
membrane 
• Avoid hepatic first-pass metabolism, 
enhanced bioavailability 
• Low systemic exposure of drugs, 
reducing side effects 
• Rapid elimination of drug due to 
mucocilary clearance 
• Enzymatic degradation by nasal 
cytochrome P450, proteases and 
peptides   
• Irritation of nasal mucosa 
• Mechanisms of drug transport are 
unknown  
• Individual variability 
 
Table. 1 Advantages and weakness of intranasal delivery. 
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	In spite of limitations, the intranasal delivery of therapeutics offers a non-invasive, safe, practical, 
cost effective and patient agreeable alternative to parenteral or oral route for rapid drug delivery to 
the brain/CNS. [5, 6] 
 
2. Nasal anatomy and physiology 
 
The nose plays an important role to heat, humidify and remove from the microorganisms and 
particles the air inhaled, before it reaches the lungs.  
The nose is divided by the midline septum in two nasal cavities, each cavity has a volume of 13 ml 
and a surface area of 152 cm2. [7] 
It is organized in three regions: the vestibule (anterior and posterior), the respiratory region 
(separated in inferior, middle and superior turbinate) and the olfactory region composed by a 
pseudostratified epithelium formed by several types of cells: ciliated, non-ciliated, basal and goblet 
cells.   
The goblet cells produce a secretion, namely mucus, that supports the mucociliary clearance and is 
structured in two layers on the nasal epithelium is composed by 95% water, 2% mucin, 1% salts, 
1% of other proteins, such as albumin, lactoferrin, lysozymes and immunoglobulins, and less than 
1% of lipids. [8] 
About the 20% of respiratory cells are covered by a layer of mobile cilia and through their 
coordinated movements drive the mucus across the epithelium towards the esophagus and finally in 
the gastrointestinal tract.     
Therefore, the exogenous materials inhaled with the air are trapped by the mucus layer and moved 
through the cilia in one direction only from the nasal cavity to the nasopharynx localized to the 
throat with a speed of 5 mm/min. [9] 
The epithelium of the olfactory region is composed by olfactory neural cells, the sustentacular or 
supporting cells and their progenitors cell, the basal cells. The olfactory neural cells, or axons 
originate from the olfactory bulb and terminate to the olfactory neuroephitelium. Potentially, the 
small molecules could be transported from the nasal mucosa along the olfactory bulb to the brain. 
These neurons terminate to the amygdala, the anterior olfactory nucleus, the entorhinal cortex and 
the hippocampus, the hypothalamus and thalamus. [10] 
Under the olfactory epithelium, the lamina propria contains the blood, the mucus secreted by 
Bowman’s glands, nasal lymphatics and neuronal supply which are composed by the olfactory 
axon, autonomic nerve fibers and the branch of trigeminal nerve. 
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	3. Biofate, nasal pathways and mechanisms involved in the nose to brain delivery 
 
The specific mechanisms underlying the intranasal drug delivery to the CNS are still unknown, but 
several studies demonstrate that four pathways are involved: the vasculature, the trigeminal and 
olfactory nerves and the lymphatic systems. [11] (Figure. 1) 
 
 
 
 
Figure. 1 Pathways for brain targeting after intranasal administration of drugs. 
 
 
Following nasal administration, the therapeutic agent is absorbed from the nasal cavity through the 
mucus. This process is easier for small and uncharged drugs compared to large and charged 
molecules. In particular, the mucin is able to bind solutes and avoid their diffusion. The drugs 
absorption across the nasal epithelium could be obstacle by clearance mechanisms or by the limited 
residence time in the nasal cavity. [12] 
The therapeutic agent can reach the brain through the absorption in the olfactory region, where 
three different pathways are involved for the transport of drug to CNS: 
Ø Olfactory nerve: transports the drug from the olfactory epithelium to the CSF or several brain 
regions, including amygdala, piriform cortex and hypothalamus. [10] 
The internalization mechanisms across the olfactory epithelium are: 
1. Transcellular, by receptor mediated endocytosis or passive diffusion. This way is used for the 
transport of small lipophilic drugs.  
Drug Nasal	Cavity
Olfactory	region
Trigeminal	
Nerves Brain	Tissue
Lymphatics	
pathway
Systemic	
Circulation
CSF
EliminationTissue/Organs
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	2. Paracellular, by diffusion through aqueous pores. It is particularly suitable for hydrophilic and 
small drugs with a molecular weight around 1000 Da or 6000 Da with absorption enhancer. 
3. The olfactory nerve pathway, where the drug permeation is obtained by endocytosis or 
pinocytosis mechanisms and transported through the intracellular axonal transport to the 
olfactory bulb. [13] 
Ø Trigeminal nerve, or the fifth cranial nerve, is the largest nerve of the all cranial nerves and 
innervates the respiratory and olfactory epithelium. Its function is the communication of sensory 
information from the nasal cavity, oral cavity, eyelids and cornea to the CNS. In particular, the 
trigeminal nerve can reach the brain from the nasal epithelium through the anterior lacerated 
foramen and the cribriform plate near olfactory bulb. 
Ø The subarachnoid space containing CSF and the nasal lymphatics are alternative routes for 
brain delivery. The neurotherapeutics are directly delivered to the CSF from the nasal cavity, 
without entering the blood to a significant amount. The fate of this drugs depends of their 
lipophilicity, molecular weight and degree of ionization. [14] In particular, several studies 
highlight a connection between the increase of the lipophilicity or partition coefficient of the 
drug administrated and the increase of drug concentration into the CSF. [15] 
An amount of drug intranasally administrated could be cleared by mucociliary clearance system, 
according to its characteristics like lipophilicity and molecular weight, and absorbed by 
bloodstream. After, the drug could be able to reach the brain and in part eliminate by cerebrospinal 
fluid (CSF).  
 
4. Strategy to enhance nose to brain delivery 
 
One of the major problems associated with nasal administration is the rapid removal of drugs or 
drug delivery system from the deposition site due to the mucociliary clearance. [16] 
Surface engineering of the nanocarrier may be a promising approach to manage the drug delivery 
properties of vesicles with a surface coating with a mucoadhesive agents. This strategy can 
potentially prolong the residence time and the contact between membranes and drug carriers at the 
absorption sites. 
This strategy mainly offers two advantages: the increase of the residence time of the drug carriers in 
the nasal cavity and the slowing down of the mucociliary drainage. [17]  
The mucoadhesion process could be defined as the attachment of the nanocarrier to the mucus and 
involves several mechanisms, like attractive electrostatic forces, diffusion and adsorption.  
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	Several polymers adhere to the nasal mucosa such as sodium carboxymethylcellulose and other 
cellulose-derivates, carbopol®, sodium alginate, chitosan, gelatin, pectin. 
 
4.1. Chitosan 
 
Chitosan (CH) is natural cationic polysaccharide composed by β-(1-4)-linked D-glucosamine and 
N-acetyl-D-glucosamine.  
This polymer is intensively used for pharmaceutical, cosmetic, biomedical and agricultural 
applications. [18] 
It is extracted from the exoskeleton of crustacean treated with an alkaline solution and producted by 
the deacetylation of the chitin. (Figure. 2) 
 
 
 
 
 
Figure. 2 Chitosan synthesis from chitin to chitosan by enzymatic deacetylation.  
 
 
The molecular weight (M.W.) and the degree of acetylation can affect the chitosan interaction with 
the nasal mucosa. (Table. 2) 
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	Type of CH % Deacetylation M.W. (kDa) 
Low 75-85 50-190 
Medium 75-85 250 
High >75 310-375 
 
Table. 2 Different types of chitosan. 
 
 
Chitosan mucoahdesive properties are due to the interaction between its protonated amino groups 
and the sialic acid residues of the mucus layers. [19] 
Furthermore, chitosan is also able to transiently open the tight junctions increasing the permeability 
via receptor-mediated signaling, enhancing the trans-epithelial transport through intercellular 
pathway. This mechanism is still unknown, but probably the chitosan is able to translocate the 
junctional proteins, claudins and ZO-1, from the cellular membrane to the cytosol. [20] 
An interesting therapeutic strategy could be a combination between chitosan induced mucoahdesion 
and nanocarrier characteristics.  
In a study has been shown the effect of chitosan-coated nanoparticles over porcine olfactory 
epithelium. In vitro studies demonstrate that the engineered vesicles were more retained in the 
mucus compared to unmodified equivalents.   
Furthermore, increasing the cationic charge on the coated vesicles, an increase of the interaction 
between particles and mucus was observed.  
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	Aims 
 
The aim of this part of my PhD project has been mainly focused on the formulation and 
characterization of carrier suitable for nose to brain delivery. 
 
In particular, the goals of this project can be summarized in the following points: 
 
ü formulation and physico-chemical characterization of hybrid niosomes in order to obtain a 
muchoadesive formulation by chitosan coating. 
 
All collected data and experimental setup are shown in the paper:  
DLS Characterization of Non-Ionic Surfactant Vesicles. 
 
ü Preparation and physico-chemical characterization of pentamidine-loaded niosomes. In vivo 
studies have been performed to evaluate the effect of pentamidine in a sub-acute MPTP mouse 
model of Parkinson’s disease (PD) after intranasal administration of pentamidine-loaded 
niosomes. 
 
All collected data and experimental setup are shown in the paper (submitted): Pentasomes for 
delivery of pentamidine to CNS by intranasal route. 
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	1. Niosomes  
 
Non-ionic surfactants, namely niosomes, are widely studied as an alternative tool to liposomes. In 
the 1970, niosomes were first reported as suitable ingredients for cosmetic application. [1] 
The main components of these vesicles are nonionic surfactants and cholesterol. Both components 
are self-assembled into an aqueous medium obtaining a closed bilayer structures, due to the high 
interfacial tension between water and hydrophobic tail of the surfactant.  
The main non-ionic surfactant classes used to obtain noisome are alkyl ethers, alkyl esters (such as 
Span® and Tween®), alkyl amides and fatty acids.  
The cholesterol, a steroidal compound, forms hydrogen bonds with the hydrophilic head of the 
amphiphile, influencing bilayer fluidity and permeability and increasing the niosomal blood 
stability. (Figure. 1) 
 
 
 
Figure. 1 Structure of niosomes. 
 
 
Niosomes, as liposomes, are able to entrap hydrophobic drugs in the bilayer and hydrophilic drugs 
in the aqueous core. Their surface may be functionalized in order to acquire a specific targeting or 
to increase the biological or physical stability. 
The main factors playing a critical role in the surfactant self-assembling are: 
Ø The Hydrophilic-Lipophilic Balance (HLB): this value represents the hydrophilic/hydrophobic 
part ratio in the surfactant molecule. Its value ranges from 0 to 20 on an arbitrary scale: values 
between 0-10 are characteristic for more hydrophobic substances, while values between 10-20 
are of hydrophilic substances. 
Bilayer
Aqueous	core
Hydrophobic	drug
Hydrophilic	drug
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	Ø The critical packing parameter (CPP) modifying this parameter nanostructures with several 
shapes will be obtained: [2] 
CPP = V / (a0 x lc) 
where V and lc represent the volume and length of the hydrophobic group, and a0 is the area of 
the hydrophilic heads.  
According with CPP value, the nanostructure shape could evolve in: spherical micelles (CCP ≤ 
1/3), cylindrical micelles (1/3 ≤ CPP ≤ 1/2), bilayers (1/2 ≤ CPP ≤ 1) and inverse micelles (CPP 
> 1). 
In order to increase the structural stability of the niosomes, charged molecules such as dicetyl 
phosphate DCP (negatively charged) and stearylamine (positively charged). are used. They enhance 
the surface charge density preventing the niosomes aggregation. Generally, these molecules are 
added to the niosomal formulation in an amount of 2.5-5 mol%, because a higher concentration 
could prevent the niosomal formation. [3] 
The niosomes can be prepared with several methods such as thin film hydration (TFH), the organic 
solvent injection method, the reverse phase evaporation method and the bubble method.  
Generally, for niosomes characterization the following parameters are evaluated: [4] 
v Size and Morphology: cumulative information about the average particles and the particle size 
distribution can be obtained by dynamic light scattering (DLS) measurements. 
The microscopic techniques (scanning electron microscopy (SEM), transmission electron 
microscopy (TEM), cryotransmission electron microscopy (cryo-TEM) and atomic force 
microscopy (AFM) are used to characterize the nanocarrier in terms of morphology, structure 
and geometry. 
v ζ-potential: the surface charge of nanocarriers play a fundamental role in the in vivo behavior, 
formulation stability and drug/vesicle interaction. A ζ-potential value more positive than 
+30mV or more negative than -30mV prevent the aggregation phenomena. 
v Bilayer characterization: according to sizes and number of lamellae, niosomes can be 
classified in: (1) small unilamellar vesicles (SUV) of 10-100nm; (2) large unilamellar vesicles 
(LUV) of 100-1000nm and multilamellar vesicles (MLV) with two or more bilayers. [5] 
The number of lamellae can be evaluated by small angle X-ray scattering (SAXS) or AFM 
techniques. [6] Membrane fluidity of niosomes is determined through the mobility of a 
fluorescent probe (1,6 diphenyl-1,3,5-hexatriene, DPH) added to the niosomal formulation. By 
fluorescence polarization measurement, the microviscosity of vesicles is evaluated to evaluate 
the packing structure of the niosomal membrane. [7]  
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	v Stability: it is evaluated by DLS in terms of mean vesicles size, ζ-potential, size distribution 
over time at different temperatures.   
Furthermore, the stability in the biological fluids can be evaluated in function of time and 
temperature.  
v Entrapment efficiency (EE): the amount of drug loaded into the niosomes is generally 
expressed as: EE = (entrapped amount / total amount) x 100, where the total amount is the 
loading drug amount and the entrapped amount is the drug entrapped in the niosomes. It is 
generally evaluated by UV/VIS spectrophotometry or high-performance liquid chromatography 
(HPLC). 
 
2. Formulation and physico-chemical characterization of hybrid niosomes 
 
An interesting therapeutic strategy for nose to brain delivery could be a combination between 
chitosan mucoahdesion and nanovesicles characteristics. 
In particular, niosomes are non-ionic surfactant vesicles capable to entrap both hydrophilic and 
lipophilic drugs, minimizing drug degradation and inactivation after administration, and increasing 
drug bioavailability and targeting to the pathological area. [8] 
In the first part this work has been focused on the complexation between negatively charged 
niosomal vesicles and chitosan, a cationic mucoadhesive polysaccharide. 
Three different formulations of unilamellar niosomal vesicles composed by a mixture of Tween 20 
or Tween 21 or Span 20 with cholesterol and dicetyl phosphate (DCP) have been prepared and 
characterized. 
The study of the aggregation behavior between the charged vesicles and chitosan has been carried 
out in terms of size and ζ-potential variation and stability over time of the selected samples. These 
experiments have been performed by dynamic light scattering (DLS) and Laser Doppler 
Electrophoresis measurements. The effect of chitosan charge ratio is investigated and discussed 
within the framework of the re-entrant condensation and charge inversion behavior. [9] 
DLS analyses were carried out to evaluate dimensions and ζ-potential characteristics in order to 
select the most appropriate formulations to be coated with chitosan. 
Span20 niosomes were characterized by a highly negative charge able to form electrostatic 
interactions with the positively charged polysaccharide. DCP was added to Tween 20 and Tween 21 
niosomes in order to support the chitosan coating. 
The aggregation of negatively charged niosomal vesicles in the presence of different amount of 
chitosan was further investigated. 
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	For all samples, the addition of chitosan led to a progressive diameter increase of the complexes, 
starting from a value close to the Z-Average of uncoated niosomes, when only few polycation 
molecules adsorb on the vesicle surface, and growing to larger and larger sizes due to the 
aggregation of chitosan-coated vesicles. At the same time, the ζ-potential value of the hybrid 
niosomes increases adding the polyelectrolyte, approaching less negative values until the point of 
charge inversion (isoelectric point) is reached. This behavior was connected to the progressive 
charge neutralization of the complexes, promoted by the adsorption of positive charges of the 
chitosan onto the negative charges at the vesicle surface. 
Further addition of chitosan promotes the reversal of ζ-potential toward positive values and the 
decrease of the Z-Average of the hybrid niosomes toward lower values. In particular, at this higher 
polyelectrolyte concentration, the hybrid niosomes reach a size similar to the one measured at low 
chitosan concentrations. 
This peculiar behavior is known in the colloid literature as re-entrant condensation and is associated 
to the charge inversion of the chitosan coated vesicles. [10] 
The aggregation mechanism and the formation of stable structures are the results of the balance 
between electrostatic repulsion and short-range effective attraction interactions due to the non-
uniform charge distribution at the particle surface (charge patch attraction). [11] 
In order to check the integrity of the hybrid niosomes during the whole aggregation process, the 
leakage of calcein entrapped in the core of the hybrid niosomal vesicles were monitored. 
The vesicular membranes of all analyzed samples are undamaged while chitosan coating occurs. 
The stability studies were carried out to investigate if significant changes of the size and ζ-potential 
of surfactant vesicle dispersion occur during storage. The uncoated and coated systems are 
characterized by no significant variations of dimension and ζ-potential during the storage period, 
especially if they are maintained at 4°C. 
 
The selected formulations are able to obtain a positively charged hybrid vesicle suspension, stable 
during polymer coating process and during the analyses period.  
The obtained results suggest the potential application of hybrid niosomes to mucosal delivery. 
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Abstract: The aim of this paper is the preparation and characterization of drug delivery systems for a potential brain delivery 
by intranasal administration. It is possible to reach the central nervous system with alternative routes through which therapeutic 
agents can bypass the blood brain barrier: that is the nasal administration. Intranasal drug administration is non-invasive and it 
could be a promising drug delivery method for patients who suffer from chronic and crippling Central Nervous System diseases. 
Among the formulation strategies for enhanced nose to brain drug delivery, the use of colloidal carriers has became a 
revolutionary approach. The success of a therapeutic strategy by using nanocarriers depends on their ability to entrap drugs, to 
penetrate through anatomical barriers, to efficiently release the incorporated drugs, to show a good stability in nanometric size 
range and good biocompatibility. The use of vesicular systems (niosomes), in nose to brain delivery is here presented. One of the 
major problems associated with nasal administration is the rapid removal of drugs or drug delivery systems, from the deposition 
site through mucociliary clearance. This effect is responsible of reduction of contact time between drug or drug delivery systems 
and nasal epithelium. This problem could be solved by coating nanocarriers with a mucoadhesive agent: chitosan. In this paper 
the preparation and characterization of hybrid niosomes by Tween 20 and Tween 21 together with dicetyl phosphate or Span 20 
and the cationic polyelectrolyte chitosan are described in order to obtain intranasal drug delivery systems. In particular through 
dynamic light scattering, laser Doppler electrophoresis and fluorescence measurements the aggregation behavior between 
vesicles and polyelectrolyte can be monitored. Overall phenomenology is well described in terms of the re-entrant condensation 
and charge inversion behavior, observed in different colloidal systems. The physical stability of hybrid niosomes obtained by the 
three different surfactants was also evaluated. 
Keywords: Niosomes, Chitosan, Dynamic Light Scattering, Laser Doppler Electrophoresis, Fluorescence 
 
1. Introduction 
The blood brain barrier (BBB) represents the major obstacle 
to a direct access to the Central Nervous System (CNS) if a 
conventional pharmaceutical approach is used. The tight 
junctions between the BBB cells are responsible of the 
inability to enter into the brain tissue for most compounds, in 
effect the penetration is possible only for the 2% of small polar 
molecules. [1] 
Actually the difficult BBB crossing has limited the use of a 
lot of therapeutic agents in Alzheimer’s disease, stroke, brain 
tumor, head injury, depression, anxiety and other CNS 
disorders treating. It’s possible to reach brain with alternative 
routes through which therapeutic agents can bypass the BBB: 
intracerebroventricular, intraparenchymal, or intrathecal 
administrations, but these routes of administration are 
invasive, risky, and expensive techniques requiring surgical 
expertise especially for multiple dosage regimens. [2] 
Up to a short time ago, the nasal route has been employed 
for therapeutic agents delivery in the treatment of local 
diseases: nasal allergy, sinusitis, nasal infections and nasal 
congestion; actually the interest of many researchers is now 
focused on the nasal administration route in the therapy of 
neurologic diseases in mice, rats, primates and humans. By 
this administration route drugs in fact is possible to reach the 
brain through the olfactory region and respiratory epithelium 
because the olfactory nerve cells and trigeminal nerves are in 
direct contact with both the environment and the CNS. 
Moreover intranasal (IN) route is non invasive, resulting in 
better patient compliance, it doesn’t require sterility 
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requirements or any drug modifications and it has the 
advantage to achieve liver degradation escape (avoidance of 
the first passage effect). Trough nasal administration the drug 
come into contact with nasal epithelium where the enzymatic 
degradation of drugs is lower if compared to that of 
gastrointestinal tract and liver. Anyway, the drug degradation 
is possible, so to enhance the stability of the IN administered 
drugs, one of the possible strategies is the entrapment 
(especially in case of peptide or protein) in drug delivery 
systems able to protect the therapeutic agent administration . 
The use of conventional and new drug delivery systems (DDS) 
allows to face the major issues in drug release: (1) unfavorable 
pharmacokinetics and biodistribution which lead to unwanted 
side effects (e.g. chemotherapy), (2) early drug degradation in 
the bloodstream by reticulo-endothelial system (RES), and (3) 
inefficient uptake at target sites that leads to low drug efficacy. 
In this sense, nanocarriers offer an innovative approach to 
drug delivery, providing a range of features including cargo 
protection and increased dose delivery to target sites. Actually, 
the complexity of human diseases may lead to ineffective in 
vivo drug treatments, consequently the development of 
biologically functional nanocarriers that incorporate drugs to 
selectively bind and target specific cells becomes crucial. [3] 
The success of a therapeutic strategy by using nanocarriers 
depends on their ability to entrap drugs, penetrate through 
anatomical barriers, release the incorporated drugs, and to 
show a good stability in nanometric size range. Many of the 
conventional DDS (e.g. liposomes, niosomes, micelles, and 
polymer based nanodevices) have reached the late stages of 
development, and some of them were approved. [3, 4] 
In particular, vesicular systems may increase nose-to-brain 
drug delivery enhancing drug chemical and biological stability. 
In fact the presence of a hydrophilic core is responsible of 
poorly water-soluble drug entrapment while the hydrophobic 
shell protect the system and, entrap lipophilic drugs enhancing 
brain uptake after intranasal administration. Numerous 
amphiphilic components together with different preparation 
techniques, lead to the formation of many vesicular systems: 
liposomes, niosomes, transfersomes, ethosomes, vesosomes, 
colloidosomes, and pharmacosomes. [5] Vesicles have 
spherical structure with a hydrophobic bilayer, and an aqueous 
core, they are prepared by phospholipids or surfactants that 
must be biodegradable, biocompatible and with a possible 
application in neuromedicine. Different studies have also 
demonstrated that surfactants can be used to prepare stable 
colloidal supramolecular devices showing a certain degree of 
selectivity for brain delivery. Surfactant nanocarriers, in 
particular niosomes, have the capability of entrap both 
lipophilic and hydrophilic drugs, in the apolar membrane and 
in the aqueous core, respectively. 
They can be functionalized on their surface to obtain 
different type of targeting or to enhance their biological and 
/or physical stability. These systems have been widely used in 
IN delivery but one of the major problems associated with 
nasal administration, is the rapid removal of drugs or DDS, 
from the deposition site through mucociliary clearance. This 
effect is responsible of reduction of contact time between drug 
or DDS and nasal epithelium. This problem could be solved 
by coating nanocarriers with a mucoadhesive agent. In 
particular the DDS can be coated by Chitosan, a cationic, 
mucoadhesive polysaccharide, able to form electrostatic 
interactions with the negatively charged epithelial cells 
reducing the mucociliary clearance. Chitosan is also able to 
open reversibly tight junctions enhancing the extracellular 
pathways through olfactory and trigeminal nerve. [6] 
Chitosan originates from chitin and in particular is 
produced by its deacetylation (Figure 1). 
 
Figure 1. Chitin to chitosan conversion. 
The aim of the present study is the evaluation of vesicular 
systems and chitosan interaction in order to obtain chitosan 
coated vesicles able to reach the brain by a IN administration 
avoiding the effect of the mucociliary clearance. Among 
vesicular systems, non-ionic surfactant ones or niosomes 
(NSVs) were chosen. Niosomes are similar, in terms of 
structure and physical properties, to liposomes. [7] They are 
prepared following the same procedures and under the same 
variety of conditions to produce unilamellar or multilamellar 
vesicles. The research interest in niosomal formulations is 
recently widening because niosomes are able to overcome 
some disadvantages associated with liposomes: surfactants are 
easily derivatized, more stable and give a higher versatility to 
the vesicular structure and moreover they have lower costs 
than phospholipids. [3] 
To this aim, the complexation between negatively charged 
niosomal vesicles and a cationic, mucoadhesive 
polysaccharide: the chitosan has been investigated. In this 
work, three different formulation of unilamellar niosomal 
vesicles composed by a mixture of polysorbate 20 (Tween 20) 
or polysorbate 21 (Tween 21) or sorbitan monolaurate (Span 
20) with cholesterol have been prepared and characterized. 
Tween 20 and Tween 21 vesicles show a quite negative 
ζ-potential value, not sufficient to perform a stable 
complexation with chitosan, so a more negative ζ-potential 
value is obtained adding to the formulation a ionic surfactant, 
dicetyl phosphate (DCP), at an appropriate concentration. 
On the other hand vesicles made of Span 20 do not need 
addition of DCP because they are characterized by a highly 
negative ζ-potential value that guarantees the right interaction 
with the chitosan. 
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The study of the aggregation behavior between charged 
vesicles with the oppositely charged macromolecule has been 
carried out in terms of evaluation of complexes physical 
properties such as size, size stability and ζ-potential in view of 
a possible application of such aggregates in brain delivery 
through nasal administration. These experiments have been 
performed by dynamic light scattering (DLS) and laser 
Doppler electrophoretic measurements. 
The effect of chitosan/ DCP charge ratio is investigated and 
discussed within the framework of the re-entrant condensation 
and charge inversion behavior [8] 
2. Materials and Methods 
2.1. Materials 
Polysorbate 20 (Tween 20), polysorbate 21 (Tween 21), 
sorbitanmonolaurate (Span 20), Dicetyl phosphate (DCP), 
Cholesterol (Chol), Hepes salt {N-(2-idroxyethyl) 
piperazine-N’-(2-ethanesulfonic acid)}, Sephadex G75, 
Calcein and Chitosan (low molecular weight) were purchased 
from Sigma-Aldrich. All other products and reagents were of 
analytical grade. 
2.2. Vesicles Preparation and Purification 
The thin layer evaporation method was used to prepare 
non-ionic surfactant vesicles from Tween 20, Tween 21 or 
Span 20. In each vesicle formulation, Chol and DCP were 
added at different molar ratios (Table 1). [9, 10] 
Table 1. Sample composition. 
Sample Tween20 Tween21 Span20 DCP Chol 
NioTw20 15mM    15mM 
NioTw20+DCP 7,5mM   7,5mM 15mM 
NioTw21 15mM    15mM 
NioTw21+DCP  17,6mM  7,5mM 15mM 
NioSpan20   15mM  15mM 
All the vesicle constituents were firstly dissolved in an 
organic mixture (CH3OH/CHCl3 3/1 v/v), then solvent were 
removed under vacuum at different temperatures depending 
on the surfactant used, as reported in the Table 2. The obtained 
“film” was hydrated with 5 mL of Hepes buffer (0.01M pH 
7.4). The suspension was vortexed for about 5 minutes and 
then sonicated (5 minutes and different amplitudes and 
temperatures) (Table 2) using a microprobe operating at 20 
kHz (VibraCell-VCX 400-Sonics, Taunton, MA, USA). 
Table 2. Sonication conditions. 
Sample Temperature (°C) Amplitude 
Nio Tw20+DCP 25 16 
NioTw21+DCP 25 16 
NioSpan20 60 18 
The vesicle suspension was purified by gel permeation 
chromatography using SephadexG75 (glass column of 50 x 
1.2 cm) using Hepes buffer as the eluent. The obtained 
purified vesicle suspension was then extruded using cellulose 
filters with appropriate pore diameters. 
2.3. Chitosan Solution Preparation 
The low molecular weight chitosan solution is obtained in 
acetate buffer (0.2 M, pH 4.4) after stirring overnight. 
2.4. Preparation of Hybrid Niosomes 
The chitosan-coated niosomes (hybrid niosomes) formation 
was promoted by adding 1ml of chitosan solution (at an 
appropriate concentration) to an equal volume of uncoated 
niosomes. The obtained suspension was stirred for 3 h in a 
thermostated water bath at 10 °C. 
2.5. Dynamic Light Scattering Measurements 
Vesicles mean diameter (Z-Average) and size distribution 
(polydispersity index, PDI) were measured at the temperature 
of 25 °C by means of the dynamic light scattering (DLS) 
technique, using a Malvern ZetaSizerNano 90S, equipped 
with a 5 mW HeNe laser (wavelength λ= 632.8 nm) and a 
digital logarithmic correlator. The normalized intensity 
autocorrelation functions were detected at a 90° angle and 
analyzed by using the Contin algorithm [11] in order to obtain 
the decay time of the electric field autocorrelation functions. 
The decay time is used to obtain the distribution of the 
diffusion coefficient D of the particles, which can be 
converted into an effective hydrodynamic radius RH using the 
Stokes-Einstein relationship RH=KBT/6πηD, where KBT is the 
thermal energy and η the solvent viscosity. The values of the 
radii reported here correspond to the intensity weighted 
average. [12] 
2.6. ζ-Potential Measurements 
The electrophoretic mobility measurements were carried 
out by means of the laser Doppler electrophoresis technique 
using the Malvern ZetaSizerNano 90S apparatus equipped 
with a 5mW HeNe laser. The mobility u was converted into 
the ζ-potential using the Smoluchowski relation ζ = uη/є, 
where η and є are the viscosity and the permittivity of the 
solvent phase, respectively. [8] 
2.7. Spectrofluorometric Analysis 
Niosomal integrity during the chitosan coating process was 
evaluated by means of fluorescence analyses (Perkin-Elmer 
LS50B spectrofluorometer). 
Calcein loaded vesicles were prepared hydrating the 
surfactant thin film with a calcein solution (0.01 M of calcein 
in Hepes buffer 0.01 M pH 7.4). Free calcein was eliminated 
by extensive dialysis (cellulose dialysis bag membrane 8000 
MWCO-Spectrum, The Netherlands). The calcein 
concentration inside vesicles was approximately 10-2 M. At 
this concentration, the dye is self-quenched and is responsible 
of a low fluorescence signal, while if the probe is released, the 
dequenching process produce a remarkable increase in 
fluorescence values due to the dilution of the probe in the 
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external aqueous medium. [13] 
3. Results and Discussion 
In this study, niosomal vesicles were prepared and 
characterized in order to obtain a delivery systems for a 
potential nose to brain application. For this purpose, 
formulations with different compositions were prepared 
(Table 1). DLS analyses were carried out to evaluate 
dimensions and ζ-potential characteristics in order to verify 
their suitability to be coated with chitosan. It can be noticed 
that, as shown in table 3, Span niosomes were characterized by 
a sufficient negative charge able to form electrostatic 
interactions with the positively charged polyelectrolyte. 
Table 3. Light scattering analysis of vesicular systems in absence and in 
presence of DCP. 
Sample Z-Average (nm) ±DS 
ζ-Potential (mV) 
± DS PDI ± DS 
NioSpan20 202,91 ± 5,31 -48,34 ± 0,23 0,31 ± 0,01 
NioTw20 152,53 ± 1,52 -26,42 ± 4,52 0,12 ± 0,02 
NioTw20+DCP 157,34 ± 1,24 -44,22 ± 1,61 0,31 ± 0,01 
NioTw21 159,32 ± 3,93 -34,23 ± 4,24 0,52 ± 0,01 
NioTw21+DCP 136,52 ± 5,21 -51,72 ± 0,62 0,34 ± 0,02 
DCP addiction to Tween formulations is needed to achieve 
a suitable negative ζ-potential value useful for the interaction 
with chitosan. Therefore, the presence of DCP plays a 
fundamental role in decreasing ζ-potential values, and this 
effect is not associated to a size variation of vesicles. On the 
other hand, the addiction of DCP leads to opposite effects on 
PDI values. In particular it produces a PDI increase in the case 
of Tween 20 vesicles, while it causes a decrease in the case of 
Tween 21 ones. This phenomenon can be explained looking at 
the molar ratio between Tweens and DCP (Table 1). The 
addiction of DCP produces a quite monodisperse vesicular 
population in both samples, but it can be noticed that it could 
be better to not use an equimolar amount of DCP. 
As previously described, the hybrid niosomes where 
obtained by adding a proper amount of chitosan to niosomal 
suspension. In particular, the aggregation behavior of 
negatively charged niosomal vesicles in the presence of 
different amount of chitosan was investigated. In figure 2 the 
behavior of the Z-Average (panels A, C, E) and the 
corresponding ζ-potential values (panels B, D, F) of different 
niosomal suspensions in the presence of different 
concentrations of chitosan solution are reported. 
For all the samples, the addition of chitosan promotes the 
progressive increase of the diameter of the complexes, starting 
from a value close to the Z-Average of uncoated niosomes 
when only few polycation molecules adsorb on the vesicle 
surface, and growing to larger and larger sizes due to the 
subsequent aggregation of chitosan coated vesicles. Also the 
value of ζ-potential of the hybrid niosomes increases adding 
the polyelectrolyte approaching less negative values until the 
point of charge inversion (isoelectric point) is reached. This 
behavior is connected to the progressive charge neutralization 
of the complexes, promoted by the adsorption of positive 
charges of the chitosan onto the negative charges at the vesicle 
surface. 
Further addition of chitosan promotes the reversal of 
ζ-potential toward positive values and the decrease of the 
Z-Average of the hybrid niosomes toward lower values. In 
particular at this higher polyelectrolyte concentration, the 
hybrid niosomes reach a size similar to the one measured at 
low chitosan concentrations. This peculiar behavior is known 
in the colloid literature [14] as re-entrant condensation and is 
associated to the charge inversion of the chitosan coated 
vesicles. 
The aggregation mechanism and the formation of stable 
structures are the results of the balance between electrostatic 
repulsion and short-range effective attraction interactions due 
to the non uniform charge distribution at the particle surface 
(charge patch attraction). [15] 
This behavior was observed for all samples studied. The 
aggregation mechanism and the formation of stable structures 
were justified in light of a balance between electrostatic 
repulsion and short-range effective attraction interactions due 
to the non uniform charge distribution at the particle surface 
(charge patch attraction). [16] 
It is interesting to highlight that the chitosan concentration 
responsible of charge inversion is similar for Tween vesicles 
and is higher in comparison with the one necessary to obtain 
charge inversion of Span 20 vesicular suspension. Probably 
this is due to the presence of PEG chains on Tween vesicle 
surfaces. PEG can act as a kind of shield to an initial chitosan 
surface deposition and interaction. 
In order to check the integrity of the hybrid niosomes during 
the whole aggregation process, the leakage of calcein 
entrapped in the core of the hybrid niosomal vesicles was 
monitored. The release of calcein induced by the coatings with 
the polyelectrolyte was studied as a function of chitosan 
concentration at a temperature of 25 °C. The percent of dye 
leakage from the aggregates (IF ) was calculated as: 
IF = (I-IN)/(IE-IN), where I is the fluorescence intensity of the 
hybrid niosomal suspension, IN is the one of the uncoated 
niosomes, and IE the value corresponding to the complete 
rupture of the vesicles caused by adding, for example, ethanol 
to the suspension. 
In the hybrid niosomes aggregates, calcein is present at a 
self-quenched concentration inside of the single vesicle 
aqueous core. To eliminate the calcein from the external 
medium, an exhaustive dialysis was carried out, but a residual 
fluorescence was observed. This fluorescence is probably due 
to some amount of calcein that remain entrapped in the 
external polyethylene hydrophilic layer on the surface of 
niosomes alone and of hybrid noisome aggregates. 
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Figure 2. Z-Average (panel A, C, E) and the corresponding ζ- potential values (panel B, D, F) of different niosomal suspensions in the presence of different 
concentrations of chitosan solution are reported. The shaded area represents the region of instability. 
The evaluation of increase of calcein fluorescence in the 
hybrid niosomal suspension, due to probe dequenching and 
dilution following complete rupture of the vesicles is useful to 
follow the resistance of the vesicles during polymer coating. 
In tables 4, 5 and 6 are reported the fluorescence of the 
samples formed by the three different surfactants, prepared 
with different amount of chitosan. 
Table 4. Fluorescence of NioTw20+DCP+Calcein in presence of different 
concentrations of chitosan solution. 
Chitosan concentration (mg/ml) Fluorescence (AU) 
Uncoated 88,49 
0,045 70,69 
0,060 67,74 
0,131 52,41 
0,135 35,60 
0,150 32,16 
0,255 38,50 
0,300 38,26 
0,500 37,56 
Table 5. Fluorescence of NioTw21+DCP+Calcein in presence of different 
concentrations of chitosan solution. 
Chitosan concentration (mg/ml) Fluorescence (AU) 
Uncoated 74,10 
0,060 68,26 
0,090 61,41 
0,105 60,29 
0,120 56,30 
0,135 47,84 
0,150 46,33 
0,200 40,633 
0,300 38,937 
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Table 6. Fluorescence of NioSpan20+Calcein in presence of different 
concentrations of chitosan solution. 
Chitosan concentration (mg/ml) Fluorescence (AU) 
Uncoated 78,92 
0,003 75,26 
0,004 72,94 
0,006 70,81 
0,015 69,36 
0,020 58,14 
0,030 57,27 
0,055 47,86 
0,070 40,71 
0,100 37,11 
Obtained data show that hybrid niosomal fluorescence 
never exceeds the one of uncoated niosomes (at the same 
dilution) confirming that no calcein release following 
vesicular degradation occurs. These results indicate that 
vesicular membranes of all analyzed samples are undamaged 
while chitosan coating occurs. For all the formulation, a 
fluorescence decrease with the increase of the chitosan 
concentration can be observed. Probably chitosan coating on 
vesicular surface, act as a fluorescence-screen for calcein 
molecules that are present on the hybrid niosome surface. The 
vesicles integrity was also confirmed by DLS measurements 
(data not shown). 
Vesicle integrity after chitosan coating, was evaluated 
during a time interval of 24 hours. In particular no variations 
of fluorescence and size were detected (data not shown), so it 
can be concluded that samples are not damaged by the 
chitosan coating. 
Vesicular formulations were stored at 4 °C and 25 °C for a 
period of 90 days to evaluate their physical stability. Samples 
from each batch were withdrawn at definite time intervals (1 
day, 30 days, 60 days and 90 days) to measure ζ-potential and 
the mean hydrodynamic diameter. These kind of 
measurements were carried out on a limited number of 
samples in particular those characterized by similar size to 
uncoated sample and by a positive ζ-potential. Apart from 
providing the hydrodynamic diameter and ζ-potential value, 
DLS provides also valuable information on the homogeneity 
of the suspension. A single sharp peak in the DLS profile 
implies the existence of a single population of scattering 
particles that correspond to low PDI value. In particular all 
samples are characterized by PDI value that is always lower 
than 0.4, and vesicular suspensions can be considered as 
monodisperse systems. 
Table 7. Mean hydrodynamic diameter (Z-Average) and ζ-Potential values of uncoated vesicles and of selected chitosan coated vesicles. 
Sample Z-Average (nm) ± DS ζ-Potential (mV) ± DS PDI ± DS 
NioTw20+DCP 157,34 ± 1,24 -44,22 ± 1,61 0,31 ± 0,01 
NioTw20+DCP+Chitosan (0,3mg/ml) 252,91 ± 4,42 37,73 ± 0,72 0,31 ± 0,02 
NioTw21+DCP 136,52 ± 5,21 -51,72 ± 0,62 0,34 ± 0,02 
NioTw21+DCP+Chitosan (0,2mg/ml) 262,12 ± 2,41 33,92 ± 0,71 0,21 ± 0,01 
NioSpan20 202,91 ± 5,31 -48,34 ± 0,23 0,31 ± 0,01 
NioSpan20+Chitosan (0,1mg/ml) 292,73 ± 6,81 43,43 ± 0,52 0,21 ± 0,01 
 
In table 8 physical stability data of the three different 
uncoated and coated formulations are reported. These studies 
were carried out to investigate if significant changes of the 
size and ζ-potential of surfactant vesicle dispersion occur 
during storage. The measurements carried out by DLS 
indicate that all selected surfactants form vesicular structures 
with no significantly different sizes and ζ-potential. The 
uncoated and coated systems are characterized by no 
significant variations of dimension and ζ-potential during the 
storage period, especially if they are maintained at 4°C. The 
high negative or positive ζ-potential values are important in 
preventing aggregation phenomena. In fact, it has been 
reported that to prevent aggregation due to electrostatic 
interactions, a nanovesicle should have a ζ-potential value of 
at least −30 mV or grater + 30 mV. [17] 
Table 8. Physical stability in terms of dimensions and ζ-potential variations of uncoated (panel A) and coated (panel B) vesicles. Data were collected at days 1 
and 90 and are the mean of three experiments ± SD. 
 
NioTw20+DCP NioTw20+DCP+Chitosan (0,3mg/ml) 
25 °C 4°C 25 °C 4°C 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
t=0 157,34±1,24 -44,22±1,61 157,34±1,24 -44,22±1,61 252,91±4,42 37,73±0,72 252,91±4,42 37,73±0,72 
t=90 153,91±1,43 -41,01±2,23 166,12±7,32 -42,84±1,11 241,94±4,43 33,82±1,43 337,01±4,82 38,22±0,73 
Table 8. continue. 
 
NioTw21+DCP NioTw21+DCP+Chitosan (0,2mg/ml) 
25 °C 4°C 25 °C 4°C 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
t=0 136,52±5,21 -51,72±0,62 136,52±5,21 -51,72±0,62 262,12±2,41 33,92±0,71 262,12±2,41 33,92±0,71 
t=90 121,12±3,43 -31,11±1,02 113,01±3,64 -53,11±2,02 197,01±3,92 31,62±1,01 253,82±2,31 36,22±1,72 
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Table 8. continue. 
 
NioSpan20 NioSpan20+Chitosan (0,1mg/ml) 
25 °C 4°C 25 °C 4°C 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
Z-Average 
(nm) 
ζ-Potential  
(mV) 
Z-Average 
(nm) 
ζ-Potential 
(mV) 
t=0 202,91±5,31 -48,34±0,23 202,91±5,31 -48,34±0,23 292,73±6,81 43,43±0,52 292,73±6,81 43,43±0,52 
t=90 258,11±7,83 -32,22±1,52 224,82±7,91 -48,51±1,52 275,82±6,72 25,72±1,22 272,92±7,62 36,22±1,71 
 
4. Conclusions 
In this work, the complexation process between negatively 
charged vesicles built up by three different surfactants (Tween 
20, Tween 21 and Span 20) and chitosan, a cationic 
polyelectrolyte, with mucoadhesive properties, is described. 
The aggregation behavior can be deeply investigated by 
size, ζ-potential and fluorescence evaluations, in order to 
select the most appropriate samples to perform intranasal 
administration. From the obtained results the selected 
Tw20,Tw21 and Span vesicles coated with a chitosan 
concentration able to obtain a positively charged hybrid 
vesicle, are: a) homogenous and monodisperse vesicular 
population; b) characterized by dimensions compatible with 
the proposed route of administration; c) stable in terms of 
dimension and ζ average variation, if stored at 4°C. 
These kind of measurements can be useful to perform an 
initial screening and needs to be confirmed by a complete 
preclinical evaluation.
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1. Introduction 
 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that involve the movement 
control and balance of the body.  
Symptoms consist mainly in the rigidity, resting tremor and bradykinesia with the progressive loss 
of dopaminergic neurons localized in the substantia nigra of the brain. [1] 
Currently, the therapy is only symptomatic and do not arrested or slow down the 
neurodegeneration. 
The protein S100 calcium-binding B (S100B) is a small protein necessary for neurodevelopment 
and plasticity of the astrocytes but it is overexpressed in several neurodegenerative diseases, 
including PD and Alzheimer’s disease. 
Its mechanism of action is the inhibition of the tumor suppressor protein p53 and the stimulation of 
the protein kinase B and the nuclear dbf2-related kinase. [2, 3] 
Furthermore, it promotes numerous pathological process such as neuroinflammation, cell growth 
and apoptosis. [4] 
Pentamidine isethionate (P) is an antiprotozoal drug generally employed for the treatment of 
Pneumocystis cariini pneumonia in the United Stated. Many researches have demonstrated the 
ability of this molecule to block the interaction between S100B and p53 in vitro resulting a 
promising agent for the treatment of Parkinson’s disease. [5] 
However, its systemic administration causes toxicity, in particular renal [6] and also the 
pharmacokinetic profile of P is characterized by low blood brain barrier crossing. [7]  
The present work focuses on the development of an intranasal formulation for the pentamidine 
delivery with the aim of achieving directly the brain, decreasing drug levels within tissues 
vulnerable to toxicity, and increased accumulation at the target site.  
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For this purpose, pentamidine loaded niosomes, namely Pentasome, have been formulated and 
characterized of suitable for nose to brain delivery.  Moreover, in order to improve the residence 
time of this vesicles in the nasal mucosa, chitosan coating was employed. 
 
2. Materials and Methods  
 
2.1. Materials 
 
Polysorbate 20 (Tween 20), Dicetyl phosphate (DCP), Cholesterol (Chol), Pentamidine isethionate 
(Pent), Hepes salt {N-(2-idroxyethyl) piperazine-N’-(2-ethanesulfonic acid)}, Sephadex G75, 
Chitosan (Chit) (low molecular weight) were purchased from Sigma-Aldrich.  
All other products and reagents were of analytical grade. 
 
2.2. Pentasomes preparation and purification 
 
The vesicles were obtained by thin layer evaporation method as previously reported [8], according 
to the compositions shown in the table 1. 
All the vesicle hydrophobic constituents were firstly dissolved in CH3OH/CHCl3 (3:1 v/v) mixture. 
After the solvent evaporation, the film obtained was hydrated with a solution of pentamidine (5 
mg/ml) in hepes buffer.  
The multilamellar vesicular suspension was vortexed for about 5 minutes and then sonicated (5 
minutes, 16% amplitude, at 60°C) using a microprobe operating at 20 kHz (VibraCell-VCX 400-
Sonics, Taunton, MA, USA).  
The unilamellar vesicle suspension was purified by gel permeation chromatography using 
SephadexG75 (glass column of 50 x 1.2 cm) with hepes buffer as the eluent. 
 
2.3. Preparation of Chitosan-coated Pentasomes 
 
The chitosan-coated pentasomes (C-pentasomes) formation was prepared by adding 1 ml of 
chitosan solution (DLS paper) to an equal volume of pentasomes.  
The obtained suspension was stirred for 3 h in a thermostated water bath at 10 °C. 
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2.4. Entrapment efficiency (E.E.%) 
 
Pentamidine entrapment efficiency in Pentasomes was determined using UV spectrophotometer. 
Spectrophotometric analyses were carried out at 270 nm, by means of a spectrophotometer (Perkin-
Elmer, lambda 3a, UV-Vis spectrometer) equipped by 1.0 cm path-length quartz cells and drug EE 
% was calculated as follows:  
 
EE% = [(Concentration of drug determined) / (Total concentration of drug loading)] X 100 
                                                                
Results are the average of three different batches ± standard deviation. 
 
2.5. Dynamic light scattering and Electron transfer studies 
 
Pentasomes and C-pentasome mean diameters (Z-Average), size distributions (polydispersity index, 
PDI) and ζ-potential were measured at the temperature of 25 °C by means a Malvern 
ZetaSizerNano 90S.  
 
2.6. Pentasomes bilayer fluidity determination  
 
The fluidity of Pentasomes bilayer was determined by fluorescence anisotropy studies using DPH 
as fluorescence probe.  
DPH was added to vesicle composition at the final concentration of 2x10-3 M and to obtain DPH-
labeled Pentasomes, DPH solution was added to the constituents and the fluorescent probe loaded 
vesicles were obtained by film technique as reported above.  
To avoid any experimental artifact, i.e. to allow the fluorescent probe disposition in the vesicle 
bilayer, samples were stored 3 h at room temperature before the fluorescence anisotropy 
experiments.   
 
2.7. Pentasomes stability studies  
 
For colloidal stability at different temperatures, the formulations were stored at 4 and 25°C for a 
period of 90 days.  
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Samples from each batch were withdrawn at definite time intervals (1, 30, 60 and 90 days) and the 
ζ-potential, the mean of hydrodynamic diameter of Pentasomes and pentamidine EE were 
determined. 
In order to study the stability of pentasome in the biological fluids, human serum (HS) or artificial 
cerebrospinal fluid (aCSF) was added to vesicle suspensions until reached at 90% [9] or 45% 
respectively.  
 
2.8. In vitro release studies 
 
In vitro release of pentamidine from niosomes was evaluated by dialysis (8,000 MW cutoff; 
Spectrum). 
Briefly, an aliquot of the pentasomes and HS (45%) or aCSF (90%) was placed in dialysis tubing 
and immersed in buffer, gently magnetically stirred at 37ºC.  
The medium was regularly sampled over a 24 h period at appropriate time intervals and reinserted 
back in the medium after the measurements, in order to maintain the volume of the medium 
constant. 
Released petamidine was detected at 270 nm, by means of a spectrophotometer (Perkin-Elmer, 
lambda 3a, UV-Vis spectrometer) equipped by 1.0 cm path-length quartz cells.  
All aliquots were analyzed immediately after sampling. All release experiments were carried out in 
triplicate.  
The values reported in the present paper represent the mean values and lay within 10% of the mean. 
 
2.9. In vivo studies 
 
Animal experiments were performed in C57Bl/6J mice (eight-weeks old male, weight range around 
30 g).  
Parkinson disease was induced by daily injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), a neurotoxin which causes symptoms of PD, 25 mg/kg 25 mg/kg) for four consecutive 
days starting from day 1.  
Mice were randomly divided into five groups: (1) vehicle; (2) MPTP group; (3 and 4)) MPTP group 
receiving daily C-Pentasomes at increasing doses (0.005-0.05 µM); (5) MPTP receiving empty 
Pentasomes, as internal group.   
 C-Pentosome was intranasally administrated from day 0 until day 5, once at day.  
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Three days after last MPTP administration, rotarod test and pole test were assessed to determine the 
functional outcomes on PD.  
After behavioral tasks, animal was euthanized and brains were isolated in order to perform 
biochemical assays and immunohistological staining.  
All the experiments were carried out in accordance with the National Institutes of Health Guidelines 
for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996) and 
those of the Italian Ministry of Health (D.L. 116/92). 
The study was approved by the Institutional Local Animal Care and Use Committees. 
 
3. Results 
 
3.1. Characterization of Pentasomes 
 
Pentasomes characterization is summarized in Table 1.  
DLS analysis showed that the size of Pentasomes is around 172.0 nm and after the addition of 
chitosan (C-Pentasomes) an increase of dimension is observed.   
The change of ζ-potential from negative surface charging to positive confirms that the vesicular 
surface is covered by chitosan. Generally, vesicles form a stable dispersion when the absolute value 
of ζ-potential is around ± 30 mV, since it guarantees the electric repulsion between particles.	[10] 
The PDI of both formulations showed values of 0.2, indicating homogenous populations of vesicles.  
In addition, EE studies show that Pentasomes encapsulate the 24% of loaded pentamidine. 
 
 
Sample	 Tw20	(mM)	
DCP	
(mM)	
Chol	
(mM)	
P	
(mg/ml)	
C	
(mg/ml)	
Hydrodynamic	
diameter	(nm)	
±	SD	
ζ-Potential	
(mV)	±	SD	 PDI	±	SD	 EE%	
Pentasomes	
15.0	 7.5	 15.0	 5	
-	 172.0	±	3.9	 -35.0	±	0.8	 0.2	±	0.0	
24%	
C-Pentasomes	 0.18	 350.7	±	17.2	 +39.0	±	1.1	 0.2	±	0.0	
 
Table.1  
 
3.2. Pentasomes bilayer characterization 
 
Anisotropy is related to the fluidity of the bilayer: it is inversely proportional to the membrane 
fluidity and the high value of anisotropy indicates a high structural order and/or a low membrane 
fluidity. 
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As shown in the table 2, the fluorescence anisotropy value is similar for all samples and the bilayer 
is mildly rigid, also after chitosan addition at the formulation. 
Therefore, chitosan is only absorbed onto the vesicle surface without intercalation in the bilayer. 
 
 
Sample	 Fluidity	(A.U.)	
Pentasomes	 0.27	
C-Pentasomes	 0.28	
	
Table. 2 
	
	
3.3. Pentasomes stability studies  
 
The stability studies of Pentasomes are shown in the figure 1 and they suggest a high colloidal 
stability. No show significant variations of size and ζ-potential are recorded at two different storage 
temperatures over 90 days. 
 
 
 
 
Figure. 1  
 
 
Moreover, the concentration of pentamidine entrapped in Pentasomes during the storage period was 
evaluated. 
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Figure. 2 
 
As shown in the figure 2, the pentamidine concentration is constant at both storage temperatures. 
The effect of biological fluids (HS and aCSF) on the stability of Pentasomes was evaluated. 
The experiments were performed observing size and ζ-potential variation at definite time intervals 
up to 3 hours at 37°C. 
 
 
 
 
Figure. 3 
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During the analyzed time interval, in both fluids an increase of dimension and a decrease of ζ-
potential values of Pentasomes is observed. 
This phenomenon is not associate at vesicular breaking, since the size increase is observed 
immediately after the contact between Pentasomes and HS or aCSF and it is maintained constant up 
to 3 h.  
In particular, in HS this increase is probably due to human proteins absorption on vesicular surface.  
 
3.4. In vitro drug release studies 
 
In vitro release profiles of pentamidine are obtained by contacting Pentasome and HS or aCSF up to 
24 hours.  
 
 
 
Figure. 4 
 
 
After 24h, Pentasomes release 80% and 100% of their pentamidine cargo, in HS and aCSF 
respectively. (Figure. 4) 
In particular, in presence of aCSF Pentasomes a 100% pentamidine release after 4 hours was 
observed. 
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3.5. In vivo studies 
 
The rotarod test is used to investigate the motor coordination and behavior of mice when they are 
placed into a center of the square arena.  
Instead, in the pole test is assessed the agility of animals and their bradykinesia. The mice are 
placed on top of a pole and the Tturn and total locomotor activity (TL) were measured. The Tturn is the 
time used to proceed to downward and the TL is the time until the mice arrive on the floor. 
 
 
Figure. 5 
 
 
In the figure 5, MPTP treatment caused a significant decrease of movement frequency in 
intoxicated mice versus vehicle group (-63%). 
This effect was reverted by C-Pentasomes treatment in a dose-dependent manner: for the mice 
treated with 0.001 mg/kg was assessed an increase of 60% and with 0.004 mg/kg of 137% 
compared to MPTP group. 
After administration of niosomes without drug (empty nanocarrier) a mild improvement of the mice 
movement.was observed  
These results confirm that the Pentasomes are able to reach the brain after intranasal administration. 
In the same experimental conditions, during the pole test both TL and Tturn were significantly higher 
in MPTP-intoxicated mice compared to respective vehicle groups (TL: +181%; Tturn: +220%).  
1. Vehicle
2. MPTP	25	mg/kg
3. MPTP+	C-Pentasomes 0.001	mg/kg/day
4. MPTP+	C-Pentasomes 0.004	mg/kg/day
5. MPTP+	empty	Nanocarrier
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Conversely, C-Pentasomes was able to revert such effect, decreasing both TL, 37% (for mice treated 
with 0.001 mg/kg of C-Pentasomes) and 56% (0.004 mg/kg), and Tturn,23% (0.001 mg/kg) and 58% 
(0.004 mg/kg), compared to MPTP group. 
Also in this study, an enhance of coordination performance is observed after C-Pentasomes 
administration in a dose-dependent manner. 
In parallel with motor impairments, MPTP neurotoxin induces in the mice a neuronal dopaminergic 
loss localized into striatum and substantia nigra. 
 
 
 
Figure. 6 
 
 
In the figure 6, immunohistochemistry staining highlighted a significant reduction of TH+ positive 
cells in MPTP-treated mice of 82% in the striatum and 68% in the substantia nigra compared to 
vehicle group. 
Pentamidine released from Pentasomes was able to rescue the dopaminergic cellular density in a 
dose-dependent fashion.  
In the group 3, the cells increase of 150% in the striatum and 58% in the subtantia nigra compared 
to MPTP group, whereas in the group 4 is observed a cellular increase of 405% and 174% 
respectively.   
Conversely, the empty vector did not show any significant improvement in TH+ protein level of 
nigrostriatal axis MPTP-induced.  
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Finally, in order to test whether pentamidine effects were due to its ability to reduce 
neuroinflammation severity, astrogliosis and proinflammatory cytokines expression were evaluated. 
Immunohistochemistry staining for GFAP showed a marked astrogliosis in the striatum of MPTP-
treated mice versus vehicle group (+800%). (Figure. 7) 
 
 
Figure. 7 
  
Once again, increasing doses of pentamidine reduced significantly the number of striatal GFAP+ 
positive cells of 32% (0.001 mg/kg) and 80% (0.004 mg/kg) compared to MPTP group.  
Whereas the empty nanocarrier did not affect the neuroinflammatory process MPTP-mediated.  
Along this line, following MPTP treatment an increased GFAP (+230%), COX-2 (+1450%), iNOS 
(+510%) and Iba-2 (+265%) protein expression was observed by immunoblot analysis, as well as 
nitrite (+855%) and PGE2 (+430%) release. 
Proinflammatory cytokines level was markedly reduced when 0.001 mg/kg of C-Pentasomes was 
administrated (GFAP: -27%; COX-2: -25%; iNOS: -40%; Iba-2: -24%; NO: -38%; PGE2: -29% 
compared to MPTP group) and 0.004 mg/kg (GFAP: -51%; COX-2: -55%; iNOS: -66%; Iba-2: -
59%; NO: -60%; PGE2: -52%; versus MPTP group). 
Instead, no effects were observed after empty nanocarrier administration. 
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4. Conclusions 
 
In these studies, Pentasomes have shown to be able to entrap the necessary concentration of 
pentamidine in order to observe in vivo therapeutic effects. 
The nanocarrier formulated are stable over time at both storage temperatures and biological fluids.  
The results obtained from the in vivo studies suggest that the encapsulation of pentamidine in C-
Pentasomes improves the nose to brain delivery of the drug after intranasal administration.  
Furthermore, the neuroprotective and neurorestorative effect of Pentasomes in a mice model of PD 
are demonstrated.  
Therefore, it can be concluded that C-Pentasomes administered by a non-invasive route such as the 
intranasal route could be a promising tool for the treatment of PD. 
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This project was developed in the last period of my PhD and deals with the preliminary 
development of nanoemulsion formulations suitable for a potential application in brain delivery. 
 
 
1. Nanoemulsions 
 
Emulsions are heterogeneous dispersions of two immiscible liquids, in which one is dispersed as 
fine droplets (internal phase) in the other liquid (external phase). 
Emulsions can be classified according to the droplet size in macroemulsion (ME) and nanoemulsion 
(NE), and according to the external phase in oil-in-water (o/w) or water-in-oil (w/o).  
These systems are extensively used in cosmetic, food and pharmaceutical field and they may be 
formulated as sprays, creams, liquids and ointments.  
Both types of emulsions are used as drug delivery system to increase the oral and parenteral 
bioavailability of therapeutic agents, in particular the peptides, but NEs are preferred for the 
treatment of brain disorders [1] because they show: 
Ø an average droplet size between 20 and 500 nm; 
Ø a high surface area per unit volume; 
Ø appear transparent, due to their inability to scatter the light [2]; 
Ø the ability to entrap poorly aqueous soluble drugs; 
Ø a long-term stability, the NEs are kinetically stable against sedimentation and creaming 
phenomena, due to their very small droplet size; 
Nanoemulsions are typically composed by oil, water and emulsifier, such as surfactants, protein or 
lipid. [3, 4] (Figure. 1) 
 
 
 
Figure. 1 Oil droplet structure in NEs. 
Emulsifier	molecule	
Hydrophilic	head
Hydrophobic	tail
Oil	
droplet
O/W
Nanoemulsion
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The emulsifying agent is necessary to obtain a homogeneous mixture between the two phases, and 
it stabilized the NEs through steric impediment and repulsive interactions. [5] 
Moreover, surfactants in the NEs could contribute to increase the brain uptake as stealth agents [6], 
Pgp inhibitors [7], permeation enhancers [8].  
In particular, poloxamer and polisorbate (Tween 80/20) surfactants have been widely evaluated for 
brain delivery as promote receptor mediated uptake via the lipoprotein receptor. Both surfactants 
promote the adsorption of apolipoprotein E on the surface of the carrier. The affinity of 
apolipoprotein E for LDL receptor localized in the BBB allows the carrier uptake by receptor 
mediated endocytosis (RME). [9, 10, 11] 
Also the oil in the NEs can be utilized as absorption enhancer. [12] For example, the oils rich of 
polyunsaturated fatty acids, such as docosahexaenoic acid (DHA) plays an important role for the 
brain healthy.  They are constituents of human brain and retina and reach the brain due to the 
presence of specific transporters, DHA transporter or specific fatty acid binding lipoprotein carriers, 
localized on BBB. [13, 14] 
Therefore, O/W NEs containing oils rich in DHA could promote enhanced brain uptake by RME 
mechanism. [15] 
Some oils can show a bioactive effect and therefore a synergic effect with the drug loaded in NEs. 
In particular, the essential oils show a wide-spectrum biological activities, including antioxidant, 
antibacterial, antiviral, antifungal, anti-inflammatory and anticancer ones. [16, 17] 
NE can be prepared by means of two methods: (1) the high-energy methods are used in the 
laboratory and industrial scale and include the high-pressure homogenization method, in which the 
mixture is exposed to high pressure to obtain a finally-dispersed emulsion with a very small droplet 
size. [18]  
Similarly, in the microfluidization method, the emulsion ingredients are exposed to high pressure 
and then are forced at very high speed across a small orifice. [19] 
(2) The low energy methods include (i) the phase inversion technique, which use the increase of 
temperature to obtain the NEs, and (ii) the spontaneous emulsification method, where the O/W 
emulsion is spontaneously obtained by using a hydrophobic oil and a water-miscible solvent. [20] 
NEs are prepared by using biocompatible compound and for this reason they are generally 
considered safe and non-toxic.  
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2. Nanoemulsions for brain delivery 
 
By virtue of their lipophilic nature and low globule size, NEs exhibit an excellent potential for brain 
delivery. [21] 
Several studies demonstrate the improvement of brain delivery of neurotherapeutic agents loaded in 
NEs. 
Kumara et al. [22], have evaluated the biodistribution of risperidone in the blood and brain of rats 
following intranasal and intravenous administration of the nanoemulsions containing risperidone. 
Their obtained a higher drug amount in the brain of the rats after NE administration compared to 
other formulations. Furthermore, NEs seemed to be more effective after nasal administration rather 
than intravenous route. 
In a similar study, Jain et al. [23] have formulated amiloride mucoadhesive NEs for intranasal 
delivery. Histopathological assessment and nasal irritation study of the nasal mucosa have shown 
that the granular cellular structure and the surface of the nasal epithelium was totally intact. 
Therefore, they have demonstrated that the NEs formulation was nontoxic and non-irritant for the 
nasal mucosa. 
In another study, NEs are used to deliver the saquinavir mesylate, a protease inhibitor with poor 
water-solubility, to the brain. [24] In vivo biodistribution studies demonstrated a higher 
concentration of drug in the brain for the NEs intranasal administrated compared to the 
formulations administrated intravenously. 
Therefore, the use of NEs as intranasal drug delivery system is set to bring about significant results 
in targeting drugs to the brain in the treatment of CNS diseases. 
 
3. Aim 
 
The aim of this part of my PhD project has been mainly focused on the formulation and physical-
chemical characterization of nanoemusions obtained by neem oil. 
 
All collected data and experimental setup are shown in the paper: Neem oil nanoemulsions: 
characterisation and antioxidant activity. 
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ABSTRACT
The aim of the present work is to develop nanoemulsions (NEs), nanosized emulsions, manufactured for
improving the delivery of active pharmaceutical ingredients. In particular, nanoemulsions composed of
Neem seed oil, contain rich bioactive components, and Tween 20 as nonionic surfactant were prepared.
A mean droplet size ranging from 10 to 100nm was obtained by modulating the oil/surfactant ratio.
Physicochemical characterisation was carried out evaluating size, f-potential, microviscosity, polarity and
turbidity of the external shell and morphology, along with stability in simulated cerebrospinal fluid (CSF),
activity of Neem oil alone and in NEs, HEp-2 cell interaction and cytotoxicity studies. This study confirms
the formation of NEs by Tween 20 and Neem oil at different weight ratios with small and homogenous
dimensions. The antioxidant activity of Neem oil alone and in NEs was comparable, whereas its cytotoxicity
was strongly reduced when loaded in NEs after interaction with HEp-2 cells.
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Introduction
According to the European Commission definition, nanotechnol-
ogy is a branch of engineering devoted to designing, producing
and using structures and devices having one or more dimensions
of about 100 nanometres or less. Nanoscience and nanotechnol-
ogy are the study and application of extremely small things and
can be used across all the other science fields, such as chemistry,
biology, physics, materials science, engineering and in
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pharmaceutical sector. New or extensively used drugs can be bet-
ter formulated if loaded in specific nanocarriers in order to over-
come problems such as low solubility, large biodistribution, low
bioavailability, adverse effects, high costs and so on. Along the
diverse nanocarriers that are widely used in pharmaceutics, nanoe-
mulsions have attracted great attention in drug delivery and
pharmacotherapy. In particular, nanoemulsions act as an excellent
and versatile vehicle for poorly aqueous soluble drugs, which are
otherwise difficult to formulate in conventional dosage forms.
Nanoemulsions are submicron emulsions composed of generally
recognized as safe (GRAS) grade excipients approved by the
United States Food and Drug Administration (FDA) and with the
possibility to use different oils that can modulate the drug activity.
Nanoemulsions are easily produced in large quantities by high
shear stress or mechanical extrusion process and can be engi-
neered with specific attributes such as size, surface charge, pro-
longed blood circulation and targeting properties. Nanoemulsions
can be prepared in order to tune their physicochemical properties
to be applied in therapy, diagnostics or theranostics.
The size of the droplets varies depending on the drug particles,
mechanical energy, composition and relative amount of the surfac-
tants1. Nanoemulsions are also known as miniemulsions, fine-dis-
persed emulsions, submicron emulsions, etc., which can be either
oil in water (O/W) or water in oil (W/O) emulsion. The amount of
oil in O/W nanoemulsions may vary but generally is within 5–20%
w/w. Sometimes a mixture of oils may be used to improve drug
solubilisation in the oil phase. A co-surfactant or a co-solvent may
be used in addition to the surfactant to facilitate the stabilisation
process2,3. The significant property that differentiates the nanoe-
mulsions from other emulsion systems is that a nanoemulsion
shows a different pattern in physical and rheological properties
with decreasing droplet size. Nanoemulsion is much more stable
than other emulsion systems and is more translucent compared to
microemulsions4. Few nanoemulsions have been manufactured
commercially in oral, topical, ophthalmic and even in intravenous
(IV) drug delivery system. IV administration of nanoemulsions
requires biodegradable surfactants. Numerous researches are pres-
ently being carried out in order to manufacture nanoemulsions
from different classes of drugs for a variety of purposes. The use
of nanoemulsions spreads from antibiotic therapy, atherosclerosis
treatment, transdermal drug delivery and ophthalmic application
to as far as cancer therapy, vaccine delivery, etc5–7.
One of the most appealing challenges in nanotechnology is to
find an opportune strategy to bypass blood–brain barrier (BBB)
and to reach the central nervous system (CNS). Among the numer-
ous approaches proposed, the direct nose-to-brain drug delivery is
a potential strategy to overcome the obstacles presented by the
BBB. Intranasal delivery bypasses the BBB to target CNS, reducing
systemic exposure of drug, thereby reducing the systemic side
effects. It is an attractive option of drug delivery due to its
noninvasiveness8–10.
Moreover, several researches suggest that the “nose-to-brain”
route is one of the most important developments of
pharmaceutical research in brain treatment, including the follow-
ing: (i) the potential to avoid gastrointestinal (GI) and hepatic first-
pass metabolism; (ii) the possibility of delivering drugs not suitable
for oral administration, such as peptides and proteins; and (iii)
most importantly, the transport of exogenous material directly
from the nasal cavity to the brain, thus bypassing the BBB11.
It is still unknown whether the drug is being released from the
carrier system in the nasal cavity and transported to CNS, or the
carrier system is transported along olfactory and/or trigeminal
nerve pathways into the CNS where the drug is released. Thus,
more basic research is required to determine the possible trans-
port pathway of therapeutic carrier to the CNS and their further
fate into the biological system8.
In addition to the vesicular systems, widely used in nasal
administration, other carriers are able to encapsulate drug and to
perform intranasal delivery to CNS, such as cyclodextrins, micro-
and nanoemulsions and nanoparticles11.
Nanoemulsions, by virtue of their lipophilic nature and low
globule size, are widely explored as a delivery system to enhance
uptake across the nasal mucosa. The possibility of using mucoad-
hesive agents such as polyelectrolyte polymers can prolong the
nasal mucosa interaction, providing an extended delivery of the
drug to the olfactory region and henceforth to the brain8.
The aim of this research study was to prepare and characterise a
functional O/W nanoemulsion by using Neem oil. Neem oil is a
deep yellow extract from Azadirachta indica A. Juss. (Meliaceae)
seeds widely used in India and in other South-East countries as ver-
satile medicinal product for several diseases, as pesticide/insecticide,
and in cosmetics due to its low toxicity in in vivo studies12. These
pharmaceutical properties are correlated with the content of limo-
noids (e.g. azadirachtin) as the most bioactive metabolites13. In this
study, we made an effort to prepare nanoemulsions from Neem
seed oil. We used Tween 20 as a nonionic surfactant because non-
ionic surfactants are known to be less affected by pH14,15. The aim
was to prepare NEs with the possibility of combining, in a future
study, the pharmacological properties of Neem oil and those of the
therapeutic agent targeted by nanoemulsion.
Materials and methods
Materials
Neem oil was purchased by Neem Italia (Moniga del Garda (BS),
Italy) and is characterised by an ECOCERT certificate (Biocert Italia
IT013BC041 – ICEA 264BC001). Tween 20 (Tw20), Hepes salt {N-(2-
hydroxyethyl) piperazine-N-(2-ethanesulphonic acid)} and pyrene
were Sigma-Aldrich products (Sigma-Aldrich, Milan, Italy). Distilled
water (Ecological Product System s.r.l., Rome, Italy) was used for all
experiments. All other products and reagents were of analytical
grade.
Nanoemulsion preparation
Nanoemulsions (NEs) were prepared using different amounts of
Tw20 and Neem oil (Table 1) in different weight ratios. Tw20
Table 1. Sample compositions, size, f-potential, PDI values and lipophilic shell features (polarity and microviscosity) of NEs.
Samples Medium Noil (%w/w) Tw20 (%w/w) HD (nm) ± SD f-Pot (mV) ± SD PDI ± SD Polarity (AU) ± SD MicroV (AU) ± SD
A1 Water 33.3 66.6 30.98 ± 0.49 !7.29 ± 1.54 0.20 ± 0.01 0.97 ± 0.01 1.18 ± 0.02
A2 Hepes 30.47 ± 0.28 !16.80 ± 1.22 0.23 ± 0.01 0.94 ± 0.02 1.19 ± 0.01
B1 Water 20.0 80.0 21.73 ± 0.30 !6.35 ± 1.87 0.22 ± 0.01 0.97 ± 0.01 1.22 ± 0.03
B2 Hepes 22.62 ± 0.23 !13.80 ± 1.40 0.24 ± 0.01 0.97 ± 0.01 1.22 ± 0.01
C1 Water 12.4 83.6 15.42 ± 0.11 !5.45 ± 0.21 0.18 ± 0.01 0.97 ± 0.01 1.21 ± 0.02
C2 Hepes 16.76 ± 0.27 !15.00 ± 1.79 0.22 ± 0.01 0.96 ± 0.01 1.21 ± 0.01
NE samples were prepared using two different aqueous media: water and Hepes buffer (10!2M pH 7.4).
Noil: Neem oil; Tw20: Tween 20; HD: hydrodynamic diameter; f-Pot: f-potential; MicroV: microviscosity.
Results are expressed as means ± SD (n¼ 3).
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concentration in the samples was always remarkably above CMC
(0.048mM in water, at 20 #C).
Where indicated, the fluorescent probe pyrene (4mM) was
added to the surfactant/oil mixture before NE preparation. The NEs
were obtained by a simple preparation method, as previously
reported16. Neem oil, Tw20 and distilled water, or Hepes buffer
(10!2M, pH 7.4) where indicated, were used in the preparation of
water-based (O/W) emulsion. The emulsions contained Neem oil
and surfactant with ratios of 1:2, 1:4 and 1:7, respectively. To form
the emulsion, the two phases were vortexed for about 5min. Each
emulsion with microscale droplets was sonicated for 20min at
50 #C using a tapered microtip operating at 20 kHz at an amplitude
of 18% (Vibracell-VCX 400, Sonics, Taunton, MA) to obtain NEs.
Dynamic light scattering measurements
Dynamic light scattering (DLS) on a Malvern Zetasizer Nano ZS90
(Malvern Instruments Ltd., Worcestershire, United Kingdom) was
used to measure the size and the f-potential of the NEs allowing
to determine the mass distribution of particle size as well as the
dispersed particle electrophoretic mobility. Obtained data repre-
sent means of the measurements of f-potential (mV) and of the
hydrodynamic diameter (nm) for the NE droplets. It is important
to notice that size distribution results are expressed as % of inten-
sity of the colloidal dispersion. The polydispersity index (PDI) value
was also determined as an evaluation of the breadth of the size
distribution: a PDI value lower than 0.3 indicates a homogenous
and monodisperse population.
Lipophilic shell characterisation
The fluorescence experiments on NEs incorporating pyrene were
carried out to evaluate the micropolarity of the lipophilic shell sur-
rounding the oil droplet by a Perkin-Elmer LS55 spectrofluorome-
ter. Using the pyrene probe, which is entrapped mainly in the
lipophilic shell, it is possible to investigate the lateral distribution
and the dynamics of membrane compounds. Pyrene is a spatially
sensitive probe, displaying a peculiar band around 460 nm when
two molecules are spatially proximal (excimer); it is worthy to
notice that when the excimer fluorescence decreases, there is an
increase in monomer fluorescence. The monomer and the excimer
possess different fluorescent signals and by evaluating the ratio of
the fluorescence intensities is possible to understand the probe
distribution in the lipid network. The pyrene monomer fluorescent
spectrum consists of five peaks. It is well established that the ratio
I1/I3 between the intensities of the first (I1) and third (I3) vibration
bands of the pyrene fluorescence spectrum (corresponding to
372 nm and 382 nm, respectively) is related to the polarity of the
pyrene environment. Low values of the I1/I3 ratio correspond to a
nonpolar environment. This ratio increases as the polarity of the
medium rises17. Since pyrene is solubilised inside the hydrocarbon
chain of the NE shell, the information obtained from fluorescence
of pyrene in our systems refers to the lipophilic shell of NE
pigeonhole18. The presence of pyrene intramolecular excimers
depends on the rate of conformational change of the molecule,
which is sensitive to the viscosity of the probe microenviron-
ment19. Hence, the IE/IM ratio, where IM and IE stand for the
intensity of the monomer and the excimer fluorescence, respect-
ively, is used to estimate the microviscosity. Because of its high
hydrophobicity, the solubilisation zone of pyrene occurs in the lipi-
dic shell, as was established in the case of polymeric micellar solu-
tions20. The pyrene probe may also evidence (only qualitatively)
the micropolarity variation in the solubilisation region, by the
change in the ratio of monomer vibronic band intensities meas-
ured at 377 nm and 397 nm21.
Physicochemical stability
Specific studies on physical stability of NEs, composed of Tw20
and Neem oil at different ratios, were carried out to investigate
whether significant size and f-potential changes in NE dispersion
occur during storage at the two selected temperatures, using
water or Hepes buffer as aqueous phase. The NEs were stored at 4
and 25 #C for a period of 90 days. Samples were analysed at defin-
ite time intervals (1, 30, 60 and 90 days) and the f-potential and
the mean of hydrodynamic diameter of vesicles were measured as
previously described.
Biological studies were carried out in the presence of simulated
cerebrospinal fluid (CSF), pH 7.3, to evaluate the stability of NE if
administered nasally. The CSF was prepared as described by
McNay et al.22. NEs were diluted in CSF to obtain a final CSF con-
centration of 45% in Hepes buffer (pH 7.4, 10mM). The average
size, polydispersity index and f-potential were evaluated at differ-
ent time points (30, 60, 120 and 180min) at 37 #C.
Small angle X-ray scattering (SAXS)
Small angle X-ray scattering (SAXS) experiments were carried out
at the European Synchrotron Radiation Facility (ESRF, Grenoble,
France). Measurements were acquired at the high-brilliance beam-
line ID02, with two sample-detector distances, in the region of
momentum transfer 0.017 nm!1$ q$ 5 nm!1 (q¼ (4p/k) sin(h/2),
where h is the scattering angle). Samples were inserted in 2mm
capillaries (KI-beam, ENKI, Concesio, Italy) and placed horizontally
onto a thermostatted sample holder (T¼ 25± 0.1 #C). Very shorts
frames were collected (exposure time 0.1 s) and checked for effects
induced by radiation damage before be averaged. After radial
integration and background subtraction, the SAXS profiles report
the scattered radiation intensity as a function of momentum trans-
fer, q. The intensity decay behaviour can give information on the
structure of the particles in solution on the nanometre length
scale. Synchrotron small-angle X-ray scattering (SAXS) techniques
can give information on the internal structure of formulations for
drug delivery23,24.
Transmission electron microscopy (TEM)
Ten microlitres of diluted samples was adsorbed for 1min onto
Formvar-coated copper grids, then negatively stained with 2% fil-
tered aqueous sodium phosphotungstate adjusted to pH 7.0.
Negatively stained preparations were observed by a Philips 208 S
transmission electron microscope (Philips Electron Optics,
Eindhoven, The Netherlands) at 80 kV.
Radical scavenging activity
Free radical scavenging activity (DPPH)
Test solution (1ml) was added to DPPH solution (4ml, 0.004%
methanolic solution). The sample absorbance was noted at 517 nm
after 30-min incubation at room temperature in the darkness.
Results were expressed as milligrams of Trolox equivalents per
sample amount (mg TEs)25.
ABTS (2,2 azino-bis (3-ethylbenzothiazoline-6-sulphonic acid)) rad-
ical cation scavenging activity
ABTSþ radical cation was produced directly by reacting 7mM
ABTS solution with 2.45mM potassium persulphate and allowing
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 1267
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the mixture to stand for 12–16 h in the darkness at the room tem-
perature. Firstly, ABTS solution was diluted with methanol to an
absorbance of 0.70 ± 0.02 at 734 nm. Test solution (1ml) was
mixed with ABTS solution (2ml) and mixed. The sample absorb-
ance was noted at 734 nm after 30-min incubation at room tem-
perature. Results were expressed as milligrams of Trolox
equivalents per sample amount (mg TEs)26.
Evaluation of total antioxidant capacity by phosphomolybdenum
assay
Test solution (0.3ml) was mixed with 3ml of reagent solution
(0.6M sulphuric acid, 28mM sodium phosphate and 4mM ammo-
nium molybdate). The sample absorbance was read at 695 nm
after 90-min incubation at 95 #C. Results were expressed as milli-
moles of Trolox equivalents per sample amount (mmol TEs)27.
Reducing power assays
Cupric ion reducing (CUPRAC) method
Test solution (0.5ml) was added to reaction mixture containing
CuCl2 (1ml, 10mM), neocuproine (1ml, 7.5mM) and NH4Ac buffer
(1ml, 1M, pH 7.0). Similarly, a blank was prepared for each sample
(sample solution (0.5ml) and reaction mixture (3ml) without
CuCl2). Absorbance at 450 nm was read after 30-min incubation at
room temperature. Results were expressed as milligrams of Trolox
equivalents per sample amount (mg TEs)28.
Ferric reducing antioxidant power (FRAP) method
Sample solution (0.1ml) was added to FRAP reagent (2ml) con-
taining acetate buffer (0.3M, pH 3.6), 2,4,6-Tris(2-pyridyl)-s-triazine
(TPTZ) (10mM) in 40mM HCl and ferric chloride (20mM) in a ratio
of 10:1:1 (v/v/v). Then, the absorbance was read at 593 nm after
30-min incubation at room temperature. Results were expressed as
milligrams of Trolox equivalents per sample amount (mg TEs)29.
Metal chelating activity on ferrous ions
Test solution (2ml) was added to FeCl2 solution (0.05ml, 2mM).
The reaction was initiated by the addition of 5mM ferrozine
(0.2ml). Similarly, a blank was prepared for each sample (sample
solution (2ml), FeCl2 solution (0.05ml, 2mM) and water (0.2ml)).
Then, the absorbance of sample and blank was noted at 562 nm
after 10-min incubation at room temperature. Results were
expressed as milligrams of EDTA equivalents per sample amount
(EDTAEs)30.
Cell culture conditions and treatments of cells with NEs
HEp-2 laryngeal cancer cells were grown in MEM medium (Sigma),
supplemented with 1% penicillin–streptomycin and 10% foetal calf
serum (FCS) in a 5% CO2 atmosphere. Proliferation was evaluated
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay as described27. Briefly, 96-well plates were seeded
with 5& 103 cells/well and different amounts of Neem oil were
added to the cells, either as NEs (A2 sample) or as free oil. After
24-h exposure of the cells to the different preparations, 20ll of a
5mg/ml MTT solution in PBS was added to each well, and the
plates incubated for 3 h. After the formazan crystals were dissolved
by the addition 100 ll of dimethyl sulphoxide, optical density (OD)
at 570 nm was determined with a spectrophotometer/fluorimeter
microplate reader (PerkinElmer, Hopkinton, MA)31 and the values
measured for treated cells, compared to those of untreated
controls.
To visualise the uptake of NEs by HEp-2 cells, NEs loaded with
Nile red dye (NE-NR) were prepared. HEp-2 cells seeded on cover
slips into a 12-well plate were exposed to either NE-NR (10lL of
sample A1 NE-NR in 1ml of the cell culture medium) or to free NR
prepared as 1mg/mL stock solution in acetone and used at a final
concentration of 100 ng/mL. After 7- or 24-h incubation, cells were
washed with phosphate-buffered saline solution (PBS) and fixed in
methanol/acetone (1:1) for 5min at !20 #C. After three washes,
coverslips were mounted on slides with 0.1% (w/v) p-phenylenedi-
amine in 10% (v/v) PBS, 90% (v/v) glycerol, pH 8.0 and the speci-
mens observed by fluorescence microscopy using a Leica DM4000
fluorescence microscope equipped with an FX 340 digital camera.
Statistical methods
Statistical significance of differences was evaluated by one-way
ANOVA with repeated measures followed by post hoc paired
Student’s t-test.
Results and discussion
The Neem oil nanoemulsions, prepared by adding the amphiphilic
substance (Tw20) at different weight ratio, were obtained by the
method previously described. The role of the surfactant in NE for-
mation is to facilitate the stabilisation process2,3. Typical examples
of aqueous soluble surfactants are nonionic surfactants (e.g. Tw20)
which are preferred because they are usually less irritating than
the ionic ones32.
The major feature of nanoemulsions is their great stability of
droplet suspension. Stability of an emulsion is hampered in two
ways: flocculation by coalescence and Ostwald ripening. In nanoe-
mulsion systems, flocculation is naturally prevented by steric sta-
bilisation, essentially due to the submicrometric droplet size. The
second one is the reduction of the configurational entropy which
occurs when interdroplet distance becomes lower than the
adsorbed layer thickness. In case of the second problem, stability
is dependent on the droplet radius r, the Hamaker constant A and
the adsorbed layer thickness d. The stability is very high if the d/r
value is high. In case of nanoemulsion droplets, d/r becomes
extremely high in comparison with macroemulsions, which com-
pletely prevents their capability to coagulate2.
The results reported in Table 1 for all NEs were part of the gen-
eral factorial design to establish the combination of variables and
their interactions yielding nanoemulsions with desirable properties
for nose-to-brain targeting. For each dependent variable (hydro-
dynamic diameter, PDI and f-potential), the effects corresponding
to the investigated factors (emulsifier amount and aqueous phase
type) and interactions were taken into account.
To stabilise the NE droplets and prevent the formation of
aggregates, NEs need to show an appropriate f-potential value
able to avoid droplet coalescence or fusion by repulsive, steric or
electrostatic effects33.
DLS measurements indicate that different surfactant ratios form
NEs with different but comparable sizes (Table 1), but in general,
it can be pointed out that increasing surfactant content, the
dimensions decrease. The dimensions of NEs in water or Hepes
buffer are the same for the same sample. Furthermore, all samples
show negative f-potential values (Table 1), indicative of the
absence of droplet aggregation. There is a significant difference in
f-potential values, if NEs have water or Hepes buffer as external
phase. This is probably due to the presence of salt and to the
1268 F. RINALDI ET AL.
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ion content. This content is greater in buffer solution, so in this
solution, ions will be able to adsorb on NE droplet surface and so
to increase f-potential absolute values.
As reported by -Dord-evi#c et al.34, at a given concentration of
surfactants in the formulation, more surfactant molecules are
expected to be adsorbed per unit area in case of larger droplets
leading to greater negative charge and, hence, more negative
f-potential values. It is obvious that all nanoemulsions prepared
with different aqueous phase types show different f-potential
values.
Apart from providing the hydrodynamic diameter and f-poten-
tial value, DLS provides also valuable information on the homo-
geneity of the suspension. A single sharp peak in the DLS profile
implies the existence of a single population of scattering particles.
The polydispersity index (PDI) values of NEs are reported in
Table 1: it is clear that all samples are homogenous and possess
NE population with limited dispersity (PDI< 0.3) and reduced
dimensions useful to carry out a nose-to-brain administration. For
the emerged reasons, only data related to samples with Hepes
buffer (10!2M pH 7.4) as external phase will be presented and dis-
cussed, although every experiment has been performed for all the
samples reported in Table 1.
In order to characterise the nature of the lipophilic shell, micro-
viscosity and polarity have been evaluated. Pyrene-loaded NEs
were prepared following the procedure described previously and
the fluorescence spectrum allowed calculating the values of polar-
ity and microviscosity reported in Table 1. Polarity and microvis-
cosity values are quite similar for all NEs; this is probably due to
the formation of the same shell and in particular of the same inner
structure independently from the surfactant amount used in the
preparation of NEs.
NEs stability is a complex issue and involves chemical, physical
and biological stability, which are all interrelated. The evaluation
of these parameters is fundamental to determine the potential in
vitro/in vivo applications in nanomedicine. The physical stability
studies of NEs are shown in Figure 1. From the analysis of
reported results, it is clear that all NE samples, stored at the two
different temperatures and prepared with the two different aque-
ous solutions, show high colloidal stability. In 90 days, dimension
and f-potential variations of all NE samples at the two different
temperatures show a similar trend, with no significant changes in
physical characteristics of the formulation. Stability studies per-
formed at 25 and 4 #C show that all analysed samples are stable
for at least three months.
The effect of CSF on the stability of the NEs is another import-
ant aspect to take into account in order to evaluate and to under-
stand the behaviour of the vesicles when they are in contact with
fluids different from Hepes buffer. Experiments were performed at
37 #C checking the size and f-potential of the droplets by DLS
analysis up to 3 h. During the time interval analysed, the same
trend is observed for all NEs. NEs in 45% CSF maintained their size
and f-potential values.
It can be concluded that in the presence of CSF, the selected
samples show a good stability, with no significant changes in
dimensions and f-potential values (Figure 2). X-ray scattering
experiments have been performed to characterise the structure
of nanoemulsions on the nanometre length scale. Figure 3
reports the SAXS intensity spectrum for A2. Structural features
are identifiable in different regions of the spectrum; at low q
(q< 0.1 nm!1, large lengths), the intensity profile shows that
aggregates have a globular shape of finite size, of the order of
30 nm. At higher q values, in the region 0.18< q< 0.75 nm!1, the
intensity as a function of q, I(q), is proportional to q!1.66. This
decay behaviour, evidenced as a line of slope !1.66 in the
log–log scale of Figure 3, is characteristic of connected substruc-
tures or sponge phases, on distances between 8 and 30 nm.
Results show that the internal structure of the aggregates is not
a classical core-shell structure with well-defined interfaces
Figure 1. Shelf-life stability of evaluated NEs. Hydrodynamic diameter and f-potential values of different NEs (A–C) prepared using water1 or Hepes buffer2 as aqueous
phase up to 90 days stored at 25 and 4 #C temperatures. Results are expressed as means ± SD (n¼ 3).
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between the oil region, the surfactant region and the water. The
oil phase is finely dispersed in nanosubstructures condensed by
Tween molecules in a 30 nm aggregate.
At lower oil content, the overall dimensions are quite smaller,
but with very similar internal structure (samples are less monodis-
perse). Similar oil substructures are confined in a smaller nano-
sized aggregate stabilised by a higher fraction of surfactant.
In order to investigate the morphology of the NEs, the
three Hepes samples (A2, B2 and C2) were investigated by TEM.
Figure 4 reveals that all nanoemulsion samples were almost spher-
ical in shape, similar to other nanoemulsions prepared with differ-
ent types of oil35. The TEM analyses confirm the presence of lipid
emulsion droplets with an internal structure characterised by the
presence of core with sponge-like features.
Starting from the promising biological activities of Neem oil,
we firstly analysed the effect of this natural product in terms of
antioxidant, reducing power and chelating properties. Pure Neem
oil was characterised by a high antioxidant effect as demonstrated
by a large number of assays with respect to reference compounds
such as Trolox and EDTA (Table 2). These results also suggest that
standardised Neem oil might be beneficial for the preparation of
nanoemulsion with putative pharmacological effects.
Moreover, the prepared nanoemulsions were subjected to the
same biological evaluation as regards their antioxidant, reducing
power and chelating properties. As shown in Table 3, antioxidant
activity (ABTS and DPPH tests) was strongly influenced by the
aqueous component, being Hepes buffer better than water. In the
other assays (CUPRAC, FRAP, phosphomolybdenum and chelating
tests), the activities were quite comparable without any
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Figure 2. Stability in CSF. Size and f-potential measurements by DLS of different NEs (A–C) prepared using water (A) and Hepes buffer 10!2M, pH 7.4 (B) at 37 #C
up to 3 h.
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Figure 3. SAXS intensity spectrum. Scattered radiation intensity as a function of
momentum transfer q of A2 sample at room temperature. The flattening of the
intensity for q< 0.1 nm!1 shows that aggregates have a globular shape of finite
size, of the order of 30 nm. At higher q (0.18< q< 0.75 nm!1), the intensity I(q)/
q!1.66. This decay behaviour is characteristic for an internal core composed by
connected substructures or sponge phases.
Figure 4. Transmission electron photomicrographs of the Hepes nanoemulsion
samples. Panel A: A2; Panel B: B2; Panel C: C2. Arrows indicate NE sizes corre-
sponding to DLS measures.
Table 2. Antioxidant and chelating properties of pure Neem oil.
Assay Resultsa
DPPH scavenging activity (mg TEs/g oil) 7.59 ± 0.07
ABTS scavenging activity (mg TEs/g oil) 14.78 ± 2.33
CUPRAC assay (mg TEs/g oil) 76.14 ± 5.57
FRAP assay (mg TEs/g oil) 51.13 ± 1.42
Phosphomolybdenum assay (mmol TEs/g oil) 0.77 ± 0.06
Metal chelating activity (mg EDTAEs/g oil) 19.26 ± 0.56
aValues expressed are means ± SD of three parallel measurements.
TE: Trolox equivalent; EDTAE: EDTA equivalent.
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significative difference between Hepes buffer and water. These bio-
logical results, in terms of Trolox or EDTA equivalents, were also
not modified by the decreasing content of loaded Neem oil
amount (from 9.2mg/mL for A/A1 to 2.6mg/mL for C/C1).
Collectively, these results could suggest not only a structural role,
but also a protective effect of Neem oil as a pivotal component for
the stability, conservation and microbial resistance of these
nanoemulsions.
It has been reported that bioactive compounds extracted from
Neem oil could affect multiple cellular pathways leading to apop-
totic cell death36. Moreover, in different tumour cell lines, Neem
oil has shown to exert anticancer activity via caspase-dependent
and independent apoptosis as well as autophagy-mediated cell
death37.
In order to use NEs as carriers of pharmacological active com-
pounds, we tested the effects of Neem-based NEs on the prolifer-
ation of tumour cell lines of different origin. Figure 5 illustrates
the results obtained from HEp-2 human laryngeal carcinoma cells,
treated for 24 h with increasing amounts of NEs. The bar graph
(Panel A) shows that the proliferation of cells exposed to 100lM
Neem oil complexed into NEs is significantly higher than that
detected in the samples treated with the same amount of free oil,
indicating that the toxic effect of this agent is reduced in our oil/
surfactant NE preparation.
To further evaluate the NEs as potential carriers of bioactive
substances, we assessed their cellular uptake by fluorescence
microscopy analysis of HEp-2 cells exposed for either 7 or 24 h to
Nile red-loaded NEs or Nile red dye alone. No signal could be
Table 3. Antioxidant and chelating properties of prepared Neem oil-loaded NEs.
Samples
ABTS radical
scavenging activity
(mg TEs/L sample)
DPPH radical
scavenging activity
(mg TEs/L sample)
CUPRAC
(mg TEs/L sample)
FRAP
(mg TEs/L sample)
Phosphomolybdenum
(mmol TEs/L sample)
Metal chelating activity
(mg TEs/L sample)
A1 35.02 ± 0.47' 22.72 ± 0.43 55.94 ± 2.28 61.90 ± 0.02 2.49 ± 0.02 39.34 ± 0.14
A2 53.06 ± 1.87 87.79 ± 9.87 55.51 ± 3.37 62.76 ± 0.97 2.91 ± 0.01 43.35 ± 0.05
B1 35.55 ± 0.24 30.52 ± 3.12 56.65 ± 0.73 60.99 ± 2.90 2.48 ± 0.07 38.49 ± 0.22
B2 46.71 ± 1.66 90.92 ± 8.64 59.91 ± 0.52 70.81 ± 12.76 2.33 ± 0.28 42.60 ± 0.22
C1 33.36 ± 0.19 15.75 ± 1.62 52.92 ± 0.14 56.69 ± 4.87 2.87 ± 0.09 40.38 ± 0.44
C2 49.02 ± 4.73 83.77 ± 3.10 50.73 ± 3.10 58.26 ± 1.85 5.54 ± 1.85 43.45 ± 0.02
'Values expressed are means ± SD of three parallel measurements.
TE: Trolox equivalents; EDTAE: EDTA equivalents; Na: not active.
Figure 5. Exposure of HEp-2 cells to Neem oil-based NEs. HEp-2 cells were treated with NEs or free Neem oil as described (see Methods). The OD values obtained by
MTT assay for treated cells were converted into numbers of cells on a standard curve and expressed as percentages of untreated controls. Bars represent the mean of
three independent experiments ± SD. 'p< .05 (Panel A). Fluorescence microscopy images of HEp-2 control cells exposed to free Nile red (Panel B) and HEp-2 cells
exposed to Nile red-loaded NEs for 7 (Panel C) and 24 h (Panel D) obtained by fluorescence microscopy as described (see Methods). Scale bar: 10lm.
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detected in HEp-2 control cells exposed to free Nile red for 7 h
and similar results were obtained after 24 h (Panel B). In contrast,
a strong fluorescent intracellular signal, as a punctuated pattern
increasing with the time of incubation, could be visualised in the
cytoplasm of cells exposed to the NEs (Panel C: 7 h and Panel D:
24 h). Altogether, these data strongly suggest that our prepara-
tions might represent suitable systems to deliver bioactive
compounds into the cells.
Conclusion
This study confirms the possibility of preparing NEs by Tween 20
and Neem oil at different weight ratios. Among the different for-
mulation tested, the three (both in water and in Hepes buffer) pre-
pared and characterised in the present research paper show the
smallest hydrodynamic size and a homogenous sample size distri-
bution. The evaluation of the antioxidant activity of Neem oil
alone or as NEs confirms that the structured oil in NEs does not
lose its activity and is less cytotoxic than the free oil after inter-
action with HEp-2 cells. A future step will be to load a drug inside
NEs to enhance Neem oil antioxidant activity or to offer a double
therapeutic effect in the same formulation. This type of system
could be successfully applied in nose-to-brain delivery.
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Nanocarrier development for the treatment of CNS disorders has opened a new opportunity for 
many researchers to enhance the delivery of therapeutic agents to the brain. 
Nanocarriers also provide additional advantages such as increased drug protection against 
degradation, enhanced drug bioavailability and drug targeting. 
In this thesis, several drug delivery systems have been specifically designed to reach the brain by 
different routes.  
The obtained results have shown that both proposed structures, Bubblesomes® and C-Pentasomes, 
are able to deliver probes/drugs to the CNS after intravenous administration, combined with FUS 
application, and intranasal administration, respectively.   
In future studies, in vivo behavior of NBs® loaded with different drugs should be investigated in 
terms of drug release into the brain after FUS application in order to confirm the findings obtained 
with fluorescent probe loaded NBs®.  
Neem oil nanoemulsions (NEs), by virtue of their lipophilic nature, low globule size and stability 
over time, are a promising tool as a drug delivery system. 
NEs will be loaded by active substances in order to enhance Neem oil antioxidant activity or to 
offer a double therapeutic effect within the same formulation. 
To enhance their uptake across the nasal mucosa, NEs could be covered by a mucoadhesive agent, 
such as polyelectrolyte polymers, in order to prolong their nasal mucosa interaction and to provide 
an extended delivery of the drug to the olfactory region and henceforth to the brain. 
The improvement of innovative neuro-nanomedicine will provide a concrete opportunity to obtain 
therapeutic benefits. 
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Nose to Brain Delivery: New Trends in Amphiphile-Based “Soft” Nanocarriers  
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Abstract: The aim of the present paper is to highlight the potential of nasal mucosa as an administration route for 
targeting the central nervous system, in particular, the brain. Among the formulation strategies for enhance nose to 
brain drug delivery, the use of colloidal carriers has became a revolutionary approach. These systems should be 
able to entrap drugs in the desired amount, to penetrate through anatomical barriers, to efficiently release the 
loaded drugs in the site of action and moreover to show a good physicochemical, biological stability and good bio-
compatibility. The use of vesicular systems (liposomes and niosomes) together with the use of micelles, in nose to 
brain delivery are here presented. Vesicle structure is characterized by the presence of a hydrophobic bilayer and an aqueous core that is 
absent in micelles. Amphiphilic molecules are responsible for soft nanocarriers formation, in particular: liposomes are formed by phos-
pholipids, while niosomes by non-ionic surfactant and micelles by amphiphilic polymers. 
Keywords: Intranasl delivery, nose-to-brain, central nervous system, liposomes, niosomes, micelles, polymerosomes. 
1. INTRODUCTION 
 The possibility to reach the central nervous system (CNS) is 
specifically regulated by three barriers: the arachnoid epithelium 
(AE), the choroid plexus epithelium (CPE) and the blood-brain 
barrier (BBB). The blood and cerebrospinal fluid (CSF) are sepa-
rated from AE and CPE, whereas brain’s cells and blood from 
BBB. 
 The selectivity of these barriers is fundamental to the protection 
and to the physiology of CNS, but it represents also a big hindrance 
for the treatment of CNS diseases with traditional systemic pharma-
ceutical delivery. The BBB can be the major obstacle for a conven-
tional approach, because it represents the only direct access to cell’s 
brain. The tight junctions between the BBB cells prevent most 
compounds from entering brain tissue and the penetration of mole-
cules in the brain is possible only for the 2% of small polar mole-
cules [1]. In fact the 100% of large-molecule drugs and the 98% of 
small-molecule drugs are not able to cross BBB and to perform 
passive diffusion the molecule drugs must have lipophilic nature 
and ! 400 DA in mass [1,2]. So, even if drugs could be adminis-
tered easily through systematic administration (e.g., by intravenous 
injection) the BBB would limit the access of drugs to the brain. So 
for many years, the BBB has inhibited the use of a lot of therapeutic 
agents for treating Alzheimer’s disease, stroke, brain tumor, head 
injury, depression, anxiety and other CNS disorders [3]. 
 It’s possible to reach brain with alternative routes through 
which therapeutic agents can bypass the BBB: intracerebroventricu-
lar, intraparenchymal, or intrathecal administrations, but these 
routes of administration are invasive, risky, and expensive tech-
niques requiring surgical expertise especially for multiple dosing 
regimens [4]. Until a short time ago, the nasal route has been em-
ployed for delivery of therapeutic agents for the treatment of local 
diseases: nasal allergy, sinusitis, nasal infections and nasal conges-
tion; today the interest of many researchers for the nasal route is 
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high; it can be employed in the therapy of neurologic diseases in 
mice, rats, primates and humans. 
 By this administration route drugs can reach the brain through 
the olfactory region and respiratory epithelium because the olfac-
tory nerve cells and trigeminal nerves are in direct contact with both 
the environment and the CNS.  
 The interest for nasal route is related to [5]: 
o High vascularization of the epithelium of nasal mucosa 
o Presence of porous endothelial membrane 
o Ease of accessibility 
o Broad surface area for rapid and greater drug adsorption 
o Fast pharmacological activity onset 
o Lower enzymatic degradation respect to gastrointestinal and 
liver degradation 
o High total blood flow per cm3.  
 Until now the mechanisms of CNS delivery through nasal route 
administration are not entirely understood, but recent data demon-
strate involvement of vasculature, cerebrospinal fluid, and lym-
phatic system pathway seems to be involved in the transport of 
drugs through nasal route. Also the fate in vivo of the therapeutic 
agent depends on the properties of drug, the formulation character-
istics and the delivery device employed [6].  
 In Fig. (1) the different fate of a drug administered by nasal 
route is represented. In particular the drug will be cleared by muco-
ciliary clearance system. An amount of therapeutic agent, according 
to typical characteristics like lipophilicity and molecular weight, 
could be absorbed by bloodstream and at a later stage eliminated by 
clearance mechanism. The drug present in the blood could be able 
to reach the brain, but later it could be also eliminated from CSF. 
 The alternative route, through which the therapeutic agent can 
reach the brain, is represented by the absorption by the olfactory 
region. This is a route very interesting for research as to the drug 
can arrive in CSF and subsequently in the brain. Three different 
pathways are involved in the passage by olfactory epithelium and 
drugs can cross this ephitelium through one or a combination of 
pathways in particular: transcellular uptake, paracellular uptake and 
1873-4286/15 $58.00+.00  © 2015 Bentham Science Publishers 
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via olfactory nerve. In the olfactory region, olfactory receptor neu-
rons are interspersed among supporting cells and basal cells to form 
the olfactory epithelium. Drugs can be transported through the nasal 
mucosa to the CNS by entering perivascular channels in the lamina 
propria or via extracellular or intracellular mechanisms involving 
olfactory and trigeminal nerves [6]. In the transcellular uptake three 
different internalization mechanisms are implicated: receptor medi-
ated endocytosis, fluid phase endocytosis or passive diffusion, 
while in the second pathway the drug permeation by olfactory epi-
thelium occurs through tight junction between the cells or by clefts 
opening in the membrane. The transport from the olfactory epithe-
lium to CSF by paracellular route is particularly suitable for small 
and hydrophilic molecules. In the case of the uptake through olfac-
tory nerve, the drug permeation can occur extracellularly or by 
intracellular axonal transport to olfactory bulb [7]. This pathway 
can be the principal route for brain delivery of some therapeutic 
agents following nasal administration. 
 Also branches of the trigeminal nerve innervate the respiratory 
and olfactory epithelia of the nasal cavity, so the trigeminal path-
way, often not considered by researchers, can represent a significant 
way for drugs to reach the brain. Therefore very important is the 
relationship between the trigeminal and olfactory routes for the 
brain drug delivery, because of the unique neural connection that 
the olfactory and the trigeminal nerves provide between the nose 
and CSF [8].  
 Equally, intranasal route (IN) is non invasive resulting in better 
patient compliance, it doesn’t require sterility requirements or any 
drug modifications, and it has the big advantage to escape liver 
degradation (first passage effect). 
 Even if nasal administration is characterized by lower enzy-
matic degradation respect to gastrointestinal and liver, the degrada-
tion of drug is possible, so the entrapment of therapeutic agents 
(especially of peptide or protein) in carriers can be useful and ad-
vantageous [9]. 
 Therefore nanocarriers offer an innovative approach to drug 
delivery, providing a range of features including cargo protection, 
increased dose delivery to target sites, enhanced drug transport 
through various biological membranes or prolonging and control-
ling drug release. Actually, the complexity of human body overall 
may lead to ineffective drug treatments. The healthy protective 
mechanisms in the body frequently may lead to ineffective in vivo 
drug treatments. Consequently, the development of biologically 
functional nanocarriers that incorporate drugs to selectively bind 
and target specific cells becomes crucial. There have been many 
attempts to functionalize and design nanocarriers so as to increase 
their efficacy; nevertheless, although the criteria for a successful 
nanocarrier are quite numerous, only few nanocarriers have actually 
shown significant clinical potential. Due to the rapid growth of 
nanotechnology, it can be asserted that the study of drug delivery 
and disease treatment has been revolutionized [10, 11]. 
 In particular, vesicular systems may increase nose-to-brain drug 
delivery enhancing drug chemical and biological stability. Numer-
ous amphiphilic components together with different preparation 
techniques lead to the formation of many vesicular systems: 
liposomes, niosomes, transfersomes, ethosomes, vesosomes, colloi-
dosomes, and pharmacosomes [9-11].  
 In addition to vesicular systems, other carriers are able to en-
capsulate drug and to perform intranasal delivery to CNS: cyclo-
dextrins, microemulsions and nanoparticles.  
 In all the proposed systems, the presence of a hydrophilic core 
is responsible for water-soluble drug entrapment while the hydro-
phobic shell protect the system and entrap lipophilic drugs enhanc-
ing brain uptake after intranasal administration. Furthermore the 
carrier can reach specifically the brain region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Possible routes of transport to the CNS after nasal administration of drugs. 
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 Several approaches have been used to improve the efficacy of 
nanocarriers and in particular they concern modifications on carrier 
surface. An example is the incorporation of CPPs (cell-penetrating 
peptides), useful as bio-enhancers. They are able to increase the 
absorption by nasal mucosa and consequently the brain uptake, 
because of this many researchers use these peptides as functional 
moieties in nanocarrier formulation.  
 There are different types of CPP that have different origin, size 
and sequence, but all CPPs are characterized by positive charge at 
physiological pH, being this a fundamental characteristic to interact 
with a lipid membrane. [12, 13] Some examples are represented by: 
the transcription-activating factor (Tat), penetratin and the SynB 
vectors (family of vectors derived from the antimicrobial peptide 
protegrin 1) [14].  
 One of the major problems associated with nasal administration 
is the rapid removal of drugs or durg delivery system (DDS), from 
the deposition site through mucociliary clearance. This effect is 
responsible for the reduction of contact time between drug or DDS 
and nasal epitelium. This problem could be solved by coating nano-
carriers with mucoadhesive agent. In particular the DDS can be 
prepared with Chitosan, that is a cationic, a mucoadhesive polysac-
charide, able to form electrostatic interactions with the negatively 
charged epithelial cells reducing the mucociliary clearance. Chito-
san is also able to open reversibly tight junctions enhancing the 
extracellular pathways through olfactory and trigeminal nerve [6]. 
Chitosan originates from chitin and in particular is produced by its 
deacetylation (Fig. 2). It can be produced with different molecular 
weight (M.W.) and in particular for the nasal delivery is employed a 
glutamate salt of chitosan (M.W. around 250 kDa) soluble in water 
(up 6.5 pH) and characterized by a deacetylation degree around 
80% [7].  
 Others mucoadhesive agents are acrylic acid derivatives, lectin 
and low methylated pectin. They are able to form a viscous gel 
when they enter in contact with the nasal epitelium with consequent 
reduction of mucociliary clearance. 
 The clearance can be reduced also through preparation of DDS 
with particular ligands able to bind receptor presents on the olfac-
tory and respiratory epithelia, such as lectin, ulex europeus agglutin 
I (UEA I). Another way to DDS surface modification can be the 
addition of efflux transporter inhibitors or vasoconstrictors. 
 Through these improvements clearance reduction, increase of 
residence time of the DDS at delivery site and consequent im-
provement of transport to CNS can be obtained [6].  
 Despite of the great interest in nose-to-brain delivery, very little 
information is available about factors such as surface characteristics 
and size that may affect the transport of nanocarriers from the nasal 
cavity to the CNS. A very recent study [15] evaluates the influence 
of nanovectors characteristics on their potential transport across the 
olfactory epithelium. Model systems - 20, 100 and 200 nm sized 
fluorescent polystyrene (PS) nanoparticles, non-modified or surface 
modified with polysorbate 80 (P80-PS) or chitosan (C-PS) - were 
assessed for transport across excised porcine olfactory epithelium. 
This in vitro study confirms the importance of tailoring nanovector 
properties to influence in vivo fate. Chitosan modified nanoparticles 
resulted in the highest tissue association amongst the tested sys-
tems, with the associated nanoparticles primarily located in the 
mucus, while the polysorbate 80 modified nanoparticles showed 
some penetration into the epithelial cell layer. Interesting data on 
nanocarrier safety were collected: C-PS nanoparticles produced 
damaging effect on the epithelial cell layer in a size dependent 
manner with 20 nm sized nanoparticles causing substantial tissue 
damage, relative to the 100 and 200 nm ones. Regarding the trans-
port across the excised olfactory tissue, none of the nanoparticle 
systems tested, irrespective of particle size or surface modification, 
seemed to be transported across the epithelium. 
 The design of the right formulation is fundamental for the nose 
to brain delivery and the choice of the device (sprays, nose droppers 
or needle-less syringes) is fundamental because different devices 
can address the entrapped and untrapped drug to different regions 
of the nasal cavity. A longer residence time is obtained by using 
nasal spray deposits in the forepart of the nose, with consequent 
better brain delivery. 
 The OptiMistTM and the ViaNaseTM are able to reach olfactory 
region or respiratory epithelia and to escape the deposition in the 
lungs or esophagus, so these devices have the possibility to trans-
port into the CNS, along olfactory nerves, the drug or the DDS. The 
nasal administration through sprays devices is very useful, because 
prevents the nasal drop deposition into nasal cavity and the conse-
quent rapid mucociliary clearance.  
 The volume of the administered dose is an important factor to 
consider because it has effect on the deposition within the nasal 
cavity. Furthermore, the position of the head of the patient, when 
the formulation is administered, is very important and represents a 
factor that can influence the delivery to CNS. For example the posi-
tion “head down and forward” is the most promising to obtain tar-
geting to olfactory region but maybe this position is not ideal in 
terms of patient compliance [6].  
 So in order to obtain the better formulation to brain delivery a 
lot of factors must be taken into account and probably a compro-
mise between them it must be achieved. 
 In this review an up-to-date overview on vesicular system 
(liposome and niosomes) applied to nose to brain delivery will be 
presented. The use of micelles will be also discussed (Fig. 3).  
 
 
 
 
 
 
 
 
Fig. (2). Chitosan structure. 
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2. AMPHIPHILE-BASED “SOFT” NANOCARRIERS 
 The aim of the present paper highlights the potential of nasal 
mucosa as an administration route for targeting the CNS, in particu-
lar, the brain. 
 Among the formulation strategies for enhanced nose to brain 
drug delivery, the use of colloidal carriers has became a revolution-
ary approach.  
 The success of a therapeutic strategy by using nanocarriers 
depends on their ability to entrap drugs, to penetrate through ana-
tomical barriers, to release the incorporated drugs, and to show a 
good stability in nanometric size range [16].  
 The use of vesicular systems (liposomes and niosomes), in nose 
to brain delivery is here presented.  
 Amphiphilic molecules are responsible for colloidal vesicles 
formation. Vesicles have spherical structures with a hydrophobic 
bilayer, and an aqueous core. Liposomes are formed by phospholip-
ids, while niosomes, by non-ionic surfactant, present liposome-like 
features [17]. 
 Lipidand surfactant nanocarriers made up of biodegradable and 
biocompatible materials show promise for application in neu-
romedicine due to their capability of passing intact across the BBB. 
Different investigations have also demonstrated that surfactants can 
be used to prepare stable colloidal supramolecular devices showing 
a certain degree of selectivity for brain delivery. 
 In this section, the use liposomes, niosomes and micelles is 
described, with particular attention to the correlation between the 
modifications that can be made on the vesicular nanocarriers and 
their therapeutic applications in nose to brain delivery. 
2.1. Liposomes and Niosomes 
 Liposomes were firstly highlighted by Alec D Bangham in the 
1960s at the University of Cambridge. They are characterized by 
single or multiple concentric lipid bilayers encapsulating an aque-
ous compartment (Fig. 3) [18, 19].  
 The first formulations were prepared solely by natural lipids, 
while nowadays they can include natural and/or synthetic lipids and 
surfactants. They have the capability of entrap both lipophilic and 
hydrophilic drugs, in the lipid membrane and in the aqueous core, 
respectively. They can be functionalized on their surface to obtain 
different type of targeting or to enhance their biological and/or 
physical stability. 
 The size of these nearly spherical lipid vesicles can range from 
a few nanometers to several micrometers. However, liposomes 
applied to medical use range between 50 and 450 nm [20, 21]. 
 The success of liposomes as drug carriers has been reflected in 
a number of liposome-based formulations, which are commercially 
available [22, 23]. 
 Intranasal drug absorption is highly dependent on physico-
chemical properties of drugs. However, there is a lack of knowl-
edge about correlations between the efficiency of direct nose to 
brain transport and the physicochemical properties of administered 
drugs. Although many different drug types (small molecules, bio-
macromolecules, and specialized drug delivery systems) have been 
shown to enter the brain via direct nose-to-brain transport, and per-
formed studies on the influence M.W, partition coefficient and dis-
tribution coefficient were unable to identify the correlations with 
the extent of direct nose-to-brain transport [24]. 
 Numerous drugs have been delivered by liposomes, but all of 
them have low molecular weight. 
 Zhen-Zhen Yang et al. have prepared rivastigmine liposomes 
(Lp) and cell penetrating peptide (CPP) modified liposomes (CPP-
Lp) to improve rivastigmine distribution in brain for Alzheimer 
disease (AD) therapy and proceed to enhance pharmacodynamics 
by intranasal administration and to minimize side effects. Liposo-
mes were prepared using: Egg Phosphatidylcholine (EPC):Choles-
terol (Chol) (1:1, molar ratio) and EPC, Chol, 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)]-
CPP (DSPE-PEG-CPP) (1:1:0.06, molar ratio) by extrusion tech-
nique. BBB model with BMVECs cells (Brain microvascular endo-
thelial cells) was used, and transport efficiency was evaluated. Lp 
and CPP-Lp at a rivastigmine concentration of 5 mg/mL were used 
for IN administration to rats. The results revealed that Lp and espe-
cially the CPP-Lp formulation could enhance the permeability 
across the BBB by murine brain microvascular endothelial cells 
model in vitro. IN administration of rivastigmine solution and rivas-
tigmine liposomes demonstrated the capacity to improve 
rivastigmine distribution and adequate retention in CNS regions 
especially in hippocampus and cortex, which were the regions most 
affected by AD, than that of intravenous administration. In addition, 
there was very mild nasal toxicity of liposomal formulations. The 
data suggest that rivastigmine CPP-Lp improve the brain delivery 
and enhance pharmacodynamics with respect to BBB penetration 
and nasal olfactory pathway into brain after IN administration and 
simultaneously decrease the hepatic first pass metabolism and 
gastrointestinal adverse effects of the drug [25]. 
 As a potential strategy for AD treatment quercetin loaded 
liposomes were also used. 
 Phachonpai et al., due to recent findings that demonstrated the 
crucial role of oxidative stress on the pathophysiology of the dis-
ease, decided to use the potent antioxidant quercetin by a nasal 
administration of quercetin liposomes in order to obtain a protection 
against neurodegeneration in AD. Quercetin dehydrate (98%), high-
purity egg L-!-Phosphatidylcholine and cholesterol were used to 
prepare quercetin encapsulated liposomes (QL). All animals were 
treated by QL, containing 0.5 mg of quercetin in 20 "L, or 
liposomes without quercetin. After 1 week of treatment, they were 
sacrificed and removed the brains to determine the density of neu-
 
 
 
 
 
 
Fig. (3). Drug delivery systems based on amphiphilic compounds.  
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rons and cholinergic neurons in hippocampus using histochemical 
and immunohistochemical techniques. 
 QL attenuated the degeneration of neurons and cholinergic 
neurons in hippocampus. Therefore, the neuroprotective effect of 
QL occurred partly via the reduction of oxidative stress [26].  
 The main proposed pathway of quercetin delivery via nasal 
administration was through the olfactory epithelium and found in 
the CSF later, because the liposomes behaved as semilipophilic 
particles. Therefore, QL could be rapidly absorbed into the CSF 
[26].  
 Terdthai Tong-un together with the authors of the previous 
study, analyzed the effects of quercetin liposomes via nasal route on 
improving cognitive behavior and reducing biochemical markers of 
oxidative stress such as Superoxide Dismutase (SOD), catalase, 
glutathione and Malondialdehyde (MDA) in the hippocampus in 
animal model of AD induced by ethylcholine mustard azirinium ion 
(AF64A). To this aim, male Wistar rats were pretreated with QL, 
containing the same dose of quercetin of the previous study (0.5 mg 
of quercetin in 20 #L), via IN route once daily continually for 2 
weeks before and 1 week after AF64A administration. Learning and 
memory were evaluated using the Morris water maze test, 7 days 
after the AF64A administration and then the rats were sacrificed for 
determining the content of MDA and the activities of SOD, catalase 
and glutathione in the hippocampus. QL via nasal administration 
significantly improved memory impairment by inhibiting the oxida-
tive damage in hippocampus. The possible underlying mechanisms 
might be partly associated with a decrease in the level of MDA 
whereas the activity of SOD, catalase and glutathione increase [27].  
 The same research group determined the effect of QL adminis-
tered IN on the anti-anxiety, anti-depression like activity and cogni-
tive enhancing effect [28].  
 Male Wistar rats were administered QL, containing the same 
dose of the previous study via IN route once daily continually for 4 
weeks. The anxiolytic activity, anti-depression like activity and 
cognitive enhancing effect were determined after single administra-
tion, 1-4 week of treatment using elevated plus maze test, forced 
swimming test and Morris water maze test respectively. QL encap-
sulation via nasal route possessed anxiolytic, anti-depression like 
activity and cognitive enhancing effect at all treatment duration 
[28]. 
 Salama et al. prepared a new system: phospholipid based col-
loidal nanocubic vesicles encapsulating olanzapine, an atypical 
antipsychotic drug that suffers from low brain permeability due to 
efflux by P-glycoproteins and hepatic first-pass metabolism, for its 
brain targeting via the nasal route.  
 The nanocubic vesicles were prepared by incorporating non-
ionic copolymers, poloxamer 188 or 407, in the lipid bilayer. The 
effect of phospholipid:poloxamer molar ratio on the physicochemi-
cal properties of the nanocubic vesicles was investigated. The in 
vivo behavior and brain targeting of these vesicles were evaluated 
in rats. TEM photographs showed that the vesicles looked spherical 
before adding poloxamer. However, after poloxamer incorporation, 
the vesicles showed a predominant cubic shape, except those con-
taining phospholipid:poloxamer in the molar ratio 5:1 which were 
spherical. Differential Scanning Calorimetry (DSC) studies con-
firmed perturbation of the packing characteristics as well as fluidi-
zation of the lipid bilayer by the polymer with consequent forma-
tion of the nanocubic structure. The mean diameter of the vesicles 
was in the range of 363-645 nm. All vesicles were elastic and the 
elasticity was found to depend on both poloxamer type and concen-
tration. The IN nanocubic vesicles were significantly more efficient 
in targeting olanzapine to the brain compared to the liposomal vesi-
cles with drug targeting efficiency values of 100% and 80%, re-
spectively, and absolute bioavailability of 37.9% and 14.9%, re-
spectively [29]. 
 The same research group investigated the presence of a possible 
direct correlation between vesicle elasticity and the amount of drug 
reaching the brain intranasally [30]. Transfersomes by phosphati-
dylcholine (PC) as the lipid matrix and sodium deoxycholate 
(SDC), Span® 60, Cremophor® EL, Brij® 58, and Brij® 72 as sur-
factants were prepared and the influence of the type of surfactant 
and PC-to-surfactant ratio on vesicle morphology, size, membrane 
elasticity, drug entrapment, and in vitro drug release was studied. 
The prepared transfersomes were mainly spherical in shape, with 
diameters ranging from 310 to 885!nm. Transfersomes containing 
SDC and Span® 60 with optimum lipid-to-surfactant molar ratio 
showed suitable diameters (410 and 380!nm, respectively) and de-
formability indices (17.68 and 20.76!mL/sec, respectively). Values 
for absolute drug bioavailability in rat plasma for transfersomes 
containing SDC and those containing Span® 60 were 24.75 and 
51.35%, whereas AUC (0-360 min) values in rat brain were 
22,334.6 and 36,486.3!ng/mL/min, respectively. This interesting 
study revealed that the deformability index, in addition to size and 
surface modifications [15], is a parameter having a direct relation 
with the amount of the drug delivered to the brain by the nasal 
route. 
 Li et al. investigated the effects of IN administration of Gal-
anthamine Hydrobromide (GH) loaded flexible liposomes on the 
efficiency of acetylcholinesterase inhibition, as well as the pharma-
cokinetic behavior of GH in rat brain. The GH loaded flexible 
liposomes were deeply characterized for shape, entrapment capac-
ity, size distribution and zeta potential by transmission electron 
microscopy (TEM), ultracentrifugation and dynamic light scattering 
(DLS), respectively. The inhibition of acetylcholinesterase was 
investigated using rat brain homogenates and microdialysis was 
used to determine the pharmacokinetic behavior of GH in rat’s 
brain. Cytotoxicity studies were also performed on rat pheochromo-
cytoma PC-12 cell line. The results revealed that GH intranasally 
administered increases acetylcholinesterase inhibition compared 
with oral administration and that GH loaded in flexible liposomes is 
the most efficient formulation with Cmax and AUC values 3.52 and 
3.36 times higher than those of orally administered GH, moreover, 
the Tmax was greatly shortened from 1.5 h for oral administration to 
0.75 h for intranasal administration of GH loaded flexible liposo-
mes. Cell viability studies showed that the flexible liposome carrier 
is not toxic to the cultured cells and the cytotoxicity of GH to cells 
was clearly decreased by loading in flexible liposomes. These 
results indicate that intranasal administration of GH loaded flexible 
liposomes could readily transport GH into brain tissues, suggesting 
some promise for this approach in successful brain-drug targeting in 
AD treatment [31].  
 Migliore et al. evaluated the efficiency of cationic liposomes 
for the delivery of proteins to the brain by employing the nasal 
route of administration. They loaded the liposomes with ovalbumin 
and 50 #g was intranasally administered to rat, it was observed that 
after 6 hours ovalbumin was widely distributed throughout the brain 
of the rat [32].  
 Niosomes were first reported in the 1970s as suitable ingredi-
ents for cosmetic application. They are formed by the self-
assemblage of non-ionic amphiphiles in aqueous media and provide 
a concentric bilayer showing architecture similar to that of 
liposomes, although lacking their bilayer arrangement. Different 
papers in literature report the use of niosomes for nose to brain 
administration [17].  
 In particular, Nagaraju et al. studied the possibility of deliver 
folic acid in niosomes (FANs), because of the low blood level of 
folates is the primary cause of depression in Alzheimer’s disease. 
Folic acid is a water-soluble vitamin showing difficulty in crossing 
the blood-brain barrier and thus was formulated as niosomal nasal 
drug delivery systems to target the brain. FANs were prepared us-
ing different non-ionic surfactants i.e., Span® 20, Span® 60, Span® 
80, Tween 20, Tween 80 and cholesterol by using lipid layer hydra-
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tion technique. These structures were characterized in terms of their 
physicochemical properties. The prepared niosomes were in the size 
range of 3.05-5.625 !m. Niosomes prepared with Span® 60 and 
cholesterol in the ratio of 1:1 shown higher entrapment efficiency 
of 69.42% and better in vitro drug release of 64.2% at the end of 12 
hrs and therefore considered as optimized formulation. Niosomes 
showed good stability over the period of storage. Ex-vivo perfusion 
studies performed using rat model, showed that about 48.15% of 
drug is absorbed through nasal cavity at the end of 6 hrs [33].  
2.2. Micelles 
 A key property of amphiphilic molecules is their capability to 
form micelles by self-assembly in a particular solvent [34].   
 Micelles are spherical aggregates of highly concentrated am-
phiphilic molecules which, in aqueous media, self-assemble point-
ing hydrophilic head groups on their surfaces hydrophobic chains 
into internal, compact matrixes. The amphiphilic molecules form a 
dynamic equilibrium between the molecules solubilized in the 
aqueous medium and the micelles present with a continuous and 
constant exchange of components. Polymeric vesicles, the so-called 
polymersomes, are self-assembled polymeric shells which form 
from copolymer amphiphile blocks, such as polyethylene glycol-
polylactic acid (PEG-PLA) and PEG-polycaprolactone (PEG-PCL). 
These biomaterials boast amphiphilic properties like the phosphol-
ipids, but they are formed by polymers covalently conjugated into 
linear or branched structures. Polymersomes are different from 
polymeric nanoparticles due to their mechanical properties and 
compositions and form a polymeric bilayer surrounding an internal 
aqueous core, which can load hydrophobic or hydrophilic drugs. 
 The nano-sized micelles have been extensively studied as core-
shell-type colloidal carriers for delivery of drugs and genes [35, 
36].  
 The use of these carriers could increase the availability of drugs 
to the CNS, since their small diameter would potentially allow the 
nanoparticles to be transported transcellularly along the neurons to 
the brain through various endocytic pathways of sustentacular or 
neuronal cells present in the nasal membrane [37].  
 Micellar nanocarriers were proposed to threat different patholo-
gies, such as migraine, psychosis and brain tumors.  
 Methoxypolyethylene glycol (MPEG)-polycaprolactone (PCL) 
(MPEG-PCL) were prepared and loaded with coumarin. The effi-
ciency of brain delivery following intravenous and intranasal routes 
of administration of MPEG-PCL nanomicelles was compared and 
the amount of coumarin measured in brain tissue after intranasal 
administration was significantly higher than that observed after 
intravenous administration, providing further evidence that the 
intranasal route is an effective method for brain-targeted drug de-
livery [38].  
 The obtained results prompted to conjugate MPEG-PCL co-
polymers with Tat peptide (MPEG-PCL-Tat) and MPEG-PCL-Tat 
micelles were loaded with coumarin. The presence of Tat, a cell 
penetrating peptide, led to a coumarin concentration in brain tissue 
of rats significantly higher than in rats administered coumarin-
loaded MPEG-PCL micelles [38]. 
 The same nanocarriers were proposed as delivery systems of 
the anti-cancer drug camptothecin (CPT) and the drug activity with 
intranasal delivery appears to be superior to the results obtained 
with the administration of simple CPT solution, which reportedly 
results in high drug levels in the systemic circulation [39]. 
 Small interfering RNA (siRNA) has great potential as a thera-
peutic agent against different CNS diseases [40] and the develop-
ment of effective strategies that would enhance siRNA delivery to 
the brain is of great clinical interest. In order to improve the effi-
ciency of brain siRNA delivery systems, an approach that combines 
siRNA nose-to-brain delivery with Tat- modified micelles was 
developed [41, 42].  
 The results reported in this studies suggest that the proposed 
system of delivery of nucleic acid to the brain by intranasal admini-
stration using MPEG-PCL-Tat relies primarily on an increase in the 
transfer of nucleic acid to the brain via the olfactory nerve and tri-
geminal nerve pathways.  
 It can be underlined that to improve drug delivery to the brain 
the above reported approaches could be applied and that drug-
loaded surface-loaded polymer micelles could be useful against 
intractable neuropsychiatric disorders, brain tumors, and cerebral 
infarction [43]. Nose to brain delivery of micellar carriers was also 
proposed as a novel approach to migraine therapy; in particular, two 
different triptans were loaded in micelles: Zolmitriptan [44] and 
Sumatriptan [45]. 
 Various GRAS (generally regarded as safe) approved surfac-
tants, such as Transcutol P® and Pluronic® F127, were employed 
for formulating micellar nanocarriers after mixing with Polyethyl-
ene glycol-400 (PEG-400), benzyl alcohol and Vitamin E-TPGS 
(TPGS, d-$-Tocopheryl polyethylene glycol 1,000 succinate). 
 In both studies, toxicity evaluation indicated the safety of the 
developed micellar nanocarrier for administration in the nasal cav-
ity. In vivo biodistribution studies in rats, conducted with the radio-
labeled drug-loaded formulations, indicated the superiority of the 
developed nanocarrier for brain targeting when compared with 
intravenous and nasal administration of drug solutions.  
 The encouraging results obtained in lower animals provided an 
excellent lead to further evaluate micellar formulations in higher 
animals and finally in clinical settings. 
 Nanomicellar carriers, as well as phospholipid based colloidal 
nanocubic vesicles [29], were also proposed for brain delivery of 
olanzapine (OZ).  
 OZ-loaded micellar nanocarriers were prepared, using a mixture 
of Pluronic® L121 (L121) as a hydrophobic block copolymer (EO5-
PO68-EO5) and Pluronic
® P123 (P123) as a more hydrophilic block 
copolymer (EO20-PO69-EO20), adopting thin-film hydration method 
and their nose-to-brain targeting potential was investigated. NMR 
studies confirmed the formation of core-shell type micelles and the 
incorporation of OZ into the micelle core. Optimizing the drug: 
Pluronic® L121: Pluronic® P123 ratio would encourage the devel-
opment of stable micelles having high drug loads as well as an effi-
cient sustained drug-release [46].  
 The presence of a mucus layer and quick clearance can 
limit the use of nose-to-brain drug delivery route. Amphiphilic 
methacrylic copolymer-functionalized poly(%-caprolactone) nano-
capsules were proposed as a mucoadhesive system to deliver olan-
zapine after intranasal administration leading to an enhanced 
amount of drug in the brain of rats (1.5-fold higher compared to the 
drug solution) with no effect on the nasal mucosa integrity after 
repeated doses [47].  
 In an interesting study by Zhuang et al. [48], “natural” vesicles, 
mouse lymphoma cell line (EL-4) derived exosomes (Exo), were 
used to encapsulate curcumin (Exo-cur) or a signal transducer and 
activator of transcription 3 inhibitor (Exo-JSI124) were delivered 
noninvasively to microglia cells via an intranasal route.  
 Exosomes are cell-derived vesicles and are present in many 
biological fluids, with a diameter between 30 and 100 nm. 
 Exo-cur and Exo-JSI124 were prepared by simply mixing ac-
tive substances with EL-4 exosomes in appropriate buffer. After 
centrifugation, samples were subsequently collected, washed and 
resuspended in PBS. Exo-cur or Exo-JSI124 was administered in-
tranasally as drops with a small pipette. Intranasal administration of 
Exo-cur or Exo-JSI124 allowed a rapid delivery of encapsulated 
drugs to the brain that were selectively taken up by microglial cells, 
inducing apoptosis [48]. 
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Table 1. “Soft” nanocarriers in nose to brain delivery. 
Carrier Drug Action Refs. 
Liposomes and 
CPP-modified 
liposomes 
Rivastigmine Alzheimer Dis-
ease 
[25] 
 
Liposomes Quercetin Alzheimer Dis-
ease; anxiety and 
depression 
[26-28] 
Liposomes Galanthamine 
Hydrobromide 
Alzheimer Dis-
ease  
[31] 
Liposomes Ovalbumin Model chemical [32] 
Niosomes Folic Acid Depression in 
Alzheimer Dis-
ease 
[33] 
Polymeric mi-
celles 
Coumarin Model chemical [37] 
Tat-modified 
polymeric mi-
celles 
Coumarin Model chemical [37] 
Tat-modified 
polymeric mi-
celles 
Camptothecin Brain tumor [38] 
Tat-modified 
polymeric mi-
celles 
siRNA Transfer of nu-
cleic acid to the 
brain 
[41, 42] 
Surfactant mi-
celles 
Zolmitriptan Migraine [44] 
Surfactant mi-
celles 
Sumatriptan Migraine [45] 
Nanocubic vesi-
cles 
Olanzapine Phsycosis [29] 
Transfersomes Olanzapine Phsycosis [30] 
Polymeric mi-
celles 
Olanzapine Phsycosis [46] 
Mucoadhesive 
polymeric mi-
celles 
Olanzapine Phsycosis [47] 
EL-4 exosomes Curcumin Anti-
inflammatory 
[48] 
EL-4 exosomes Activator of 
transcription 3 
inhibitor (JSI124) 
Anti-
inflammatory 
[48] 
 
 These results should prompt further investigations on the effects 
of exosomes released from resident cells located in intranasal cavity 
on brain cells, in particular, brain immune cells [49]. 
 It is conceivable that exosomes or other vesicular carriers show-
ing the same feature of these “natural” vesicles, delivered to the 
nasal cavity, could play a role in brain immune tolerance. 
 
 Analyzing literature related to intranasal delivery, interesting 
approaches using particular amphiphilic based soft nanocarriers can 
be found. In particular systems as virosomes and lyophilized gels 
containing unsaturated fatty acid liposomes (ufasomes) [50, 51] 
have been proposed as innovative carriers for intranasal delivery. 
The study of their potential use in nose to brain delivery could be 
the object of future researches.  
CONCLUSION 
 A feasible approach to CNS delivery is the nasal route of ad-
ministration of vesicular carriers (Table 1), which bypasses the 
blood-brain barrier and delivers active substances inducing consid-
erably less, if any, peripheral uptake than other administration 
modes. Intranasal drug administration is non-invasive and it could 
be a promising drug delivery method for patients who suffer from 
chronic and crippling CNS diseases. According to this evidence, it 
can be looked forward to many more efforts in developing vesicular 
carriers able to reach CNS by the nasal route, according to the evi-
dence that, despite the many stimulating studies there is still a long 
road ahead to becoming a clinical reality. 
 It has been shown that the application of drug loaded am-
phiphile-based nanocarriers to the nasal cavity can increase the 
amount of bioactive substances that reaches the CNS directly from 
the nasal cavity. However, the factors that govern the transport of 
the drug and/or nanocarriers are still unclear. 
 In sum, and considering that data on long term therapeutic and 
side effects of nasal administration of drugs in humans are still 
sparse, much more work is needed to fully characterize the potential 
of nose to brain delivery in patients. 
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Abstract: The blood–brain barrier (BBB) plays a fundamental role in protecting and 
maintaining the homeostasis of the brain. For this reason, drug delivery to the brain is much 
more difficult than that to other compartments of the body. In order to bypass or cross the 
BBB, many strategies have been developed: invasive techniques, such as temporary disrup-
tion of the BBB or direct intraventricular and intracerebral administration of the drug, as 
well as noninvasive techniques. Preliminary results, reported in the large number of stud-
ies on the potential strategies for brain delivery, are encouraging, but it is far too early to 
draw any conclusion about the actual use of these therapeutic approaches. Among the most 
recent, but still pioneering, approaches related to the nasal mucosa properties, the permea-
bilization of the BBB via nasal mucosal engrafting can offer new potential opportunities. It 
should be emphasized that this surgical procedure is quite invasive, but the implication for 
patient outcome needs to be compared to the gold standard of direct intracranial injection, 
and evaluated whilst keeping in mind that central nervous system diseases and lysosomal 
storage diseases are chronic and severely debilitating and that up to now no therapy seems 
to be completely successful.
Keywords: CNS, BBB, nasal mucosa, grafting, lysosomal storage diseases, enzyme replace-
ment therapies
Introduction
There are more than 1,000 agents which are active on central nervous system (CNS) 
pathologies that have shown promising perspectives in preclinical studies but failed 
to show good results in the later phases of the development process (at Phase III or 
even after registration).1–5
For this reason, disorders of the CNS represent one of the largest areas of unsatis-
fied medical needs, with about 2 billion people affected worldwide and many pharma 
companies moving away from such fields of innovative research because of the high 
risk of failure associated with CNS medicines, together with the ever increasing 
approval time.6,7
One of the major reasons for the poor translation of neuroscience research into 
medicines is the high degree of complexity of the human CNS, and effective nonin-
vasive treatment of neurological diseases is often limited by the very limited access 
of therapeutic agents into the CNS owing to the presence of two anatomical and bio-
chemical dynamic barriers: the blood–brain barrier (BBB) and the blood–cerebrospinal 
fluid barrier (BCSFB).8
It is already well known that BBB is formed by endothelial cells (ECs), which line 
up in capillaries of the brain and spinal cord by a variety of pericytes, vascular smooth 
muscle cells, astrocytes, and microglia.9 The BBB, composed of densely packed cells 
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with copious intercellular tight junctions (TJs), active efflux 
pumps, and a trilamellar basement membrane, regulates the 
synaptic signaling function. Furthermore, BBB protects the 
CNS from neurotoxic substances, ensures brain nutrition, and 
prevents the entry of unwanted cells into the brain as well 
as the absorption of polar or high molecular weight (HMW) 
molecules larger than 500 Da; in other words, more than 98% 
of therapeutic drugs.10–12
The BBB also displays immunological and transporta-
tion features. The immune barrier is composed of microglia, 
perivascular mast cells, and macrophages. The transport 
barrier includes para- and transcellular routes. In addition, 
the brain is extremely rich in vascularity, with each neuron 
in contact with a capillary.13–15
The BCSFB is formed by the TJs of choroid plexus cells 
surrounding the microvascular endothelium with intracellular 
gap and fenestration. Owing to their structural difference, 
BBB and BCSFB have different main functions, but they 
both participate in controlling the transfer of molecules 
between the blood and the brain parenchyma or cerebrospinal 
fluid (CSF).
Under certain physiological conditions, circulating 
molecules can only gain access to the brain or CSF via 
a transcellular route through the capillary endothelial 
cells or choroid plexus cells, by either passive or active 
transport, or both.
Furthermore, if molecules overcome the BBB, they are 
not able to do so in high amounts, and they are exposed to 
degradation and/or rapid efflux from the CNS.16
Different transporters suitable for targeting molecules and 
delivering endogenous and exogenous compounds across the 
BBB are located on the BBB (Figure 1).
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Figure 1 Transport routes across the blood–brain barrier.
Note: Green lines indicate tight junctions; blue boxes indicate no carrier or receptor mediated transport.
Abbreviations: BBB, blood–brain barrier; RMT, receptor-mediated transcytosis; AMT, adsorptive-mediated transcytosis.
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All these highly regulated and efficient features supply 
BBB with multiple functions as a physical barrier (TJ), a 
transport barrier (P-gp), a metabolic or enzymatic barrier, 
and an immunological barrier.17,18
Functions and organization of the BBB can be altered 
under pathological conditions, such as multiple sclerosis, 
epilepsy, acquired immune deficiency syndrome (AIDS), 
dementia, stroke, and brain cancer.19,20
It should also be pointed out that alterations in the barrier, 
as in the blood–brain tumor barrier (BBTB), often form an 
increased obstacle in CNS therapy by preventing the delivery 
of potentially effective therapeutic agents.21
Molecular and physiological mechanisms involved in 
the transport of compounds through the BBB can be used to 
design drug and drug carriers for brain delivery.
Ligands such as peptides, monoclonal antibodies (mAbs), 
modified proteins, peptidomimetic antibodies, and penetrat-
ing peptides can be conjugated to bioactive compounds or to 
colloidal supramolecular aggregates and potentially used to 
cross the BBB and accumulate inside the CNS.22
The paradox is that more than 99% of the global CNS 
drug development effort is devoted to CNS drug discovery, 
while less than 1% is devoted to CNS drug delivery.23
Fortunately, scientists realized how important is the 
pathway from the systemic circulation to the CNS, and 
a few years ago, the Stroke Therapy Academic Industry 
Roundtable Preclinical Recommendations group highly 
recommended that future neurological disease research 
should consider also the method of drug delivery when 
developing novel drugs.24
Current methodologies for drug 
delivery across the BBB
In order to bypass or cross the BBB, many strategies have 
been developed: invasive techniques, such as temporary dis-
ruption of the BBB or intraventricular and intracerebral direct 
administration of the drug, and noninvasive techniques. The 
invasive strategies, however, compromise the integrity and 
the functions of the BBB, allowing the potential accumulation 
of neurotoxic xenobiotics and exogenous agents; a state that 
is moderately to severely neurotoxic.25,26
Noninvasive chemical approaches involve the “manipula-
tion” of active substances to be administered with the aim of 
increasing physiological stability and degree of penetration 
into the brain by passive diffusion or by active targeting. 
For this purpose, several methods have been proposed, such 
as the lipidization via addition of lipid-like molecules to 
the structure; the addition of molecules able to use specific 
endogenous transporters (eg, nutrients and other essential 
compounds), and the synthesis of prodrugs. Chemical modi-
fications can be considered a safe, noninvasive approach, but 
they need chemical or enzymatic in vivo transformations that 
sometimes may lead to the loss of therapeutic activity or the 
activation of the physiological defense mechanisms of the 
membrane pumping out exogenous compounds.
Along with chemical modifications, there is an increase 
in multidisciplinary investigations, intended to facilitate 
the crossing of BBB, that combine biological, nanotech-
nological, and even biophysical expertise. In this sense, 
the most recent approaches concern TJ opening (eg, 
through the utilization of compounds like bradykinin 
via second messengers), receptor-mediated, adsorptive-
mediated transportation (some potentially useful tech-
nologies based on receptor-mediated transcytosis are 
currently under clinical evaluation for brain tumor therapy – 
Clinicaltrials.gov: NCT01967810, NCT02048059, 
NCT01480583, NCT01386580, NCT01818713), and efflux 
pump inhibition by specific inhibitors that appears to be a 
strategy capable of delivering the drug to the brain without 
affecting the integrity of the endothelial layer and TJ that 
might cause toxicities. Also, energy-based physical methods, 
such as ultrasound, microwave, or electromagnetic fields, 
are under evaluation.
Another approach for the improvement of brain targeting 
is represented by the combination of the drug with the living 
cells, acting as Trojan horses that can cross the BBB.27–29
In recent times, much attention has been given to nano-
technology in many areas because of its significant potential 
for the successful treatment of severe diseases such as cancer 
and neurological diseases.
A promising noninvasive approach to brain delivery 
involves nanomedicine, which takes advantage of the pos-
sible assembly of several biomaterials that can provide 
a delivery platform, at nanoscale size, capable of raising 
brain levels of drug substances otherwise unable to cross 
the BBB.23,30
The success of a therapeutic strategy by means of nano-
carriers depends on their ability to entrap drugs, to penetrate 
through anatomical barriers, and to release the incorporated 
drugs, accompanied by a good stability in the nanometric 
size range.26
One possible strategy is the drug encapsulation into 
brain-targeted nanocarriers such as polymeric nanopar-
ticles, dendrimers, vesicular carriers, metal, and silicon. 
These nanocarriers can have an organic or inorganic core 
and a surface coating with organic moieties able to interact 
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with the biological system at a molecular level for crossing 
the BBB.31
Modification of nanocarrier surface by adsorption or 
covalent linking of hydrophilic polymers, such as PEG, 
polysorbate 80, or polysaccharides, leads to an increase in 
nanocarrier circulation in the blood, whereas the surface 
derivatization with molecules that recognize cellular 
receptors facilitates the penetration of nanoparticles through 
the BBB.32
The strategy often termed active targeting involves two 
types of transports: adsorptive-mediated transcytosis (AMT) 
and receptor-mediated transcytosis (RMT). The AMT has 
gained considerable attention because several studies assess 
that this strategy has the possibility to enhance the transport 
of nanocarriers across the BBB, using cationic proteins or 
cell-penetrating peptides.33 However, as AMT is a nonspecific 
process, conjugation of such cationic proteins will also increase 
the adsorptive uptake process of nanocarriers in other parts of 
the body, which may possibly create toxic and immunogenic 
concerns. Transport of nanocarriers to the brain using the 
RMT process is more specific than AMT. The RMT involves 
addition of endogenous molecules on the nanocarrier surface, 
which are substrates for specific receptors expressed on the 
BBB. Addition of proteins (eg, transferrin, lactoferrin, Apoli-
poprotein E [ApoE]); peptides (eg, glutathione); or antitrans-
ferrin receptor antibody OX26 on the surface of liposomes, 
polymeric nanoparticles, and lipidic nanoparticles significantly 
increased the BBB penetrations of such nanocarriers.34
Size of the nanocarrier along with surface charge, surface 
hydration, and targeting strategy are important characteristics 
for development of a successful brain-targeted nanocolloid 
drug delivery system for glioblastoma multiforme (GBM) 
treatment. Among various possible nanocarriers, liposomes, 
polymeric nanoparticles, and lipid nanocarriers are the most 
widely studied, and will be discussed in detail in the follow-
ing sections.
Preliminary results reported in the large number of 
studies on the potential strategies to overcome and/or cross 
the BBB are encouraging, but it is far too early to draw any 
conclusion about the actual practical applications of these 
therapeutic approaches.
Challenge in nasal delivery to CNS
Nasal delivery has conventionally been restricted to topically/
locally acting therapeutic agents for the treatment of nasal 
problems (eg, cold and nasal hypersensitivity). Recently, 
nasal route received increased attention as a substitute for 
oral and parenteral routes for several systemic therapeutic 
agents. The highly vascularized and immunogenic nasal 
mucosa allows fast onset of action, enhanced bioavailability 
and patient compliance.35–37
The pioneering method of intranasal delivery for drug 
delivery into the CNS was first described in 1991 by 
Dr William H Frey, and nowadays, it has proven to be a 
safe and efficient way to deliver exogenous molecules to 
the CNS.38–42 After nasal administration for CNS delivery, 
four physiological steps are possible, and they include the 
olfactory nerve pathway, trigeminal nerve pathway, vascular 
pathway, and the lymphatic pathway.43
During the last two decades, four areas, including intra-
nasal delivery validation, pathway elucidation, intranasal 
delivery of various therapeutics for the treatment of 
neurological diseases, and enhancement of the efficiency of 
intranasal delivery, have been explored.44,45
Nasal cavity delivery and nasal absorption are promising 
approaches but are still uncertain. Direct intranasal transport 
is not always well established, and controversial results were 
obtained when similar substances were administered, and 
sometimes, even opposite results have been reported after 
nasal delivery to the CSF.46,47
A few years ago, Merkus and van den Berg,48 reviewing 
more than 100 papers, reported that no significant phar-
macokinetic evidence was yet capable of establishing that, 
in humans, the intranasal route of administration actually 
provides enhanced targeting to the CNS, compared to the 
systemic route.
The real potential of the nasal route for drug delivery 
purposes clearly needs to be explored, developing new 
approaches and amending theories.37
Nasal mucosal properties (ie, permeability to very large 
and polar molecules), are used in recent but still pioneering 
approaches, and among the various techniques, the permea-
bilization of the BBB via nasal mucosal engrafting could 
offer new important opportunities.
Nasal mucosal grafting: potential for 
drug delivery and implications for 
enzyme replacement therapies
Nasal mucosal grafting
Over the last few decades, the management of anterior skull 
base defects, CSF leaks, and encephaloceles by endoscopic, 
minimally invasive approaches is improving. Whether the 
etiology of these defects is spontaneous, traumatic, or surgical 
(eg, removal of brain tumors through the nose without facial 
incisions), the large majority of such defects can be repaired 
by means of free mucosal grafts that can be applied as a 
single layer reconstruction for small leaks or as a multilayer 
reconstruction for larger defects.49
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Middle turbinate, inferior turbinate, and nasal septum can 
be used as donor sites for free mucosal grafts for endoscopic 
endonasal reconstruction of the skull base. In this sense, 
the harvest of a nasal floor free mucosal graft was recently 
proposed as a rapid, potentially less morbid method.50 
Accessibility, ease of placement, and high take rate make 
free mucosal grafts suitable candidates for reconstruction 
of many skull base defects.51
The repairs by mucosal grafts are permanent, watertight, 
and immunocompetent, and they can also be used to replace 
large regions of the BCSFB within the arachnoid with 
relatively permeable mucosa.52,53 In principle, the engrafted 
mucosa can be dosed with therapeutic agents applied 
topically. Given the lack of underlying arachnoid membrane, 
these mucosal grafts, using purely autologous tissues, could 
be proposed to solve problems related to the BBB crossing 
by HMW or polar agents and a direct delivery to the brain 
and to the subarachnoid space (Figure 2).
This approach was tested for the first time by Bleier 
et al54 in a proof-of-concept extracranial graft model in 
mice. The applied mucosal grafting method was adapted 
by a surgical technique that is currently used in the field 
of endoscopic skull base surgery defects.55 The ability of 
septal mucosal grafts to allow diffusion of HMW markers 
into the CNS was investigated. A murine model, mimick-
ing the human skull base, was developed and validated. 
A polypropylene reservoir, allowing topical dosing of the 
graft with different fluorescent markers (20–500 kDa), was 
surgically implanted over the mucosal graft. The whole 
mucosal implant was well tolerated, and no evidence of 
subcutaneous infection or distress related to the surgi-
cal site was observed. Furthermore, the delivery via the 
mucosal graft was compared to the intranasal delivery, and 
a minimal delivery, similar to that of the negative control 
(dura membrane kept intact), was obtained. The direct 
exposure of the brain to the marker solution was used as 
positive control (no intervening dura or nasal mucosa). 
This study showed that the mucosal grafts allowed good 
permeability to HMW molecules and that the transport rate 
seemed to be molecular weight dependent. By extending 
the exposure duration, this effect was partially overcome. 
By developing different drug eluting polymers, the release 
rate can be modulated over time, and this could be a great 
challenge in combining innovative surgical and technologi-
cal approaches.54
The interesting findings of this study are limited by the 
possibility of comparing an animal model to a clinical setting 
owing to regional differences in convection throughout the 
murine and human brain. First of all, in humans, the ratio 
between mucosal graft area and brain volume ratio is much 
higher. In addition, in the clinical application, diffusion to 
more distal regions of the brain can be possible via CSF 
circulation, while it should be quite impossible in the murine 
model because of the occlusion of the smaller subarachnoid 
space after craniotomy.
Despite the aforementioned limitations of nasal mucosal 
grafting, the delivery of glial-derived neurotrophic factor 
(GDNF) was investigated in a mouse model for the treat-
ment of Parkinson disease (PD).56 In this study, a murine 
6-hydroxydopamine PD model was applied. A parietal 
craniotomy and arachnoid defect was repaired with a 
heterotopic donor mucosal graft. Given the permeability 
of these mucosal grafts to HMW molecules, as previously 
reported, the possibility, by means of this approach, to 
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$IWHUPXFRVDOJUDIWLQJ
%UDLQ
%UDLQ
'XUDDUDFKQRLG
%RQH
0XFRVD
0XFRVDOJUDIW
Figure 2 Graphic description of nasal mucosa graft.
Notes: The area circled in red indicates the nasal mucosal grafting area; the green arrow indicates absorption direction; and the white boxed area indicates removed bone 
and dura/arachnoid.
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bypass the BBB and to deliver HMW neuroactive sub-
stances, engrafted over an arachnoid defect, directly to the 
CNS was evaluated.54
GDNF was released by a polypropylene reservoir placed 
over the mucosal graft. Cyanoacrylate adhesive was used 
to attach the reservoir to the skull, and dental cement was 
applied to the skull. To maintain structural integrity, two 
bone screws were implanted into the skull before cement 
application.
GDNF was delivered through the mucosal graft, and the 
therapeutic efficacy was evaluated and compared with direct 
intrastriatal GDNF injection using behavioral assays (rotarod 
and apomorphine rotation). To compare the preservation of 
substantia nigra cell bodies, an immunohistological analy-
sis was also used. Both behavioral and histological results 
demonstrated the therapeutic efficacy of transmucosal GDNF 
delivery. No significant difference was reported in neuronal 
survival between the transmucosal and injected GDNF mice, 
suggesting that the transmucosal pathway could be as effective 
as direct intraparenchymal injection in GDNF delivering to 
the end-target structures deep within the brain. Furthermore, 
the proposed mucosal grafting method could show advantages 
over the simple intranasal drug delivery while avoiding the 
concerns over the limitations of olfactory uptake in humans. 
In principle, the graft may be placed adjacent to the sphenoid 
sinus, which creates an intrinsic reservoir capable of retaining 
a greater volume of any intranasally applied solution. This 
reservoir can also help to enhance mucosal residence time by 
limiting the immediate clearance of the drug from the nose 
because of the mucociliary clearance.57
This chirurgical procedure can be an efficient method to 
assure drug localization in the CNS, especially in the case 
of HMW drugs, such as enzymes that are widely used in the 
treatment of lysosomal storage diseases.
The local effect of this surgical procedure is the replace-
ment of BBB and BCSFB, while the effect on the remain-
ing part of BBB and BCSFB has not been evaluated and is 
not easily predictable by the results reported in the three 
cited research papers. Furthermore, the long-term effects of 
grafting nasal mucosa have not yet been evaluated because 
this technique has only been reported in a few very recent 
experimental studies on mice.54–56
Lysosomal storage diseases
Lysosomal storage diseases (LSDs) include more than 
50 inherited metabolic disorders characterized by the 
intralysosomal accumulation of undegraded substrates. 
Chemical properties of the accumulated substrate allow 
classification of the different types of LSDs. Individually, 
these disorders are rare, but their cumulative prevalence is 
relatively high when compared with other groups of rare 
diseases, and they reach an incidence of one over 8,000 
newborns.58
LSDs are responsible for various clinical consequences 
on multiple organs and systems with visceral, ocular, hema-
tological, skeletal, and neurological manifestations, and there 
is partial phenotypic overlap among different disorders. 
Symptoms may emerge in utero, during the newborn period, 
or in late adulthood. About 75% of LSD patients present a 
neurological impairment.
LSDs are often responsible for physical and neurologi-
cal disabilities, and they can interfere with patients’ health 
and life expectancy. Therefore, the LSD therapy requires a 
multidisciplinary collaboration.
LSDs are caused by mutations in genes encoding soluble 
acidic hydrolases, integral membrane proteins, activator 
proteins, transporter proteins, or nonlysosomal proteins that 
are necessary for the lysosomal functions. These deficien-
cies are responsible for intralysosomal accumulation of 
undegraded substrates in multiple tissues and organs.
Perturbation of lysosomal function may also lead to less 
obvious consequences, such as PD, which is the prevalent 
neurodegenerative disorder. Histopathologically, PD is 
characterized by the accumulation of insoluble aggregates 
of the presynaptic protein A-synuclein in typical intran-
euronal inclusions (Lewy bodies), by the selective loss of 
dopaminergic neurons in the substantia nigra, and clinically 
by movement and postural defects. Although the mechanisms 
underlying this connection have not been fully elucidated, 
dysfunctions in several lysosomal proteins (and lysosomal 
gene mutations) have been involved in the pathogenesis 
of PD.
Mutations in gene encodings, essential components of 
the endolysosomal–autophagic pathway, have also been 
described in other neurodegenerative diseases, including 
Alzheimer disease, Huntington disease, frontotemporal 
dementia, and Charcot-Marie-Tooth type 2B.
In the past 25 years, much effort has been directed at 
developing specific therapies to correct the metabolic defects 
of these disorders by means of different strategies that were 
intended to target a specific event in the pathogenetic cascade, 
increasing the activity of the defective enzyme or protein by 
different ways.
The normal enzyme, obtained by recombinant technol-
ogy or its precursor secreted in the circulation by engineered 
cells, may be administered through the endocytic pathway, by 
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intravenous administration. It is also possible to correct the 
gene mutation by delivering a wild-type copy of the mutated 
gene or to protect from degradation the mutant enzyme by 
increasing its residual activity.
Other strategies, aimed at restoring the equilibrium 
between the synthesis of substrates and their degradation 
by lysosomal enzymes, have been studied. They include 
reduction of substrate synthesis, enhancement of the clear-
ance of substrates from cells and tissues, and manipula-
tion of specific cellular pathways, involved in vesicle 
trafficking (Figure 3).59
Moreover, alterations in the BBB are likely involved in 
LSDs as well as in all neurodegenerative diseases.60 Actu-
ally, neuroinflammatory changes present in neurodegenera-
tion commonly affect the BBB or its function by altering 
transport systems, affecting the integrity of TJ, enhancing 
immune cell entry, or influencing the BBB’s role as a sig-
naling interface.61 In addition, ion balance, disruption of 
transport systems, and altered function of BBB constitutive 
enzymes61,62 are also induced by BBB dysfunction. The 
BBB impairment influences drug therapy, in particular the 
process regulating the entry of drugs normally excluded 
from the brain.61,63
Enzyme replacement therapy
Enzyme replacement therapy (ERT) is one of the approaches 
for several LSD treatments. In the early 1990s the efficacy 
of ERT in Gaucher disease was demon strated, and this 
approach has been used to treat other LSDs, including Fabry 
disease, Pompe disease, and Mucopolysaccharidosis I, II, 
and VI.64–71
After the conclusion of the first phase of ERT develop-
ment, advantages and limitations of this approach have 
emerged. Important limitations include the reduced bio-
availability of intravenously injected recombinant enzymes, 
and, therefore, strategies to improve ERT efficacy need to 
be identified. Recombinant enzymes are HMW molecules 
that are unlikely diffuse across membranes and are unable 
to reach therapeutic concentrations in some target tissues, 
particularly the brain. An additional major goal in future years 
should be the discovery of a BBB crossing enzyme because 
two-thirds of LSDs are involved in neurological symptoms 
and progressive neurodegeneration.
Strategies to improve the delivery of enzymes to the 
CNS are currently undergoing preclinical and clinical evalu-
ation. For example, B-glucuronidase, which is deficient in 
Mucopolysaccharidosis VII, has been chemically modified to 
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Figure 3 Schematic representation of therapeutic approaches to LSDs.
Abbreviations: LSDs, lysosomal storage diseases; ERT, enzyme replacement therapy.
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increase its plasma half-life and facilitate its traffic through 
the BBB.72,73 Other approaches consider the use of so-called 
Trojan horses, made of chimeric enzymes conjugated with 
peptides that can allow penetration through the BBB leading 
to brain delivery by specific pathways such as the apolipo-
protein and receptor pathways. These approaches have been 
evaluated in preclinical studies for A-iduronidase, iduronate-
2-sulfatase, arylsulfatase A, and tripeptidyl peptidase I.74–78
In addition to these approaches, preclinical studies 
are evaluating the use of invasive procedures to deliver 
recombinant enzymes directly into the CSF for the treat-
ment of several lysosomal disorders. Intrathecal and lum-
bar or cisterna magna punctures have been studied for the 
administration of various types of mucopolysaccharidoses 
in animal models.79–82 Intrathecal ERT has been translated 
into human therapy for mucopolysaccharidoses types I and 
VI. Devices for continuous intrathecal infusion have been 
developed and tested in preclinical studies. Some clinical 
trials of intrathecal administration of ERT are ongoing, and 
others have been completed. Invasive techniques for BBB 
crossing were based on neurosurgery or on a temporary 
chemical/physical disruption of the barrier, produced by 
biochemical and immunological changes or by an osmotic 
shift.83–85 However, both these approaches entail several 
drawbacks such as the invasiveness and the high costs of neu-
rosurgery, the physiological stress, or the transient increase 
in the intracranial pressure, along with high risk of infec-
tions and damages from toxins, due to the BBB temporary 
opening. Therefore, to improve drug delivery to the brain, 
noninvasive techniques have been explored, and among them 
the nanotechnology-based approach surely represents one of 
the most encouraging procedures.
To obtain a selective targeting to receptors highly 
expressed on the BBB, several possible ligands have been 
identified including transferrin, lactoferrin, insulin and leptin, 
and the LDL-receptor related protein LRP1.11 The proposed 
nanocarriers include a wide variety of drug-delivery vehi-
cles, including dendrimers, micelles, liposomes, nanoscale 
ceramics, and polymer nanoparticles.86–88 Different carriers 
offer different approaches to enzyme delivery. Liposomes 
are the first generation of nanoparticulate drug-delivery 
systems that reached the market, and they consist of one or 
more phospholipid bilayers delimiting an internal aqueous 
compartment. They are able to deliver hydrophobic, hydro-
philic, and amphiphilic molecules. It has been reported that 
B-galactosidase loaded liposomes injected by rat tail vein 
can penetrate the BBB and reach the lysosomes in the CNS 
more efficiently than the free enzyme.89 Similar results 
have been obtained by ex vivo and in vivo studies on 
saposin C-loaded liposomes that improve the neurologi-
cal condition.90 Liposomes modified with lysosomotropic 
octadecyl-rhodamine B (Rh) and loaded with therapeutic 
glucocerebroside velaglucerase A (VPRIVTM) increase 
lysosomal delivery of the enzyme into Gaucher cells.91 
Biodegradable and biocompatible nanoparticles, composed 
of poly (D,L-lactide-co-glycolide) (PLGA), have been inves-
tigated for recombinant proteins, plasmid DNA, and low 
molecular weight compounds brain delivery.92 Recently, 
in vitro and in vivo animal studies demonstrated the ability of 
PLGA nanoparticles, modified with glycopeptides (g7-NPs), 
to efficiently cross the BBB and to be transported intra- and 
intercellularly within vesicles for a more effective treatment 
of neurological disorders.93–95 Pegylated immunoliposomes, 
derivatized with the 8D3 antitransferrin receptor antibody, 
have been used to target the luciferase and A-galactosidase 
genes into the rat brain and to assure their activity after 
intracellular delivery.
Systemic gene therapy, together with several recombi-
nant vector systems, is under evaluation and appears to be 
promising.96,97 Finally, it was shown that hemopoietic stem 
cells, derived from the monocyte/macrophage lineage and 
genetically modified to produce replacement enzymes, are 
capable of crossing the BBB in rodent models and enter-
ing into the CNS.98,99 However, so far neither nanocarriers 
nor adeno-associated virus vectors nor cell-based therapies 
capable of crossing the BBB have reached clinical trials in 
LSD, for both technological and toxicological problems.
Conclusion
The BBB plays a fundamental role in protecting and main-
taining the homeostasis of the brain. For this reason, drug 
delivery to the brain is much more difficult than to other 
compartments of the body. The brain capillary endothelium 
excludes from the brain around 100% of large-molecule and 
more than 98% of small-molecule drugs.
Consequently, possible therapies with charged or mac-
romolecular drugs, which could be capable of preventing or 
even reversing certain neurologic diseases, are actually clini-
cally ineffective owing to their inability to cross the BBB. 
This is the central and crucial problem for an effective treat-
ment of both LSDs and the associated neuropathology.
The fact that therapeutic approaches capable of modify-
ing the natural evolution of many LSDs in the peripheral 
organs have been published and/or are under development 
(eg, enzyme replacement therapy, nanotechnology, gene 
therapy, and the use of stem cells) makes LSDs the ideal 
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environment in which to further investigate the relationship 
between lysosomal dysfunction-related neurodegeneration 
and the development of new strategies capable of crossing 
the BBB and reaching the brain compartment.
A number of studies showed that, in neurodegenerative 
diseases and LSDs, the function and integrity of the BBB and, 
in particular, of TJ, might be compromised. In these condi-
tions, an increased passive extravasation of solutes, including 
proteins up to at least a molecular weight of 150 kDa, into 
the brain can be demonstrated. In general, damage to the 
BBB can induce even worse CNS damages. Furthermore, 
the neuropathology, related to the accumulation of storage 
products, and the correlation between the two processes, 
needs to be better understood.
It must be clarified that the ERT treatment or other 
approaches must bypass the BBB barrier function. At present, 
the best way to reach the CNS crossing the BBB, whether by 
a clinical approach or a technological one using innovative 
drug delivery systems, is not clearly defined. Valid results 
obtained on a large-animal are still not available and the 
nasal mucosal grafting approach appears not yet feasible for 
clinical translation.
Mucosal grafting requires an endoscopic procedure, 
and this can seriously limit patient compliance. However, 
because the grafting technique is adapted from an existing 
endoscopic surgical procedure, its safety profile has been 
well established over several decades of clinical use and is 
associated with a lower morbidity rate than other currently 
accepted methods of BBB invasive penetration. It should be 
emphasized that this surgical procedure is quite invasive, but 
at present, patients are subjected to direct intracranial injec-
tion that is not always tolerated, because neurodegenerative 
diseases and LSDs are chronic and severely debilitating 
diseases, and to this day no therapy seems to be completely 
successful.100–102
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